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                                           Abstract 
 
This thesis describes colon targeted, fast dissolving delivery systems prepared 
through electrospraying and electrospinning. An overview of relevant literature on 
electrospraying and electrospinning is given at the start. Biodegradable polymer 
polyvinylpyrrolidone (PVP), and polycaprolactone (PCL) were used in the projects 
to produce nanomaterials using simple and straight forward techniques of 
electrospinning and electrospraying.  
In the first project, preparation, and characterization of PCL and PVP nanoparticles, 
using coaxial electrospraying was carried out. Electrosprayed nanocomposite 
coaxial nanoparticles with polyvinylpyrrolidone 10000 (PVP10) in the shell and 
polycaprolactone (PCL) 14000 in the core, were fabricated. Spherical, fiber-free 
particles were obtained with 5% solutions of polyvinylpyrrolidone. Confirmation of 
the presence of polycaprolactone inside the polyvinylpyrrolidone particles 
remained a challenge. Due to time constraints further work on this aspect of the 
project was abandoned, but a useful outcome was that low molecular weight PVP 
(av. mw10 kDa) could be used to prepare particles less than 100 nm.  
For the second project, hemin was selected for preparation of formulations for 
treatment of anaemia, as current treatments have side effects like gastric irritation 
and low bioavailability. Electrospun nanofibers and electrosprayed nanoparticles 
were tailored to enhance cellular uptake of low bioavailability drugs (hemin). DMF 
and MeOH was used to make hemin soluble. PVP-360 and eudragit L 100 were 
initially selected to make hemin formulations by electrospinning. A variety of 
electrospinning conditions were attempted and  optimal conditions for producing 
high quality fibers were found to be 0.5 mL/hr, 14 cm (distance) and 12.22 kV 
(voltage) for PVP/1% (w/w) hemin fibers. Preliminary dissolution tests showed that 
PVP/ hemin fibres completely dissolved in PBS within 10 minutes. Whereas 
eudragit/hemin fibres took 2 to 3 days to dissolve. PVP-360 made hemin dissolve 
successfully in PBS, so further development was focused on developing PVP 
formulations.  
DLS (Dynamic light scattering) gave two or three sizes of populations in biological 
media. The proportion of aggregates increased as the concentration of hemin 
increased which might be due to hydrogen bond between PVP and hemin.  
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Uptake from the nanoparticles obtained from hemin formulations was assessed in 
HepG2, THP-1  and Caco-2 cells. Fibers were generally well tolerated by HepG2 cells 
except when treated with fibers with 5% (w/w) hemin where there was loss of 
76.7% of cells. According to the ferrozine iron assay there was a 22% increase in 
iron in cells treated with fibers with 1% (w/w) hemin preparation compared with 
119% increase in iron in cells treated with 5% fibers, with respect to control. In THP-
1 cells the viability after treatment with PVP hemin fibres decreased as the 
proportion of hemin in the fiber increased.  An average viability of 70% was found 
in cells treated with 5% hemin preparation. The viability data showed that PVP 
fibers with hemin are not strongly toxic to THP-1 cells and are better tolerated in 
THP-1 in comparison to HepG2 cells and Caco-2 cells. There is a trend of increased 
iron uptake in THP-1 cells as the hemin content of fibers increased. The iron content 
of cells treated with5% hemin fibers was found to be 100 times higher than control 
cells. There is significant increase in iron from 2 and 5 % hemin preparation in Caco-
2 cells.  
Electrospraying and electrospinning were successfully used for the production of 
nanomaterials. Nanoparticles less than 100 nm were successfully produced from 
PVP 10 kDa, which has not been reported before. Cellular uptake of iron from PVP-
hemin formulations was demonstrated and is attributed to previously unobserved 
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                                          Chapter1  
 
1.1 Nanoscience, Nanotechnology, and its applications  
Nanoscience is an exciting diverse area of science that deals with the study of 
materials at atomic, molecular, macromolecular scale. Nanotechnology is the 
application of methodologies to the design, synthesis and characterisation of 
structures at the nanoscale i.e. size 1-100 nanometers. Nanotechnology is 
becoming increasingly pertinent as we are discovering that the physical properties 
and biological functions of many materials changes at sizes between a few 
nanometers to 100 nanometers (Whatmore, 2006).   
Nanotechnology has been implemented across a wide range of fields. 
Nanomedicine is the implementation of nanotechnology in diagnosis, treatment 
and prevention of disease, improvement of human health and improving health 
outcomes (Ganipineni et al., 2018).  Nanodiagnostics deals with the use of 
nanodevices in making the diagnosis of health-related conditions. The technology 
has been playing a pivotal role in regenerative medicine by improving cell therapy 
and tissue engineering. There is another important area of medicine which is being 
revolutionized by nanotechnology and that is  drug delivery systems (Patil et al., 
2008).   
Many drugs have limitations in medical use due to poor bioavailability, inability to 
pass through the cell barrier, and lack of selectivity. However, the small size of 
nanomaterials can allow them to cross natural barriers in the human body hence 
they can play an important role in drug delivery (Reinholz et al., 2018). 
Nanotechnology has been used extensively to formulate biocompatible 
nanomaterials which can play a role as carrier molecules (Xi et al., 2012). 
Nanomaterials have revealed great potential as carriers for drugs, due to the small 
size, greater reactive area, and ability to diffuse through the cell barriers 
(Wilczewska, 2012).   
Nanoparticles can penetrate and accumulate in the target tissue, which not only 
improves the bioavailability, but also helps to reduce unwanted side effects 
(Chauhan et al., 2014), as less amount of drug is needed for the same action. Drug 
delivery systems based on nanoparticles can control the drug release and can give 
a sustained drug level and prolonged action. This can also reduce the risk of an 
acute surge in drug levels and potential side effects associated with it. Therefore, 
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the role of nanoparticles in the field of drug delivery needs to be explored (Shi et 
al., 2010).  
The focus of this research work is to produce polymeric nanomaterials for drug 
delivery. For example, Panyam (2004) reported a greater anti-proliferative activity 
of dexamethasone where biodegradable nanoparticles, made up of 
polylactic/glycolic acid (PLGA) and polylactic acid (PLA), were used for the 
cytoplasmic delivery of the drug. Research has also shown that nanomaterials could 
be used for targeted delivery of drugs in specific cells/tissues (Owais et al., 1995). 
This is achieved due the small size of nanomaterial which allow penetrance to most 
tissues. Nanomaterials can also be tailored to respond to stimuli such as changing 
pH, temperature, light etc (Owais et al., 1995).   
There are some concerns associated with the use of nanoparticles as well. De Jong 
and Borm, 2008, have reviewed previous work looking into the possibility of side 
effects associated with nanoparticles. Although nanoparticles of gold/silica were 
considered to have toxicity, with modifications such as reducing the dose of 
stabilizer in the case of gold, or using amino-hexyl-aminopropyltrimethoxysilane as 
a surface modification in case of silica nanoparticles, significantly reduces the 
toxicity. However, not much evidence is available on the toxicity profile of organic 
nanoparticles. There is need of more research to establish the safety of 
nanoparticles in drug delivery systems and various other usages.  
  
1.2 Nanoparticles and diffusion through lipid bilayer  
Nature has designed phospholipid bilayers in order to protect cells from the 
external environment. The overall structure of the cell membrane (studded with 
proteins and possessing a hydrophobic core), is selectively permeable, and can act 
as a strong barrier for e.g. some proteins and drugs. Nanomaterials need to 
overcome this barrier to enter the cell (Pogodin and Baulin, 2010). Passive diffusion 
through the lipid bilayer generally occurs with small particles (less than 100 nm in 
diameter); however, high molecular weight species, including those larger than 100 
nm in diameter, face difficulty in passive translocation. Instead, their transport 
through the membrane is generally considered to be mediated via pores, 
membrane fission and budding, surface aggregation, inclusion in the membrane or 
lipid membrane permeation (Pogodin et al., 2012).   
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Pogodin (2011), modelled nanotubes of various diameters, translocated them 
through the lipid bilayer vertically, and calculated the energetic cost of their 
perpendicular translocation. Baulin drew the conclusion that simple translocation 
was unlikely to occur for single-walled carbon nanotubes (SWNTs), and the likely 
mechanism was an energy-dependent translocation such as endocytosis. However, 
insertion of short amino-functionalized SWNTs into the phospholipid bilayer was 
found to occur by passive diffusion (Kraszewski et al.  2012).   
Simulations by Pogodin (2012) showed that the relative membrane permeability of 
a nanoparticle increases with the increase in the average hydrophobicity (number 
of homogenous particles). This is shown in figure 1.1, where number of 
nanoparticles represent hydrophobicity (36 = blue, 72 = green, 144 = black, 288 = 
red).                                          
                        
Figure:1.1 A plot of average hydrophobicity versus relative membrane permeability 
of different nanoparticles (Pogodin., 2012).  
As stated previously, inspiration for this project came from extending this carbon 
nanotube work onto other nano-objects whose physical and chemical properties 
can be tailored more easily, namely  electrospun or electrosprayed nanomaterials. 
Both processes (electrospinning and electrospraying) are explained in detail later 
in this chapter, as these are used in the production of nanomaterials made in this 
research work.   
 
1.3 Nanomaterials as drug delivery system (DDS)  
Nanomaterials with optimized physicochemical and biological properties are taken 
up by cells more easily, and they can be used as drug delivery systems of bioactive 
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compounds (Agrahari et al., 2017; Wilkzewska et al., 2012).  Liposomes, which are 
spherical vesicles composed of phospholipids and steroids, have been used to 
improve the therapeutic index of chemotherapeutic agents (Wilczewska, 2012).   
Similarly, polymeric nanomaterials have been used as drug delivery systems. 
Sodium alginate has been used as a nano-carrier for carboplatin (an example of an 
anti-tumor drug), gelatin as a nano-carrier for rifampicin and PEGylated poly (lactic-
co-glycolic acid) (PEGylated PLGA) as a carrier for doxorubicin (Wilczewska., 2012).    
Polymers chosen are often biodegradable, such that polymer nanoparticles can 
undergo hydrolysis in the body and produce harmless metabolites. For example, 
Kumari et al. (2009) studied PLGA metabolism and reported minimal systemic 
toxicity.    
1.4 Electrohydrodynamics  
Electrospinning and electrospraying are sister technologies (Kostakova 2012; Zong 
2017), combinedly described as electrohydrodynamics (Rodríguez-Tobías et al., 
2016). Electrohydrodynamics refers to the dynamics of electrically charged fluids 
(Chakraborty et al., 2009). Electrospinning and electrospraying apparatus are 
similar and simple, consisting of a high voltage supply, syringe pump, collector, and 
syringe. If particles are produced, the process is called electrospraying and, if fibers 
are produced the process is called electrospinning.   A schematic diagram of the 
apparatus used for electrospinning and electrospraying is shown in Figure 1.2.   
                                                                                                             
  
Figure 1.2. Single fluid electrohydrodynamic apparatus for electrospinning or 
electrospraying. Single fluid means only one type of solution is used for production 
of nanoparticles/nanofibers.   
  32  
  
In electrohydrodynamics, there are numerous geometrical features and various 
types of cone-jet observable at the nozzle of the needle (or tip of the spinneret). 
The most stable and used mode is the cone-jet (Figure 1.3), as it produces almost 
uniform size particles and fibers (Enayati et al., 2010).   
                                                       
Figure 1.3.  Image of an ideal cone-jet from electrohydrodynamic process (Enayati 
et al., 2010). The arrow pointing to cone formed during the process of 
electrospininning/electrospraying and the dotted line is the emerging point of the 
cone from the needle.  
During the process of electrospraying and electrospinning, polymer chain 
entanglement occurs, which is responsible for the final morphology of the particles 
and fibers. The fewer the entanglements are, the smaller the diameter of particles 
and fibers would be. The number of entanglements can be calculated by equation 
1.1 (Bock et al., 2012).                 
                                                         (ηe)sol = ᵠ
𝑀𝑤
𝑀𝑒
      
                                                       Equation 1.1  (Bock et al., 2012).  
Equation 1.1.  (Bock et al., 2012). Where (ηe)sol = entanglements per chain in 
solution, ϕ = polymer volume fraction, Mw = the average molecular weight 
(g/mol), Me = the average entanglement molecular weight (g/mol).  
Research has shown that the process of electrospraying occurs with one 
entanglement per chain ((ηe)sol = 2). However, with 2.5 entanglements per polymer 
chain ((ηe)sol = 3.5) electrospinning occurs, leading to the fibre formation. The 
entanglement constraint model can be used to estimate the Me, if it is not known 
(Bock et al., 2012).  
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Polymer concentration also dictates the outcome i.e. whether particle or fibre 
formation would occur. This introduces the concept of Cov, which represents the 
critical chain overlap concentration, which is the point when the concentration of 
solution is equal to the concentration inside the radius of gyration of every single 
macromolecular chain and is inversely proportional to the intrinsic viscosity as 
shown in equation 1.2 (Bock et al., 2012).                                                                
                                                                 COѴ  α 1/η  
                                              Equation  1.2  (Bock et al., 2012).  
Based on polymer concentration, regimes could be described as,  
1. Dilute regime: when the concentration (C) is below Cov resulting in no chain 
entanglements.   
2. Semi-dilute unentangled regime: when the concentration, C, is above Cov, 
and the concentration is large enough for chains to overlap but not enough 
to generate a significant degree of entanglement. Such a regime can be 
used to produce electrosprayed films.  
It is found that a semi-dilute moderately entangled regime is ideal for 
electrospraying of particles.  
However, for C/Cov > 3, molecular cohesion is generally too high for electrospraying 
and beaded fibers or fibers are electrospun, corresponding to the semi-dilute highly 
entangled regime. For optimal particle electrospraying, it is thus essential to work 
above Cent (critical entanglement concentration) but not beyond C/Cov > 3 (Bock et 
al., 2012).   
1.4.1 Electrospinning   
Electrospinning is a versatile fibre forming process generally used to make 
macroporous scaffolds, which consist of randomly aligned nanofibers (Chew et al., 
2006). Formhal was the first to document production of nanoscale nanofibers in 
1934, using viscoelastic solutions, by the method of electrospinning (Zhu et al., 
2017). The name electrospinning is derived from “electrostatic spinning'', a term 
used in 1994. We find evidence of electrospinning in history since the end of the 
19th to 20th century (Thakur, 2014).  However only limited production and 
applications remained until 1990, when it was discovered that electrospinning can 
be carried out with organic polymers (Zhu et al., 2017). In recent years with an 
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increase in the popularity of nanotechnology, electrospinning is becoming an area 
of increased interest.  
  
Using this method, nanometer range fibers can be produced. A polymer solution or 
melt is passed through a narrow needle or nozzle which works as an electrode at 
the same time (figure 1.2). During this process, the utilized current varies from tens 
of nanoampere to several microampere (Zheng et al., 2019). The setup of the 
electrospinning apparatus could be vertical or horizontal. With the application of 
high voltage, an electric field is produced between the electrode and a collector. 
Once electrostatic forces overcome the surface tension, polymer solution is ejected 
from the nozzle/needle tip in the form of a very thin and long jet. Fibers are 
collected on the surface of the collector (Kiyak and Cakmak, 2014).     
  
Various types of collectors are available for electrospraying and electrospinning, 
and a metallic plate collector was used in this research work (Ulubayram et al., 
2015).   
  
Electrospinning is a cost effective, simple, and versatile technique for the 
production of polymer fibers. These fibers have high surface area to volume ratios, 
making them suitable for scaffolds for tissue engineering, wound healing devices, 
semiconductors, cosmetics, textiles, filtration and drug-delivery systems (Mouthuy 
et al., 2015). To augment functionality, researchers are increasingly attracted to 
integrate drugs into fibres (Chakraborty et al., 2009). A typical SEM image of PVP 
360 (polyvinylpyrrolidone 360 kDa) fibers is shown in figure 1.4.   
  
                                  
  
                                       Figure 1.4. Typical SEM of PVP 360 fibers.  
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Various modifications of electrospinning techniques have been used in recent 
years, and one such variation is co-axial electrospinning.  
  
                                    1.4.1.1 Co-axial Electrospinning  
In this method, two different polymer solutions (or possibly melts) are used. These 
polymer solutions from two different syringes are diverted towards the coaxial 
needle, resulting in formation of the Taylor cone.  Evaporation of solvent happens 
during spinning and results in the solidification of a compound jet.  Production of 
core shell nanofibers happens because of solidification. With this method, core 
shell nanofibers can be produced for the polymers which cannot be electrospun by 
the monoaxial electrospinning method. These fibers have multiple applications 
such as in microelectronics (Kiyak and Cakmak, 2014). This technique was used in 
this research project as well. The arrangement of apparatus is shown in figure 1.5. 
 
Figure 1.5. Production of co-axial particles or fibers using coaxial electrospraying or 
electrospinning. In this method two syringe pumps and a co-axial needle are used. 
The core and sheath solutions are different from each other.  
Novel functionalities and properties of two different nanomaterials could be 
combined using co-axial electrospinning/electrospraying. Using this technique, 
fibers with multichannel, hollow, thin-wall and porous structures with tuneable 
inner structure, and large surface area have been produced. The polymeric 
nanofiber shell can be used as a diffusion barrier for delivery of drugs, facilitating 
the burst release of APIs (active pharmaceutical ingredients) (Zong et al., 2017).  
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One of the limitations of the electrospinning is the requirement to ultrasonicate the 
fibers to control their length (Sawawi, 2013). An approach that may circumvent this 
is the use of electrospraying that generates particles rather than fibers.  
  
1.4.2 Electrospraying  
Poor solubility of numerous pharmaceutical ingredients results in their poor 
bioavailability. To overcome this issue, numerous methods have been 
implemented, one of which is electrospraying. Currently the process of 
electrospraying is implemented in various industries such as ceramics, food 
industry, paints etc. Drug delivery is another emerging field for the implementation 
of the electrospraying process (Smeets, 2017).   
In electrospraying, solutions are sprayed in an electrostatic field, resulting in 
production of submicron polymer particles with distinctive functional 
nanostructures (Zhang et al., 2009). A polymeric solution is pumped from a syringe 
at a constant rate through a needle attached to an electric field. When the polymer 
solution comes out from the needle, it forms a cone (Taylor cone). The jet of 
charged particles elongates and detaches from the cone. The solvent evaporates 
after the detachment of the droplets from the Taylor cone, nano-objects are 
generated and collected on the collecting plate (Cavalli et al., 2011). A typical SEM 
image of PVP 10 particles produced by electrospraying is shown in figure 1.6.  
                            
           Figure 1.6. PVP 10 (10 kDa) Nanoparticles produced by electrospraying.   
  
     1.4.2.1 Co-axial electrospraying   
Co-axial electrospraying is a nano-encapsulation process based on a single jet 
electrospraying. It has been developed to engineer multifunctional nanoparticles 
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with improved qualities and efficiency. In co-axial electrospraying, a co-axial nozzle 
is used which contains an inner and an outer needle. Two different liquids from co-
axial needles are ejected using syringe pumps. An electrode is placed under the 
nozzle and an electric filed is generated, which results in the formation of Taylor 
cone at the nozzle. The jet flow containing sheath and core fluids is eventually 
broken down into nanoparticles, which are collected on the collector (see figure 
1.5).   
There are minor variations to the coaxial electrospinning apparatus such as size of 
the needles, and the distance between the nozzle and ground electrode could vary. 
Also, aluminium foil could be used which serves as both collector and the ground 
electrode. Several parameters such as voltage, flow rate, solution properties etc 
could affect the outcome (Zhang et al., 2012).   
  
  
 1.4.3 Factors affecting the electrohydrodynamic process  
Various factors can affect the nanofiber formation during the electrospinning 
procedure. Indeed, the qualities of nanofibers produced can be tuned by the choice 
of the polymer, viscosity, flow rate and voltage applied to the polymer solution 
(Ramakrishna et al., 2005). These factors can be divided into solution properties 
and processing parameters.   
1.4.3.1 Solution properties  
Several characteristics of the polymer solution can influence the outcome of 
electrospinning. The surface tension of the solution has an important impact on the 
process of electrospinning. Solutions with higher surface tension require a higher 
applied voltage for nanofiber production (Gazquez et al., 2017).  
The other significant characteristics are the molecular weight and viscosity of the 
solution. Increased molecular weight increases chain entanglement of the solution 
leading to greater viscosity (Li and Wang, 2013).  
The viscosity of the polymer solution creates a profound effect on the morphology 
of fibers. High viscosity of polymer solution results in formation of smooth fibers 
whereas, low viscosity favours formation of beaded fibers. The viscosity of a 
solution is related to the chain entanglement between polymer chains. The extent 
of chain entanglement tells whether fibres or particles would be formed during 
electrospinning (Ramakrishna et al., 2005).   
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Another important character to consider is the conductivity. In each electric field, 
conductivity of the solution determines the voltage needed to be applied. The 
conductivity can be increased by adding salts (as salt increases the ionic 
concentration of the solution) which improves fiber formation (Gazquez et al., 
2017).  
The choice of solvent is also crucial. Solvents with larger dielectric constant and 
higher conductivity contain higher charge density in the polymer solution. In this 
case, the jet will carry more charge density and more elongated forces will be 
executed on the jet. Self-repulsion and excess of charge under electric field will 
produce straighten and small diameter fibers and particles (Xu et al., 2017).  
  
1.4.3.2 Processing parameters  
Processing parameters such as voltage and flow rate have an effect on the diameter 
of the nanomaterials formed (Dhanalakshmi et al., 2015). Some of the relevant 
parameters are discussed below.  
The diameter of nanofibers and particles decrease with an increase in the voltage, 
as it provides surface charge to the jet causing greater electro repulsive forces. 
However, very high voltages facilitate the flow of polymer thus increasing th 
diameter. In addition to this, beaded fibers are obtained at high voltage (Okutan et 
al., 2014). The SEM of PVP 40 (Polyvinylpyrrolidone MW 40,000 g/mol) with beaded 
fibers is given in figure 1.7. The concentration of solution was 25% (w/v), flow rate 
was 0.5 mL/hr, the distance from the needle tip to the collector was 14 cm and, the 
voltage was 16.25 kV.   
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Figure 1.7. Typical picture of beaded fibers of PVP 40 (40 kDa). SEM image of fibers 
produced from a 25% (w/v) solution.  
The next parameter to consider is the flow rate. Low flow rate will result in 
inhibition of the electrospinning process, whereas high flow rate can result in the 
formation of beaded fibers. This happens due to the reduced time available for 
solvent evaporation (Okutan et al., 2014). The rate of the feeding affects the 
solution transfer and jet velocity. A lower flow rate of solution is required to obtain 
solid material with complete evaporation of solvent (Bhardwaj and Kundu, 2010).  
The collector plate is another important parameter. The architectural deposition of 
particles or fibers and the electrical field are strongly influenced by the collector’s 
characteristics (Alfaro De Prá et al., 2017).  The collector is normally used as a 
conductive surface. Aluminium foil is mostly used as a collector but transferring the 
fibers or particles from the foil could be challenging. Different types of collectors 
such as liquid bath, wire mesh, parallel  or gridded bar rotating wheel or rod, grids 
or pins can be used to solve the problem (Li and Wang, 2013).  
The diameter of the spinneret tip does not affect the fiber’s diameter, but it affects 
the flow rate of polymer solution. It also affects the size and shape of the solution-
air interface. Various types of spinneret designs are found in the literature. The 
simplest one is the hypodermic needle with blunted flat tip, which has been used 
extensively in this project. Additionally, a co-axial spinneret has been used in this 
project, which consists of two concentric needles which can be used for the 
formation of core-shell or hollow fibers (Robb and Lennox, 2011).    
Tip to collector distance affects the diameter and morphology of the 
particles/fibers. An important aspect in electrospraying and electrospinning is the 
evaporation of the solvent during the journey of polymer solution from tip to 
collector. Optimum distance is required for successful production of 
particles/fibers. If the distance is short, complete solvent evaporation will not be 
possible, but too long a distance will result in beaded fibers (Li and Wang, 2013).  
The dimensions of the nanomaterial can have an impact, for example, on 
penetration in the cell. Therefore, it is particularly important to control this factor 
(Garmarudi et al., 2010). Parameters which influence the diameter of nanofibers 
and nanoparticles are summarized in figure 1.8.   
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Figure 1.8. Parameters that affect the diameter of nanomaterials. Diagram created 
from Chakraborty et al., 2009.  
  
1.4.3.3 Ambient parameters  
Temperature and relative humidity can affect the diameter of particles or fibers. 
The diameter of the particles or fibers decreases with an increase in the relative 
humidity or temperature (İçoğlu and Oğulata, 2017). Higher temperatures produce 
smaller diameter fibers due to more rapid evaporation of the solvent. Low humidity 
facilitates the flow of solution and thus increases fiber diameter.  
  
1.5 Biodegradable polymers  
Biodegradable polymers can easily be degraded through the action of enzymes 
and/or chemical deterioration associated with living organisms (Vroman and 
Tighzert, 2009).  
Polymers could be broadly classified as synthetic and natural biodegradable 
polymers. Some examples of naturally existing biodegradable polymers include 
polysaccharides (starch, cellulose, hyaluronic acid etc.) and proteins (collagen, 
albumin etc.). Examples of synthetic biodegradable polymers are polyesters (such 
as polylactones, polycarbonates), polyanhydrides, polyurethane etc. Natural 
biodegradable polymers have good biocompatibility, but due to undesirable 
properties such as antigenicity have not been widely investigated. Synthetic 
biodegradable polymers are more versatile and have a wide range of applications 
(Doppaladupi et al, 2014).   
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The biodegradable nature of polymers makes them very desirable for use in drug 
delivery, tissue engineering, gene therapy, temporary coating on devices etc. The 
choice of polymer depends on the mechanical needs for the application. For 
example, in a drug delivery application, the choice of biodegradable polymer will 
be governed by the time taken to release the drug. When used as suture material, 
the rate of degradation should be long enough to allow sufficient strength until the 
healing of the tissue is achieved (Doppaladupi et al, 2014).   
For this research project, we have used PVP (polyvinylpyrrolidone) and PCL 
(polycaprolactone) as the biodegradable polymers.   
  
 1.5.1 Polyvinylpyrrolidone (PVP)  
PVP was used as the carrier in both projects undertaken in this thesis, therefore it 
is discussed in the first chapter of the report (the other polymers used will be briefly 
discussed in relevant chapters). PVP has a well-defined structure: it contains N-
vinylpyrrolidone monomers and synthesized by polymerization in isopropanol or 
water (Aria et al., 2016; Kadajji and Betageri, 2011). The structure of PVP is shown 
in figure 1.9.  PVP is available in various molecular weights; three different 
molecular weights PVP (10,000, 40,000 and 360,000 Da) were used in this research 
work.  
                                                      
                                  Figure 1.9. Structure of polyvinylpyrrolidone  
PVP or povidone has been widely used in many applications in pharmaceutical 
technology, medicine, and cosmetic science. This is owing to its chemical and 
physical properties such as being colourless, physiologically compatible, chemically 
inert, pH-stable, temperature-resistant, and non-ionic (Rasekh et al., 2014). PVP 
has a high glass transition thus increases the temperature of the amorphous drug 
which enhances the conversion to more stable crystalline form (Lopez et al., 2014).  
It has good film making characteristics, adhesive properties, and high complexing 
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quality. The film forming property of PVP was used in the initial project described 
in chapter 2 to improve the quality of PCL nanoparticles. PVP exhibits special 
properties such as high solubility in organic solvents or water. Consequently, PVP 
is broadly used to improve the solubility of poorly water-soluble drugs in simple 
pharmaceutical formulations (Kadajji and Betageri, 2011).  
Many active ingredients are poorly soluble which limits their bioavailability. 
Solubilizing agents like PVP can be used to solve this problem by forming soluble 
complexes with active ingredients hence enhancing dissolution or solubility of the 
active ingredients. The solubilizing quality of PVP was used in the second project of 
this thesis (hemin formulation), in which PVP solubilized the hydrophobic 
compound hemin (discussed in chapters 3 and 4).   
  
1.6 Formulation of drugs  
Nanomaterials have gained attention in recent years due to their physicochemical 
properties. Nanomaterials made of biodegradable biopolymers, synthetic 
polymers, metal oxides and metals are a significant innovation for targeted drug 
delivery (Banerjee et al., 2017). The projects discussed in this thesis are based on 
the production of polymeric nanomaterials which will be used as carriers of the 
active pharmacological ingredients (APIs): 5-fluorouracil (5-FU) and hemin. Both of 
these drugs are currently administered intravenously (Regazzoni et al., 1996) 
(Schiller et al., 2004).  The aim of this project is to develop an orally administered 
targeted delivery system for these active ingredients.   
There are various routes of drug administration such as oral, nasal, inhalation, 
intramuscular, intravenous, subcutaneous, transdermal, transmucosal, rectal and 
topical (Mignani et al., 2013). The enteral route has distinctive high patient 
acceptability, as well as high convenience. Through the enteral route medicines are 
swallowed or absorbed sublingually. However, there are limitations  to the oral 
route, including intake of the drug with food and/or with other medication, and the 
drug’s metabolism in the gastrointestinal tract and liver can have significant impact 
on its absorption and bioavailability (Finkel (PharmD.) et al., 2009).This project 
focusses on the design of formulations for oral administration.  
Enteric coated tablets are designed to prevent dissolution and release of drug in 
gastric acid, and the rate of the drug release is predominantly determined by the 
drug delivery system used. This allows controlled release of the drug. The 
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formulation of gastro-resistant and controlled released medicine has many 
benefits (Lozoya-Agullo et al., 2018; Zema et al., 2013). Thepurpose of controlled 
release medicine is to lower toxicity, have a better therapeutic efficacy, to reduce 
fluctuation in plasma levels and to reduce number of doses needed per day, which 
would improve patient compliance (Prajapati et al., 2011). The aim of the second 
project was to create a formulation of gastro-resistant capsules for the release of 
hemin in the intestine.  
In recent years, the focus on prolonged release medicines, which release their 
contents in the intestine, has increased (Macchi et al., 2015; Modi et al., 2012). 
Both local and systemic delivery of drug is possible in the colon. In certain colonic 
diseases targeted delivery is beneficial, for example for colon cancer, colitis, local 
infection, and Crohn’s disease. Targeted delivery to the colon has benefits as lower 
dose of the drug would be required hence fewer systemic side effects (Lozoya-
Agullo et al., 2018). In the first project we targeted the colon for delivery of 5-FU 
(an anticancer drug) and in the second project intestine was targeted for the uptake 
of hemin (for treatment of anaemia). The aim was to reduce the side effects and 
improve the bioavailability of these APIs. 5-FU metabolizes in the intestine by uracil 
reductase or dihydropyrimidine dehydrogenase (Wilson et al., 2012), due to which 
it has short half-life. This problem was planned to be addressed by targeted delivery 
of 5-FU to the colon in colorectal cancer. Oral iron supplements cause gastric 
irritation and only a small quantity (1-2 mg) of iron is absorbed from the intestine 
in a day (Coad and Pedley, 2014).  Therefore, a gastro resistant formulation was 
planned to improve the bioavailability of hemin and reduce the gastric side effects.   
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Chapter 2 
Preparation and characterization of Polycaprolactone and 
Polyvinylpyrrolidone nanoparticles 
 
2.1 Introduction   
Synthesis of polycaprolactone (PCL) nanoparticles is an appealing approach, as PCL 
based therapeutic delivery devices have many advantages. These include high 
permeability for small drug molecules, and during degradation, failure to generate 
an acidic environment (as is the case with polylactides and glycolides) which can be 
useful for the sustained release delivery of proteins or peptides. Additionally, PCL 
has slow degradation speeds (more than one year) as compared to poly lactic-co-
glycolic acid (PLGA) and, this quality makes PCL a more suitable choice for long term 
delivery systems (Enayati et al., 2010). This chapter describes attempts to 
formulate and characterise NPs of this type. Background theory and an outline of 
the practical details of the electrospinning and electrospraying processes were 
provided in Chapter 1.                                                                                  
During this phase of the project, NP electrospraying was carried out on two 
different substrates: foil and distilled water.   
Firstly, electrospraying was carried out in the conventional way, collecting the 
particles on aluminium foil, which was wrapped on a metal collector (discussed in 
section 2.3.1).  
The second approach involved liquid–liquid electro-dispersion, or dispersion of a 
liquid in a bath of another liquid (Barrero et al, 2004), (discussed in section 2.3.2).  
The main advantage of this approach was that PCL particles were automatically 
collected in the liquid phase, making it more convenient.  PCL was initially selected 
as a polymer to produce nanoparticles. The structure of PCL is shown in figure 2.1. 
PCL is biodegradable and has less immunogenicity and toxicity than many other 
polymer systems (Celan et al., 2013). It is used in drug delivery, tissue engineering 
and additive manufacturing (Kotula et al., 2017).   
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                                  Figure 2.1. The chemical structure of the 
repeat unit in PCL     
The degradation of PCL is reproduceable and predictable, and this quality is used in 
bone and tissue engineering (Bose et al., 2018). It has been combined with PEG to 
form a copolymer for production of nanoparticles by precipitation (Danafer, 2016).  
                                          
Attempts to modify the surface characteristics of the NPs were also undertaken. 
This involved using co-axial electrospraying (discussed in chapter 1), generating NPs 
which had PCL in the core and PVP in the shell.  
Once the various forms of PCL/PVP containing NPs were generated, they were 
characterised by using scanning electron microscopy (SEM), infrared spectroscopy 
(IR), and nuclear magnetic resonance spectroscopy (NMR). The next steps involved 
attempting to form NPs loaded with the model drug and assessing bioavailability 
of these NPs as potential DDS (drug delivery system).   
  
2.2 Method and materials  
2.2.1 Materials  
The polymers polycaprolactone (PCL), (M.W 10,000-14,000 & 45,000) and 
polyvinylpyrrolidone (PVP) (M.W 10,000, 40,000 & 360,000) were purchased from 
Sigma Aldrich. 1,2-dichloroethane was purchased from Fisher Scientific. Distilled 
water and absolute ethanol were of analytical grade. Sodium dodecyl sulphate 
(SDS) (FW 288.38 Da) GC grade was purchased from Sigma Aldrich.   
  
2.2.2 General instruments  
Precise characterization of nanomaterials produced by electrospraying or 
electrospinning is crucial to associate nanomaterial physicochemical properties 
with cellular response. It is also essential for meaningful, accurate and 
reproduceable results (Shang et al., 2014). In this part of the thesis, different 
techniques used for characterization of nanomaterial are discussed.  
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2.2.2.1 Infrared spectroscopy (IR)   
FTIR spectra of samples were obtained using an Agilent Cary 630 FTIR spectrometer 
with diamond ATR attachment and Microlab PC software. A small quantity of 
sample was placed on the platform with the help of spatula. The knob was rotated 
till the screw touched the sample. The IR spectra of samples were collected against 
background. The range of wavelength used was 4000-400 cm-1, with resolution of 
4.  
2.2.2.2 Scanning electron microscopy (SEM)   
The instrument used for SEM was a Zeiss Supra 55VP FEGSEM. The imaging 
conditions were 3kV accelerating voltage, a small (20 micron) aperture for good 
depth of focus, and high current mode for good resolution. Samples were mounted 
on 12 mm diameter aluminium SEM stubs using carbon sticky tabs. Gold sputter-
coating was achieved using a Polaron SC7640 sputter coater, with a coating time of 
40-60 seconds to give 5-10 nanometres thickness coating.   
 
2.2.2.3 Microscopy   
An Olympus X81 light microscope was used to take the images of fibers and 
particles at magnifications of 100x and 400x.  
  
                                 2.2.2.4    NMR  
A Bruker Avance 500 MHz spectrometer was used for 1H NMR. CDCl3 was used as 
the solvent for all samples.   
  
2.2.2.5 Dynamic light scattering   
A Brookhaven Nanobrook Omni particle size analyser was used to measure the 
particle size distribution in solution, with supporting BIC Particle Solutions (version 
2.6) software. Measurements were performed at 22°C at an angle of 90°. The EPSRC 
Equipment Loan Pool is gratefully acknowledged for the loan and use of the 
Brookhaven Nanobrook Omni particle size analyser.  
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             2.2.3 Preparation of solutions  
                  2.2.3.1 Polymer solutions   
0.25 - 10% (w/v) PCL solutions were made by adding PCL (M.W 10000-14,000 & 
45,000) into 1,2-dichloroethane at room temperature. The solution was 
continuously stirred until the required amount of PCL was dissolved in 1,2-
dichloroethane. 1-10% (w/v) PVP-360 solutions were made by dissolving an 
appropriate amount in distilled water or absolute ethanol.   
  
When electrospraying directly into water, 0.25-5% (w/v) PCL solutions were made 
by adding appropriate amounts of PCL (M.W 45,000) to acetic acid at room 
temperature. The solution was continuously stirred until the required amount was 
dissolved in acetic acid and 5% and 10% (w/v) PVP solutions were made by 
dissolving appropriate amounts in distilled water.   
  
                   2.2.3.2 Sodium dodecyl sulphate (SDS) solution   
5% (w/v) solution of SDS (sodium dodecyl sulphate) was made by stirring an 
accurate amount in distilled water at room temperature (22°C) until SDS had 
completely dissolved.  
  
           2.2.4 Electrospraying   
                   2.2.4.1 Single fluid electrospraying   
Electrospraying was performed at 22°C ± 3°C. The spinneret was attached to the 
syringe (5 mL), which was filled with the polymer solution. The syringe was 
attached to the syringe pump (ColeParmer pump (78-9100C)). A power supply (FuG 
Elektronik HCP 35 – 65000, supplied by Omiran Ltd, UK) with voltages ranging from 
10 - 20 kV and 16-20 cm tip to collector distance was used. The needle was attached 
to the positive electrode and the collector to the grounded electrode. Aluminium 
foil was wrapped on the metal collector. The solution was ejected from the needle 
at a controlled rate between 0.25 mL/hr and 1.5 mL/hr.   
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         2.2.4.2 Co-axial electrospraying   
The setup of coaxial electrospraying is same as the single fluid set up, but two 
syringe pumps and the coaxial spinneret were used. A photograph of the co-axial 
spinneret is given in figure 2.2. In the case of collection on foil, 5% PVP (flow rate 
1.5 mL/hr) was used as the ‘shell’ fluid and 4% PCL (flow rate of 0.25-0.5 mL/hr) 
was used for the ‘core’. The voltage used ranged from 15-20 kV and the tip to 




Figure 2.2. A photograph of the co-axial spinneret used in this project. It shows the 
structure of the concentric nozzle.  
Co-axial electrospraying was also used for electrospraying in distilled water (80 ml), 
in which 10 % PVP 360 in distilled water was used in the shell and 0.5-5% PCL 45 in 
acetic acid was used for the core of the co-axial spinneret. The collector distance 
ranged from 5-10 cm and the voltage used was between 15-20 kV. 5% SDS was used 
for collection of nanomaterial, which was stirred continuously to prevent 
agglomeration of PCL particles. The apparatus of co-axial electrospraying in liquid 
is shown in figure 2.3.  
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Figure 2.3. Schematic representation of electrospraying into distilled water 
containing SDS.   
  
2.2.5 Methods attempted for separation of core PCL particles   
                    2.2.5.1 Method 1   
PVP is a water-soluble polymer (Oliveira et al., 2011) and to confirm the presence 
of PCL in coaxial particles, the mat was dissolved in distilled water. The solution was 
centrifuged twice for 10 minutes at 25000 g (at highest speed available on 
centrifuge). The supernatant was removed, in this way the PVP was removed from 
the PCL particles. The pellet was dispersed in the distilled water and NaOH solution 
(1.25 M), the solution was then dried on two different SEM stubs. NaOH was used 
to prevent aggregation of the PCL particles. The SEM images of the dried distilled 
water and NaOH treated pellet are shown in figure 2.14a1 and 2.14b1, respectively.  
  
                     2.2.5.2 Method 2   
0.026% and 0.05% (w/v) of brilliant green dye was incorporated in the 4% PCL 
solution to enhance visibility of the core. The electrospraying was carried out with 
same conditions as mentioned in figure 2.13. The samples were collected on foil 
and both samples were dissolved in few mL of distilled water. Samples were 
transferred in eppendorf tubes and centrifuged at 25000 g at 22 ℃ for 10 minutes. 
Dark black pellets appeared at the bottom of the Eppendorf tubes. Pellets were 
spread on a carbon tab for SEM.  
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2.3 Results and discussion   
   2.3.1 Electrospraying of polymer on foil   
Previous work by Zhou and co-workers (2016) used electrospraying with a range of 
PCL solutions to produce microspheres of controlled size and shape. They found 
that PCL solution concentration and molecular weight have a clear effect on 
morphology and the formation of the particles. The aim of this work differs 
significantly from Zhou’s, in that this project aimed to produce PCL nanoparticles 
instead of microspheres as they should have enhanced cellular uptake and be more 
effective as DDS.   
  
Firstly, the results obtained from single fluid electrospraying of PCL 45 (molecular 
weight of 45,000 g/mol) on foil is discussed. Initially 5-10% (w/v) solutions of PCL 
45 in 1,2-dichloroethane were used for electrospraying, but SEM micrographs 
indicated that the particles produced were larger than expected (i.e. 3-10 µM). 
Further experiments were then performed using PCL at lower concentration 0.25 - 
5% (w/v), as lower concentrations are known to reduce particle diameters (Jagtap 
et al., 2012). Some representative SEM micrographs of those samples are shown 
 in figures 2.4 (the rest of the SEMs are given in appendix A). 
                                       
Figure 2.4. SEM of particles obtained from A) 4% (w/v) sample SPCH (with a 1 mL/hr 
flow rate, 10.49 kV voltage 16 cm distance from tip to collector), B) 3% (w/v) sample 
SPCH (with a 1 mL/hr flow rate, 10.49 kV voltage and 20 cm distance from tip to 
collector), C) 0.5% (w/v) sample SPCH (with a 1 mL/hr flow rate, 17.63 kV voltage 
and 18 cm distance from tip to collector).  
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According to these results, the particles made from 3% and 4% (w/v) solutions 
appear to be more circular when compared with the particles made from the lower 
concentration PCL solutions. The samples obtained from 3% and 4% (w/v) solutions 
have particle sizes with diameters around 4 – 5 µm. Conversely, particles made 
from 0.5 % (w/v) PCL are of various sizes, with some particles smaller than 100 nm 
and these have been highlighted in figure 2.4C.  The prevalence of these smaller 
particles or nanoparticles observed at 0.5% PCL led to further investigation of the 
electrospraying parameters for this solution. The experimental conditions for this 
investigation are summarized in table B1 of appendix B.  
  
As per table B1 in appendix, thirteen different processing parameters (SPCH 1- SPCH 
13) were tested for electrospraying, out of which seven sets of conditions (with 
voltage from 15-20 kV, 18-20 cm tip to collector distance and flow rate 1-1.5 mL/hr) 
resulted in continuous electrospraying of material. The rest of the conditions 
resulted in spitting along with intermittent electrospraying.  
There are many similarities observed in the SEM micrographs described in table B1. 
Figure 2.5 shows an indicative micrograph with the remainder given in appendix B.        
        
Figure 2.5. SEM micrograph obtained for sample SPCH 3 mentioned in table B1 in 
the appendix B.  
The SEM images of particles produced from 0.5% (w/v) PCL solution showed 
production of fibres along with non-spherical particles (see, for example figure 2.5). 
To overcome the problem of particle nonuniformity, PVP was used since it is widely 
reported in the literature to improve the morphology of the particles (Jaberolansar 
et al., 2016; Seo et al., 2018). The aim of this work was to coat the PCL particles 
with PVP by using co-axial electrospraying. This was carried out to produce 
spherical fibre free PCL particles. The diagram of a co-axial particle is shown in 
figure 2.6.  
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                     Figure 2.6. Co-axial particle with PCL in core and PVP in shell.  
Further experiments were performed on PCL 45 and PVP 360 (360,0000 Da) using 
the method of coaxial electrospraying (CPVCH). Initially, 5% (w/v) PVP 360 was 
dissolved in water as the shell and 4% (w/v) PCL 45 was dissolved in 1,2-
dichloroethane as the core. A range of samples were collected under various 
electrospraying parameters, as shown in Table C1 of appendix C.  
A representative SEM micrograph from the experiments summarised in table C1 is 
shown in figure 2.7 and the rest are given in appendix C.  
                                   
Figure 2.7. SEM micrograph obtained for sample CPVCH 1 mentioned in table C1 in 
the appendix.  
The SEM micrographs resulting from the experiments detailed in Table C1, 
indicated that the PVP coated PCL particles seemed to be more spherical than 
particles obtained using PCL alone. However, it was also clear that fibres were still 
present (see figure 2.7). It was suggested that an alternative solvent for PVP might 
influence the morphology observed in the nanomaterials. PVP is freely soluble in 
ethanol as well as water so coaxial-electrospraying was carried out by keeping PVP 
in ethanol in the shell and PCL in 1, 2-dichloroethane in the core.   
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Figure 2.8. SEM of sample from table C1 in appendix C with 5 %(w/v) PVP in ethanol 
in the shell A) CPVCH 3 with 0.5% (w/v) PCL in 1,2- dichloroethane in the core, B) 
CPVCH 2 with 2 % (w/v) PCL in 1,2- dichloroethane in the core.                                      
The SEM images of these samples showed that using ethanol as the solvent for PVP 
(M.W 360,000 Da) resulted in a whole mesh of fibres. Distilled water seemed to be 
a more suitable solvent for obtaining particles. The PVP solution in ethanol resulted 
in fibre formation as ethanol is more volatile and evaporated more readily and 
hence left the solution more viscous (noticed by observation) (Pillay et al., 2013). 
In addition to the solvent, the molecular weight of polymer also affects the fibre or 
particle production.  
To investigate whether the fibres observed in figure 2.7 were due to the PVP or PCL 
in the samples, a co-axial electrospraying experiment was carried out by keeping 
PVP (in water) in both the core and shell. A representative SEM micrograph from 
those samples is shown in Figure 2.9.   
                              
Figure 2.9. SEM of sample CPV2H 5% solution was used in the shell with flow rate of 
1.5 mL/hr and 3% solution was used for the core with flow rate of 0.25 mL/hr: at a 
15 kV voltage and 10 cm tip to collector distance.  
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The SEM image shown in figure 2.9 indicated that PVP is most likely responsible for 
the production of fibres, in addition to coating the PCL nanoparticles. However, this 
is not definitive.   
These initial experiments demonstrated that fibre-free samples containing both 
PVP and PCL were challenging to make. Recent work indicated that lower 
concentrations and lower molecular weights were likely to favour (nano)particles 
over nanofibres (Gómez-Mascaraque et al., 2016). Therefore, it was decided that 
the next stage of the project was to work on lower molecular weight PVP (40 and 
10) and PCL (10-14).   
In this section of the report, the work carried out on lower molecular weight of PVP 
40 (MW 40,000), PVP 10 (MW 10,000) and PCL 10-14 (MW 10-14,000) is discussed.   
The first lower molecular weight (MW) polymer investigated in this part of the 
study was the target shell polymer, PVP. The earlier studies described in the 
previous section had used PVP with a MW of 360,000. The PVP chosen for this part 
had a significantly lower MW of 40,000 (PVP 40). Our initial focus in this part of the 
project was to investigate whether we could generate fibre-free particles. For that 
aim, it was decided to keep the system as simple as possible, so co-axial 
electrospraying was attempted using both PVP (in distilled water) as the core and 
the shell fluids. A range of solutions with concentrations between 8-10% (w/v) of 
PVP 40 dissolved in distilled water were electrosprayed. However, all these samples 
led to spitting and dripping rather than electrospraying. The solvent was then 
changed from distilled water to ethanol, in a similar manner to Kostakova (2012) 
who had successfully electrosprayed PVP 40. A range of samples were collected 
under varying electrospraying conditions (table 2.1) where the observation 
‘spitting’ refers to an unstable spray whereas ‘dripping’ is the formation of larger 
droplets. Electrospraying or spraying is therefore the target, which achieves a 









(mL hr-1)  
  
Distance (cm) 






Observation   
CPV2M 1  0.25  1  10  19  Electrospraying  
(getting 
particles)  
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CPV2M 2  0.25  1  20  10  Spitting (drops 
were collecting 
on foil)  
CPV2M 3  0.25  1  20  11  Spitting + 
spraying  
CPV2M 4  0.25  1  20  12  Spitting + 
spraying  
CPV2M 5  0.25  1  20  13  Spitting + 
spraying  
CPV2M 6  0.25  1  20  14  Spitting + 
spraying  
CPV2M 7  0.25  1  20  15  Mostly spraying 
then spitting  
CPV2M 8  0.25  1  20  16  Electrospraying  
CPV2M 9  0.25  1  20  17  Electrospraying  
CPV2M 10  0.25  1  20  18  Electrosraying  




CPV2M 12  0.25  1  20  20  Electrospraying  
+ some dripping  
CPV2M 13  0.25  1  30  10  Dripping  
CPV2M 14  0.25  1  30  11  Fast spraying  
CPV2M 15  0.25  1  30  12  Fast  spitting 
 &  
Electrospraying  
CPV2M 16  0.25  1  30  13   Spitting  &  
Electrospraying  
CPV2M 18  0.25  1  30  15   Spitting  and  
Electrospraying  
CPV2M 19  0.25  1  30  16  Spraying and 
spitting  
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CPV2M 20  0.25  1  30  17  Spraying and 
spitting  
CPV2M 21  0.25  1  10  20  Spraying and 
spitting  
CPV2M 22  0.25  1  30  19  Electrospraying  
CPV2M 23  0.25  1  30  20  Electrospraying  
 Table 2.1. Processing parameters used for CPV2M of 5 % (w/v) solution in ethanol.  
  
A representative SEM micrograph from table 2.1 is given in figure 2.10 and the rest 
are given in appendix E.  
                                  
                            Figure 2.10. SEM of sample CPV2M 1 from table 2.1.                     
It is clear from figure 2.10 that 40,000 M.W PVP gave fibre-free donut shape 
particles, which are rather similar in size (around 500 µm). Similar samples were 
made using PVP 10. Again, experiments initially focussed on electrospraying where 
both the core and shell fluids comprised of PVP 10 in ethanol. A representative SEM 
micrograph is shown in figure 2.11. 
 
                        
                                 Figure 2.11. SEM of sample CPV2L 8 in table 2.3.    
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It is apparent from figure 2.11 that the resulting NPs (from PVP 10) were more 
regular shaped and smaller (some are less than 100 nm) than those obtained with 
PVP 40. It was therefore decided to focus on PVP 10 in greater detail.  
  
Co-axial electrospraying was carried out using 3-6% (w/v) solutions of PVP 10. A 
wide range of processing parameters was used for each concentration of polymer 
solution. The details of the processing parameters are given in tables (2.2-2.5). 
During these investigations, the effect of concentration on morphology and particle 
size was assessed.  









(mL hr-1)  
  
Distance (cm) 
from tip of 
needle to 
collector  
         
Voltage 
(kV) of the 
apparatus  
Observation  
CPV2L 1  0.25  1.00  10.00  10.00  Spitting  
CPV2L 2  0.25  1.00  10.00  15.00  Spitting +spraying   
CPV2L 3  0.25  1.00  10.00  20.00  Spitting +spraying 
collecting sample  
CPV2L 4  0.15  0.75  10.00  10.00  Spitting + spraying  
CPV2L 5  0.15  0.75  10.00  15.00  Spitting less 
+more spraying 
collecting sample  
CPV2L 6  0.15  0.75  10.00  20.00  Spraying 
 (collecting 
sample)  
CPV2L 7  0.25  1.00  20.00  10.00  Spitting +spraying   
CPV2L 8  0.25  1.00  20.00  15.00  Spitting   
CPV2L 9  0.25  1.00  20.00  20.00  Electrospraying 
and spitting  
CPV2L 10  0.15  0.75  20.00  10.00  Dripping  
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CPV2L 11  0.15  0.75  20.00  15.00  Spitting +spraying  
CPV2L 12  0.15  0.75  20.00  20.00  Spitting +spraying  
CPV2L 13  0.25  1.00  30.00  10.00  dripping  
CPV2L 14  0.25  1.00  30.00  15.00  spitting +spraying  
CPV2L 15  0.25  1.00  30.00  20.00  spitting +spraying  
CPV2L 16  0.15  0.75  30.00  10.00  dripping +spitting  
CPV2L 17  0.15  0.75  30.00  15.00  spitting +spraying  
CPV2L 18  0.15  0.75  30.00  20.00  spitting +spraying  
  






(mL hr-1)  
  
PVP flow 








(kV) of the 
apparatus  
Observation  
CPV2L 1  0.25  1.00  10.00  10.00  Spitting +spraying  
CPV2L 2  0.25  1.00  10.00  11.00  Spitting +spraying  
CPV2L 3  0.25  1.00  10.00  12.00  Spitting +spraying  
CPV2L 4  0.25  1.00  10.00  13.00  Sparking  
CPV2L 5  0.25  1.00  10.00  14.00  Spitting +spraying  
CPV2L 6  0.15  1.00  10.00  15.00  Spitting +spraying  
CPV2L 7  0.15  1.00  10.00  16.00  Spitting +spraying  
CPV2L 8  0.15  1.00  10.00  17.00  Spitting +spraying  
CPV2L 9  0.25  1.00  10.00  18.00  Spitting  
CPV2L 10  0.25  1.00  10.00  19.00  Dripping  
CPV2L 11  0.25  1.00  10.00  20.00  Spitting +spraying  
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CPV2L 12  0.25  0.75  10.00  20.00  Mostly spraying  
CPV2L 13  0.25  0.75  10.00  15.00  Fast dripping  
CPV2L 14  0.25  0.75  10.00  10.00  Dripping  
CPV2L 15  0.25  1.00  20.00  10.00  Dripping  
CPV2L 16  0.25  1.00  20.00  15.00  Drpping  
&electrospraying  
CPV2L 17  0.25  1.00  20.00  20.00  Dripping  &  
electrospraying 
collected sample  
CPV2L 18  0.25  0.75  30.00  15.00  Spitting  &  
electrospraying  
CPV2L 19  0.25  0.75  30  17  Spitting  
&electrospraying  
CPV2L 20  0.25  0.75  30  18  Spitting + spraying  
CPV2L 21  0.25  0.75  30  20  Spitting and 
spraying   
CPV2L 22  0.25  0.75  30  21  Spitting and 
spraying  
CPV2L 23  0.25  0.75  30  22  Spitting & spraying 
& sparking  
CPV2L 24  0.25  1  30  10  Dripping  
CPV2L 25  0.25  1  30  15  Spitting and 
spraying  
CPV2L 26  0.25  1  30  20  Spitting and 
spraying  
CPV2L 27  0.25  1  30  22  Spitting and 
spraying  
 CPV2L 28   0.25  1  30  23  Spitting and 
spraying  
& sparkimg  
  
      Table 2.3. Processing parameters used for CPV2L of 4% (w/v) solution in ethanol.  













 Distance (cm) 








CPV2L 1  0.25  1.00  30.00  21.00  Spitting + spraying  
CPV2L 2  0.25  1.00  30.00  22.00  Spitting + spraying  
CPV2L 3  0.25  1.00  30.00  23.00  Spitting + spraying  
CPV2L 4  0.25  1.00  30.00  24.00  Sparking  
CPV2L 5  0.25  0.75  30.00  20.00  Spitting + spraying  
CPV2L 6  0.15  0.75  30.00  20.00  Spitting + spraying  
CPV2L 7  0.15  0.75  30.00  22.00  Spitting + spraying  
CPV2L 8  0.15  0.75  20.00  15.00  Spitting + spraying  
CPV2L 9  0.25  1.00  20.00  15.00  Spitting + spraying  
CPV2L 10  0.25  1.00  20.00  16.00  Spitting  
CPV2L 11  0.25  1.00  20.00  17.00  Spitting + spraying  
CPV2L 12  0.25  1.00  20.00  18.00  Spitting + spraying  
CPV2L 13  0.25  1.00  20.00  19.00  Spitting + spraying  
CPV2L 14  0.25  1.00  20.00  20.00  Spitting + spraying  
CPV2L 15  0.25  1.00  20.00  21.00  Spitting + spraying  
CPV2L 16  0.25  1.00  20.00  22.00  Spitting + spraying  
CPV2L 17  0.25  1.00  10.00  10.00  Fast spitting (fast 
spraying)  
CPV2L 18  0.25  1.00  10.00  15.00  Spitting  
CPV2L 19  0.25  1.00  10.00  16.00  Spitting  
CPV2L 20  0.25  1.00  10.00  17.00  Spitting + spraying  
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CPV2L 21  0.25  1.00  10.00  18.00   Spitting  and  
spraying   
CPV2L 22  0.25  1.00  10.00  19.00  Spitting  and  
spraying  
CPV2L 23  0.25  1.00  10.00  20.00  Spitting (very less)  
+electrospraying  
  
                   Table 2.4. Processing parameters used for CPV2L of 5% (w/v) solution in 
ethanol.  










(mL hr-1)  
  
 Distance (cm) 
from tip of 
needle to 
collector  





CPV2L 1  0.25  1.00  10.00  10.00  Spitting + spraying 
(got inside and 
outside circle  
because of 
dripping  
CPV2L 2  0.25  1.00  10.00  15.00  Spitting + spraying  
CPV2L 3  0.25  1.00  10.00  16.00  Spitting + spraying  
CPV2L 4  0.25  1.00  10.00  17.00  Sparking  
CPV2L 5  0.25  1.00  10.00  18.00  Spitting + spraying  
CPV2L 6  0.25  1.00  10.00  19.00  Spitting + spraying  
CPV2L 7  0.25  1.00  10.00  20.00  Spitting + spraying 
collecting sample  
CPV2L 8  0.15  0.75  10.00  20.00  Spitting + spraying 
collected sample  
CPV2L 9  0.25  1.00  20.00  10.00  Dripping  current  
zero  
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CPV2L 
10  
0.25  1.00  20.00  15.00  Spitting + spraying  
CPV2L 
11  
0.25  1.00  20.00  20.00  Spitting + spraying  
CPV2L 
12  





0.25  1.00  30.00  15.00  Spitting + spraying  
CPV2L 
14  
0.25  1.00  30.00  20.00  Spitting + spraying  
                 
                Table 2.5. Processing parameters used for CPV2L of 6% (w/v) solution in 
ethanol.  
  
The samples collected at a voltage of 20 kV with 10 cm distance were the only ones 
that were successfully electrosprayed. A representative SEM and frequency 
distribution of particle size is shown  
In figure 2.12a1. Figure 2.12a2 shows a SEM micrograph from the same sample as 
that shown in figure 2.12a1, but in a region that is more densely populated with 
particles. This picture showed the effect of it on particle size and other properties. 
The rest of the images of these samples are given in appendix F.   
  
                    
Figure 2.12. (a1) SEM of particles (b1) frequency distribution graph of particles 
obtained for sample CPV2L 11 from table 2.3. (a2) SEM and (b2) frequency 
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distribution graph (but with a different scale from b1) of a dense area of same 
sample, showing that the average particle diameter is essentially independent on 
the particle density of the sample.   
  
A comparison of figure 2.12b1 and figure 2.12b2 indicates that the diameter of 
particles in dense and sparse areas are similar but the ratio of numbers of particles 
that lie in the 0 – 200 nm or 200 - 400 nm ranges are different.       
           
SEM micrographs of the 3-6% (w/v) solution of PVP 10 shows that the 
concentration of the polymer solution does not make a large difference to the 
particle size (the SEMs are given in appendix F).                
                         
The size distribution of particles containing minimum particle size diameter, 
maximum particle size diameter and mean ± SD of all processed images obtained 














































CPV2L 11  2.14 in table 
2.3  
100.00   50.82  460.19  178.6 ± 80.8  
CPV2L 11  2.15 in table 
2.3  
100.00   65.93  684.50  185.25 ± 72.5  
CPV2L 12  F1 in table 2.3  100.00   21.98  447.44  180.45 ± 79.3  
CPV2L 23  F2 in table 2.4  100.00   45.44  352.72  177.17 ± 74.04  
CPV2L 7  F3 in table 2.5  100.00   22.47  1033.00  186.45 ± 156.09  
CPV2L 8  F4 in table 2.5  100.00   22.47  638.15   
CPV2L 3  F5 in table 2.2  100.00   16.66  290.91   
  
Table 2.6. Size distribution of 100 particles from samples of CPV2L. The data was obtained from 
Image J and processed through Graph Pad Prism.  
The minimum particle size was found to be 16.66 nm as per data compiled from 7 
samples in table 2.6. In this project, the aim was to produce particles less than 100 
nm and, according to the data compiled in table 2.6, this aim has been achieved.   
All the samples recorded in Table 2.6 have a minimum diameter less than 100 nm 
with the mean of all samples found to be less than 201 nm. The maximum particle 
size was found to be 1033.00 nm. The D'Agostino & Pearson normality test was 
carried out for all sample mentioned in table 2.6. The sample shown in figure 2.12 
failed the normality test, presumably because of outlier large particles.   
After successful production of PVP 10 nanoparticles, PCL 10-14 was incorporated in 
PVP 10 nanoparticles. As the aim of this research project was the production of PCL 
nanoparticles, PCL 10-14 was used in the core and PVP 10 was selected for the 
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formation of the shell of the particles. An SEM image of the sample CPVCL is given in 
figure 2.13.   
               
Fig 2.13. (a) SEM and (b) frequency distribution graph of sample CPVCL obtained 
from 4% PVP 10 in shell (with flow rate of 0.25 mL/hr) and 4% PCL 10-14 in core 
(with a flow rate of 1.0 mL/hr) with 10 cm tip to collector distance and voltage of 
20 kV.   
The diameter for 100 particles of sample CPVCL was determined using Image J. The 
minimum particle diameter was found to be 29.85 nm; the maximum particle 
diameter was 422.41 nm and mean of the sample was   ̃180 nm. PVP/PCL particles 
in figure 2.13 passed all the normality tests, which means the frequency 
distribution graph is bell shaped and the data is normally distributed.  
The results of this research work confirmed that we produced nanoparticles much 
smaller than reported before. Liposomal nanoparticles have been used as a drug 
delivery system. According to Wilczewska and coworkers (2012), most of liposomal 
particles range from 80 – 300 nm. Park et al. (2009) used PEGylated PLGA 
nanoparticles for the improved delivery of doxorubicin, where the average 
diameter of particles was 130 nm. Bilensoy et al. (2009) studied various 
nanoparticles for the delivery of mitomycin C for bladder tumours. The average size 
of chitosan particles was 291 nm, and PCL nanoparticles used had an average size 
of 179 nm, Poly-L-lysine-PCL nanoparticles diameter was 190 nm, and Chitosan-PCL 
nanoparticle size was 336 nm. Particles produced in this project are smaller than 
the work published by Wilczewska in 2012.  
A range of tests were carried out to confirm the presence of PCL inside PVP 
particles. These are summarised below.  
The SEMs of the dried distilled water and NaOH treated pellet are given in figures 
2.14a1 and 2.14b1, respectively. The procedure of collection of this sample is given 
in section 2.3.5.1. The SEM of the material did not confirm the presence of PCL 
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nanoparticles. One of the reasons could be that NaOH hydrolysed the PCL polymer 
backbone (McInnes et al., 2018). The effect of 0.5 M and 2.5 M NaOH was directly 
observed on PVP/PCL particles, by applying 100 µL of NaOH solution and observing 
the changes by SEM. SEM images of the samples are given in figures 2.14a2 and 
2.14b2, indicating loss of all particulate material, and hence treatment with NaOH 
was not found useful for the separation of PCL particles.  
                
Figure 2.14. SEM of sample CPVCL, obtained from 4% PVP 10 and 4% PCL 10-14 with 
10 cm tip to collector distance and flow rate of 0.25 mL/hr for core and 1mL/hr for 
shell and voltage of 20 kV. The sample was dissolved in distilled water and 
centrifuged the pellet was dispersed in (a1) distilled water and (b1) NaOH. The 
same sample of particles were directly treated with NaOH on foil (a1) 0.5 M and 
(b1) 2.5 M.  
Brilliant green dye was incorporated in PCL solutions to aid identification of PCL 
nanoparticles, as NaOH treatment failed to separate PCL particles from the 
preparations. The dissolution of different dyes was tested in PCL solutions. Brilliant 
blue was found to be insoluble in 1,2-dichloroethane, the solvent used to make the 
PCL solution. Brilliant green dye was used by Loon and Barefoot (2003) at 0.05% 
(w/v), which was found to be soluble in PCL solution. 0.026% and 0.05% (w/v) of 
brilliant green were used in this experiment. The dye was incorporated in 4% PCL 
solutions, the electrospraying was carried out with same conditions as mentioned 
in figure 2.13. Samples were collected on foil and both samples were dissolved in 
few mL of distilled water. Samples were transferred in eppendorf tubes and 
centrifuged at 25000 g at 22 0C for 10 minutes. The SEM of the pellet did not 
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confirm the presence of PCL particles. The result obtained from treatment of CPVCL 
nanoparticles remained inconclusive.  
Further experiments were carried out to confirm the presence PCL in the core of 
particles. Rhodamine b, which is a fluorescent dye (Yilmaz and Soylak, 2018) was 
selected, as this dye gives a neon yellow light when exposed to ultraviolet light. 
Firstly 0.05% (w/v) of dye was incorporated into a preparation of CPVCL. The flow 
rate of PCL was kept the same (0.25 mL/hr) as mentioned in the figure 2.13. The 
pink colour dye confirmed that the flow of PCL is not continuous, and IR and NMR 
did not confirm PCL presence in the sample, due to which the flow rate of PCL was 
increased to 0.5, 0.75 and 1 mL/hr.   
The SEM of the samples run at flow rate of 0.75 mL/hr with 10% PCL is given in 
figure 2.15. The SEM showed that electrospraying did not produce particles at the 
higher flow rate.        
                
Figure 2.15. SEM of sample CPVCL, obtained from 4% PVP 10 with flow rate of 1.5 
mL/hr and 10% PCL 10-14 core with flow rate of 0.75 mL/hr at 18 kV voltage and 
10 cm tip to collector distance.  
  
2.3.1.1 Characterization   
 2.3.1.1.1  Infrared (IR) Spectroscopy  
IR spectroscopy is a classical tool used for the determination of the structure of 
molecules. The chemical composition and architecture of molecules is sensitive to 
IR light (Barth, 2007). IR spectroscopy results from the vibration of atoms and 
bonds in a molecule, in which the fraction of incident radiation is absorbed at a 
specific energy. During this work, it was primarily used to elucidate the presence or 
absence of a polymer. To this aim, the IR of a pure sample of PCL and PVP and CPVCL  
sample (with low flow rate 0.25 mL/hr of PCL in core) nanoparticles was obtained 
to confirm the presence of both in that same  sample (figure 2.13). Table 2.7 shows 
the absorption band of representative functional groups in PCL and PVP.  
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Figure 2.16. Comparison of IR of CPVCL (sample in figure 2.13), PVP 10 and PCL 10-
14.   
  
Absorption band  (cm-1)  Functional group  Reference  
PCL  
2940-2860       C-H    
   (Abderrahim et al., 
2016)  
1722       C=O  
1238       C-O-C (asymmetric)  
1160       C-O-C (Symmetric)  
                                                                                    PVP   
1645        C=O    
       (Gutul et al., 2014).  1287.6, 1437.8, 1422.4        C-N, attachment of 
CH2 in pyrrole ring  
                      
Table 2.7. The table shows the absorption bands of representative functional 
groups in PCL and PVP.                            
The peak at 1645 cm-1 for CPVCL in figure 2.16 resembles the C=O peak of PVP in the 
same figure. The other absorption bands at 1280 cm -1, 1422 cm-1 and 1437cm-1 for 
CPVCL resemble the peaks in the PVP spectrum around the same wavenumber for 
the C-N stretch. The distinctive peaks of PCL spectrum were not found in the CPVCL 
  69  
spectrum. Due to this, NMR was carried out to further investigate the presence (or 
absence) of PCL in this sample.  
The FTIR spectrum of sample CPVCL   prepared with a high flow of PCL (0.75 mL/hr) 
in the core, compared with PCL 10-14 and PVP 10 IR is given in figure 2.17.   
                                           
Fig 2.17. Comparison of IR of CPVCL (sample in figure 2.15), PVP 10 and PCL 10-14, 
indicating the presence of PCL in the CPVCL preparation.  
The comparison of IR of PCL 10-14, and PVP 10 with CPVCL at a high flow rate of PCL 
(0.75 mL/hr) confirmed that the absorption bands at 2940 cm-1 and 2860 cm -1are 
due to the C-H groups and at 1722 cm-1 is due to a stretching vibration of the ester 
carbonyl (C=O) in CPVCL . These match with peaks in the IR spectra of PCL, suggesting 
that PCL is present in the sample. The absorption band at 1645 cm1  in CPVCL  was 
assigned to C=O group which resembles the peak in the PVP spectrum. This shows 
that both PCL and PVP are present in the sample CPVCL (in figure 2.13), which 
clarifies that an increased flow rate affected the sample composition and enhanced 
incorporation of PCL in the particles.  
  
                                       2.3.1.1.2 Nuclear Magnetic Resonance (NMR)  
This technique is widely used for the analysis and identification of the organic 
compounds. 1H NMR was carried out in this section, which determines the chemical 
environment of protons in a compound (Balci, 2005).  
NMR spectra of pure samples of PCL and PVP, and of CPVCL nanoparticles prepared 
at low flow rate 0.25 mL/hr of PCL, were obtained to confirm the presence of both 
PCL and PVP in CPVCL (figure 2.13). The NMR spectrum showed four peaks in the 
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case of PCL, as shown in figure 2.18, but the peak at 4.06 ppm (e), which represents 
the two methylene protons adjacent to the carboxylic acid group, is distinctive. The 
other peaks for PCL are further upfield, and less significant for comparative 
purposes as these are more likely to overlap with the peaks from PVP.   
The comparison of 1H NMR spectra of PCL, PVP and CPVCL particles in figure 2.18 
clearly showed that the CPVCL sample contains PVP, but it did not confirm the 
presence of PCL, because the distinctive peak of PCL at 4.06 ppm is not seen in the 
CPVCL sample.  The pattern of peaks found in the CPVCL spectrum resembles d the 
pattern of PVP NMR peaks in figure 2.18. Both IR and NMR analysis indicate that 
particles prepared at a low flow rate (0.25 mL/hr) of PCL in the core did not contain 
detectable amounts of PCL.  
                             
Figure 2.18 1H NMR of PCL, PVP and sample CPVCL (PVP/PCL coaxial particles with 
low flow rate that is  
0.25 mL/hr of PCL) run in CDCl3 for sample in figure 2.13 (SEM).            
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Figure 2.19. 1H NMR of PCL, PVP and sample CPVCL (SEM in figure 2.15, the PCL was 
used in the sample at a high concentration (10%) and high flow rate, 0.75 mL/hr, 
4% PVP was used with flow rate of 1.5 mL/hr).  
When the flow rate and concentration of PCL is increased in the coaxial 
electrospraying experiment both the 1H NMR and IR (Figure 2.19 and 2.17) 
obtained from those samples confirms the presence of PCL but the SEM (figure 
2.15) confirmed that the sample consists of lumps rather than nanoparticles.  
  
  2.3.2 Electrospraying of polymer in to distilled water   
The plan of this work was to obtain PCL particles of smaller size, using a coaxial 
electrospraying strategy with water-soluble PVP as the shell polymer. Given the 
difficulties, described above, of generating core-shell nanoparticles that retain PCL, 
it was decided to attempt collection of particles into water directly, following a 
technique described by Luo et al. (2015).  The particles would be generated with 
the higher flow rate of PCL, which allows the PCL and PVP components to remain 
together. As the shell polymer PVP is water soluble, the hope was that the PVP from 
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CPVCH particles would dissolve in water, leaving free PCL particles that could be 
collected directly.   
The presence of particles collected after electrospraying into water was 
determined using dynamic light scattering (DLS). In these experiments coaxial 
electrosprayed material was collected in an aqueous solution of 5% (w/v) SDS, in 
which the SDS acts as an excipient. Samples (CPVCH) with concentrations of 0.25% -
5% (PCL) and 5 % or 10% (PVP) were used for particle size measurement. A 
representative graph is given in figure 2.20.   
                     
Figure 2.20. DLS graph of sample CPVCH. 10% PVP (in core 0.5 mL/hr and in shell with 
1.5 mL/hr flow rate) at 20 kV voltage with 6.5 cm tip to surface of SDS solution.  
Figure 2.20 shows two main particle size distributions, one at around 1.5 nm and 
the other at approximately 100 nm. The first peak is representative of SDS for which 
the hydrodynamic radius of micelles in solution (in the absence of added salt) is 
known to be around 1.95 nm (Missel et al., 1980). The second peak is possibly due 
to PVP-SDS aggregates. This has previously been observed by Prasad et al. (2006) 
for PVP40 and SDS where the hydrodynamic radius was found to increase with an 
increasing SDS concentration (specifically, from 108 nm at 4.15 mM, i.e. half the 
CMC (critical micelle concentration), to 158 nm at 24.9 mM) (Prasad et al., 2006). 
The DLS graph of a further sample is given in figure 2.21, where three particle size 
distributions are seen. This is typical of the DLS graphs obtained for this set of 
samples.  
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Figure 2.21. DLS graph of sample CPVCH. 4% PCL (in core with 0.5 mL/hr flow rate) 
and 5% PVP (in shell with 1.5 mL/hr flow rate) at 20 kV voltage with 6.5 cm from 
the tip to the surface of the SDS solution.   
As with figure 2.20, the two extreme particle size distributions (~1.5 nm and 200 
nm) are still seen; however, a third peak denoting another particle size can also be 
seen at ~ 50 nm, for which we postulate that it could potentially be due to 
suspended PCL nanoparticles. The comparison of the result of electrospraying into 
liquid with already published work, shows that Luo et al. (2015) used static solvent 
displacement to collect near-monodisperse polymeric particles with diameters 
between 100 nm and 10 μm. Pinto Reis et al. (2006) achieved a 50–300 nm size 
range of monodisperse polymeric NPs by solvent displacement.  
After the collection of PCL particles in the liquid, the separation of these particles 
from water remained a significant challenge.   
                                         
2.4 Conclusion  
Electrospraying parameters play an important role in the production of 
nanomaterial but the molecular weight of polymer and the nature of the solvent 
both have a significant effect on production of particles as well. PVP 360 and PCL 
45 both produce fibres, however low molecular weight PVP (10 & 40) had fewer 
entanglements and hence it can produce fibre free particles. Low molecular weight  
PVP therefore successfully gave nanoparticles with less than 100 nm diameter, but 
the formulation of PCL (10-14) nanoparticles remained a challenge and there were 
problems in identifying the presence of PCL in the particles produced.  
The electrospray precipitation technique, which involves electrospraying directly 
into aqueous media, described by Luo et al. (2015), gave smaller nanoparticles in 
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comparison to either electrospray or agitated solvent displacement alone. This 
technique enabled us to get particles less than 100 nm, compared with the more 
standard electrospray technique producing particles of around 4-5 µm. The same 
molecular weight of both polymers was used in electrospray precipitation and 
these experiments gave particles less than 100 nm. This suggest that electrospray 
precipitation can give smaller particles than electrospraying on foil. The particle 
size can be further decreased by the adding surfactant and reducing the 
concentration of polymer solution further. However, the collection of 
nanoparticles from the solvent (distilled water) remained a challenge, even when 
the solvent was centrifuged at high RCF (relative centrifugal force).  
Due to time constraints further work on this aspect of the project was abandoned 
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                                              Chapter 3 
Preparation and characterization of novel formulation of hemin 
for better management of anaemia 
 
3.1 Introduction  
Iron is the most abundant element on planet Earth.  According to estimates, the 
core of the Earth is predominantly composed of iron and nickel, and the 6% of 
Earth’s mantle is also compos 
ed of iron. Similarly, iron is abundant in the human physiological system and it is an 
essential element required (Himmelfarb, 2007).  
In 1932, it was established that iron is required for the synthesis of hemoglobin, 
which is a carrier of oxygen in humans (McDowell, 2017). It has been recognized 
that iron is required for numerous physiological processes, such as transport of 
oxygen, synthesis of deoxyribonucleic acid (DNA) and transport of electrons in the 
production of ATP (Abbaspour et al., 2014).   
The importance of iron for human life is further established by the health 
conditions which can result from its imbalance in the human body. Both its 
deficiency as well as its excess in the human body can lead to pathologies. Low iron 
can result in iron deficiency anaemia. Similarly, excess iron could lead to a condition 
known as haemochromatosis, in which the excess free iron can lead to the 
formation of free radicals which can cause tissue damage (Abbaspour et al., 2014).    
In the first part of the chapter, the absorption and utilisation of iron in the human 
body will be discussed briefly.   
  
3.1.1 Iron and its availability in diet  
Iron is vital for the synthesis of haemoglobin and myoglobin, flavin-containing iron 
enzymes, cytochromes, catalase, some hormones, and neurotransmitters 
(Abbaspour et al., 2014). The daily adult iron requirement is 8 - 18 mg, but only 1-
2 mg iron is absorbed, through the proximal intestine (duodenum) (Johnson-
Wimbley and Graham, 2011). The remaining iron required for normal body 
maintenance is recycled from the breakdown of senescent RBCs (Coad and Pedley, 
2014). In the diet, iron is present as heme (in the form of haemoglobin and 
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myoglobin, mainly from red meat), and non-heme forms from white meat, 
vegetables and cereals (Conrad and Umbreit, 2002). Components in the diet such 
as phytates and tannins can reduce, whereas ascorbic acid can increase, iron 
absorption (Fuqua et al., 2012; Lynch and Cook, 1980).  
  
3.1.2 Mechanisms of iron absorption  
Figure 3.1 describes the three molecular pathways for the intestinal iron 
absorption, involving the heme transporter HCP1, the transporter of divalent 
metals DMT1 and the integrin-mobilferrin pathway. Once the heme is internalised, 
heme-oxygenase degrades the heme and releases the iron (West and Oates, 2008).  
Hemin formulations used in this work will therefore be able to release the iron from 
the hemin inside the duodenal cells, which is described later in chapter 4.   
  
Figure 3.1. Intestinal pathways of iron absorption A) heme and non-heme iron is 
taken up enterocytes brush border. Non-heme iron is reduced to Fe2+ by the ferric 
reductase. Some of the non-heme iron transported in the form of Fe3+ via the 
integrin-mobilferrin pathway (IMP).] B) Heme iis transported via receptor mediated 
membrane endocytosis of HCP1, and heme Fe2+ is released by the heme oxygenase. 
Fe2+ is transported by the ferroportin to the cytoplasm. Fe3+ can be imported by the 
intergrin-mobilferrin  (IMP) complex, and then reduced to Fe2+.  
  
3.1.3 Regulation of iron absorption  
Iron is regulated closely in the human body, as both deficiency and excess, can be 
harmful (Kew, 2014). Hepcidin, a peptide produced by liver, exerts a negative 
control on the absorption of dietary iron by reducing the expression of DMT-1 
receptors in the duodenum (Bergamaschi et al., 2017). Another hormone, 
erythroferrone (ERFE) acts directly on the liver to decrease the hepcidin production 
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resulting in an increase in iron absorption (Hanudel et al., 2018), in response to an 
increased demand for red blood cell synthesis.  
  
  
            3.1.4 Transport and distribution of iron in the body  
Fe2+ is exported into the circulation through ferroportin. Hephaestin, a membrane-
bound ferroxidase converts Fe2+ to Fe3+.  Fe3+ binds to the plasma protein 
transferrin for transportation to the cells (Fuqua et al., 2012). See Figure 3.2.  
                                                            
Figure 3.2. Cycle of iron utilisation & distribution in human body diagram modified 
from “Distribution of Body Iron – All About Blood,” n.d.                                        
  
3.1.5 Iron deficiency anaemia and its impact on human health  
Anaemia is defined as a low oxygen-carrying capacity of RBCs,  or low hemoglobin 
concentration <13 g/dL in an adult male or <12 g/dL in an adult female (“Anaemia 
- iron deficiency - NICE CKS,” n.d. & (“WHO | Anaemia,” n.d.).   
The causes of iron deficiency anaemia (IDA) include poor diet, gastrointestinal 
bleeding, menstrual losses, malabsorption syndromes, or pregnancy (“Anaemia - 
iron deficiency - NICE CKS,” n.d.). Worldwide, IDA is one of the most significant 
nutritional problems (Yang et al., 2016). Anaemia could increase maternal mortality 
and morbidity, premature births and low birth weight, developmental delays 
(WHO, 2017). IDA is common in both underdeveloped and developed countries 
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3.1.6 Prevention of iron deficiency: Food fortification and its limitations  
Universal iron fortification of cereals has been attempted. However, there are 
concerns for example it will not be suitable for people with haemochromatosis, and 
bioavailability is limited (Waldvogel-Abramowski et al., 2014). A double-blind 
randomised control trial published by Zimmerman. et al. in 2010 showed that 
children who received iron fortified biscuits had higher levels of faecal calprotectin, 
increased enterobacteria and fewer microfloras (lactobacilli and bifidobacteria), 
but no improvement in anaemia/iron status.  
  
3.1.7 Parenteral iron supplements   
Intravenous (IV) preparations of iron are effective treatments for anemia, but are 
only administered at in-patients clinics where facilities are available.  Whilst 
generally successful, IV administration can sometimes have side effects such as 
anaphylaxis (Silverstein and Rodgers., 2004). Some of the common formulations 
used are iron dextran, iron sucrose, ferric carboxymaltose, and iron isomaltoside 
(Araya and Zaritsky, 2017).  
However, as there is evidence of significant side effects from IV iron transfusion, 
the Medicine and Healthcare Products Regulatory Agency (MHRA) published 
guidelines on its safety and use. The evidence suggests that intravenous iron does 
not result in a faster increase in haemoglobin production when compared to oral 
iron supplements, provided oral iron supplements are taken as advised and 
intestinal absorption is not affected (“British National Formulary (BNF) 70,” n.d.). 
Also, intravenous iron administration is associated with significant risk of serious 
hypersensitivity reactions. The hypersensitivity reactions are not only limited to 
first administration, in fact this could happen at any subsequent administration. 
Hence, every time, a person is having an intravenous iron administration, trained 
staff and resuscitation facilities should be available (“Intravenous iron and serious 
hypersensitivity reactions,” n.d.; Litton et al., 2013).   
Based on the above, in 2013 the MHRA published a document which suggested that 
intravenous iron should only be reserved for treatment when oral iron 
supplements are ineffective.   
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3.1.8 Oral iron supplements   
Oral iron supplements are widely used for the prevention and treatment of iron 
deficiency. There are various iron formulations available in the form of ferrous salts 
such as ferrous sulphate, ferrous fumarate, and ferrous gluconate (BNF, 2015). 
According to the BNF (2015), there is no significant difference between the various 
ferrous formulations in terms of absorption of iron.    
Ferrous sulphate is available as 200 mg tablets. Each 200 mg tablet of ferrous 
sulphate is equivalent to 65 mg of ferrous iron. The daily recommended dose for 
treatment for an adult is 130-195 mg ferrous iron (2-3 tablets) in divided doses, 
whereas the prophylactic dose is 65 mg ferrous iron (1 tablet) daily. Ferrous 
fumarate is available in tablet form, usually 210 mg. Each 210 mg tablet is 
approximating to 65-70 mg of elemental iron. The recommended dose of ferrous 
fumarate for iron deficiency anaemia is one tablet two to three times a day, 
whereas prophylactic dose is one tablet once or twice a day (“About the eMC - 
electronic Medicines Compendium (eMC),” n.d.).  
Fei (2015) looked at the intestinal absorption of the orally administered ferrous 
salts, and evidence suggests that only 10-15 % is actually absorbed (Fie, 2015).  In 
iron deficiency anaemia, there are low levels of stored iron in the body, so that 
higher daily doses are needed. According to the BNF (2015), the total dose of 
elemental iron needed to be given for IDA is 100 – 200 mg daily. Hence, this results 
in 2-3 daily doses of oral iron and it can cause GI (gastrointestinal) side effects such 
as heartburn, epigastric discomfort, nausea, constipation, diarrhoea, and 
constipation/faecal impaction. Thus, higher doses are associated with issues such 
as intolerance of oral formulations and reduced cost-effectiveness (Johnson-
Wimbley and Graham, 2011; Sazawal et al., 2006)  
According to Fei (2015), these side effects result in poor compliance with the 
treatment, which could be as low as 40-60%. The ferrous salts are best absorbed 
on an empty stomach but to reduce the side effects some patients take it with food; 
however, this may cause further deterioration in iron absorption (Abbaspour et al., 
2014).  
Animal trials have shown an increase in systemic infections, alteration of gut 
bacteria and changes in the pro-inflammatory signalling from gut epithelium 
following treatment with iron supplements (Carrier et al., 2002). Kortman et al. 
(2012) evaluated the impact of iron supplements on the gut bacterial flora.  The 
importance of gut flora (the microbiome) is well established and is known to affect 
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the immune system and provide protection against pathogenic microbes.  An in 
vitro experiment was designed by Kortman et al. (2012) using the differentiated 
monolayers of intestinal epithelial cell lines. Characteristics such as bacterial 
attachment, infiltration and translocation were studied using a panel of enteric 
pathogens. The panel was exposed to iron rich conditions. The results of the 
experiment suggested oral iron supplements can increase growth and virulence of 
enteric pathogens.   
Supplements with the ferric form of iron are better tolerated but have poor 
absorption (Seril et al., 2002). As we have seen in previous sections that the ferrous 
form of iron is more soluble than the ferric form (“Iron Deficiency Anemia,” n.d.). 
Chelation has been considered to improve the bioavailability of ferric iron; 
however, it has shown increased risk of colon cancer in rodents (Seril et al., 2002). 
The WHO recommend the use of ferrous over ferric salts due to better 
bioavailability, in which 10 – 15 % of iron is absorbed. The ferric form has poor 
solubility in an alkaline environment and needs to be converted to the ferrous form 
before being absorbed, and the bioavailability is 3 – 4 times less than ferrous salts 
(Santiago, 2012).   
Therefore, tailoring the iron in a nano formulation could help to overcome above 
mentioned issues. This research describes efforts to develop a novel oral iron 
preparation which could be better tolerated with improved bioavailability 
compared with formulations currently available.   
  
3.1.9 Developments in iron supplements  
Due to the disadvantages and side effects of available iron supplements, 
researchers are constantly working to develop formulations which are safer and 
have improved bioavailability.   
Pereira et al. (2014), developed organic acid-modified Fe(III) oxo-hydroxide 
nanomaterials. The preparation of iron hydroxide adipate tartrate (IHAT) showed 
~80% relative bioavailability when compared to Fe(II) sulfate in humans. IHAT did 
not accumulate in the intestinal mucosa and promoted a beneficial microbiota. 
Also, the research showed that IHAT is less toxic than Fe(II) sulfate/ascorbate.   
Latunde-Dada et al. (2014), assessed the efficacy of IHAT on iron-deficient and iron-
sufficient Swiss mice. The mice were given ferrous sulphate or nano Fe(III) [acidic 
concentrated solution of Fe(III) was added to adipic and tartaric acid solutions]. The 
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research showed that absorption of nano Fe(III) was significantly increased in iron-
deficient mice compared to iron-sufficient mice.   
Powell et al. (2014) studied 2-5 nm Fe(III) oxo-hydroxide, which is less ordered and 
more readily bioavailable compared to its pure synthetic analogue ferrihydrite. 
They co-precipitated, the ferrihydrite with tartrate inclusion, which resulted in 
stabilization of the cross links. The murine models showed that gastrointestinal 
uptake was independent of luminal Fe(III) reduction to Fe(II) and absorption was 
equivalent to that of ferrous sulphate. The side effect of ferrous sulphate was not 
found in Powell’s formulation. However, the bioavailability is not significantly 
better than the ferrous sulphate and crucially these are unstable in acidic 
environment, which poses a barrier for oral administration.  
Shafie et al. (2016) demonstrated that a single dose of nanoparticles containing iron 
showed more bioavailability compared to a single dose of ferrous sulfate, in rats in 
which iron deficiency anemia was induced. This was measured by levels of 
haemoglobin in control and experimental groups using the formulation from 
Powell’s group (Pereira et al. 2014).   
  
3.1.10 Potential of heme and hemin as an iron supplement   
Heme could be an alternative to inorganic iron supplements. It has a different 
absorption pathway by duodenal cells. The transporter for heme is not well 
characterized (Conrad and Umbreit, 2002; Gaitán et al., 2012). HCP 1 is primarily a 
folate transporter, but it has low affinity for heme transport as well (Le Blanc et al., 
2012).  
Heme is a prosthetic group, and it is present in cellular hemoproteins which execute 
diverse biological functions, such as: oxygen transport, oxygen sensing, cell 
respiration and metabolism, cell growth, cell self-renewal, and differentiation, all 
needed for survival and function of organisms (Tsiftsoglou et al., 2006).  
Heme and hemin structures are given in figure 3.3 a and b respectively. Heme is a 
metallo-compound, comprising of an iron atom bound to a tetrapyrrole ring system 
known as protoporphyrin, through its four nitrogen atoms. Iron in hemoglobin is in 
the ferrous (Fe2+) form, which allows reversible binding with molecular oxygen 
(Berg et al., 2002).   
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                             Figure 3.3. Structure of a) heme, b) hemin.  
Heme iron polypeptide (HIP) has been developed as a heme formulation derived 
from bovine haemoglobin and is highly soluble (Naraju et al., 2013).  It was seen 
earlier that there is a separate pathway for absorption of heme. Heme absorption 
is generally not affected by food; hence it can be taken on empty stomach or with 
food. The Canadian Agency for Drugs and Technologies published a review paper 
in 2007 comparing the efficacy of HIP, oral ferrous salts and IV iron. The paper 
concluded that the available evidence for HIP evaluation is limited and more 
research is needed to determine its efficacy. In a randomised control trial, patients 
with chronic kidney disease were given HIP or IV iron. The results showed that HIP 
had similar efficacy to IV iron in maintaining haemoglobin levels.  
However, patients who received IV Iron had higher levels of ferritin, the significance 
of which is unclear. Both HIP and IV iron had similar profiles of side effects 
(Nagaraju et al., 2013).  
Hemin is the oxidized form of iron protoporphyrin IX, which is an essential growth 
promoter (Tsiftsoglou et al., 2006). Structurally hemin contains a chloro ligand, 
which is not present in heme. Hemin is insoluble at neutral pH but is soluble in 
sodium hydroxide. In sodium hydroxide, the chloro ligand is substituted by a 
hydroxyl group, which results in the formation of hematin (Egan et al., 1999a).   
  
3.1.11 Development of new hemin supplement  
This research is aimed at developing an oral iron supplement with improved 
stability and bioavailability. Therefore, if hemin is used for oral iron supplements, 
it should be soluble in physiological media and able to resist the harsh environment 
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of the GI tract (Span et al., 2016a). The Lipinski rule of 5 determines whether a drug 
is orally active or not. According to the Lipinski rule of 5, it is not easy to make 
hemin soluble because its molecular weight and log P values are out of the range. 
As hemin is the poorly soluble drug, it needs to be delivered efficiently, which can 
be achieved with nano formulations.   
To achieve these objectives, Eudragit L 100 and PVP-360 were used in the initial 
experiments. PVP is very well tolerated, amphipathic, cost-effective, available in 
various sizes, has been used in health products for many years, and hence more 
data is available.   
PVP forms molecular adducts with substances, which can help solubilization or 
precipitation of some substances. This property of PVP was shown to enhance 
hemin solubility in physiological medium (Melent’eva et al., 1980).  
The use of electrospraying and electrospinning to create micro/nano particles and 
micro/nanofibers of the PVP and hemin to enhance its uptake, was investigated.  
  
3.2 Aim and objectives  
The aim of the research project was to gain insight into the characteristics that 
affect the uptake of nanofibres and their associated cargo (such as a drug with low 
bioavailability, hemin) by cells.   
To address the aim, the following objectives were attempted  
1. Development of ultra-fine nanofibres (diameters less than 100 nm) by 
electrospinning.  
2. Production of nanofibres and nanoparticles containing hemin.  
3. Measurement of hemin release from nanoformulaions. 
4. The treatment of cells with nanofibers/nanoparticles containing hemin, 
and to monitor hemin uptake by ferrozine assay of iron and Perls staining 
of iron in cells.  
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3.3 Material and methods  
               3.3.1 Materials   
Hemin (molecular weight= 651.9 Da) was purchased from Calbiochem. 
Polyvinylpyrrolidone (PVP) (average MW 360,000, 40,000 and 10,000 Da) was 
purchased from Sigma Aldrich. Poly(ethylene oxide) (PEO) (average MW 100,000 
Da) was purchased from Acros Organics. Poly(vinyl alcohol) (PVA) (average MW 
89,000-98,000 Da) analytical grade was obtained from Sigma Aldrich. MeOH 
(methanol), EtOH (ethanol), CHCl3 (chloroform), THF (tetrahydrofuran), DMAc 
(dimethylacetamide), DMF (dimethylformamide) were manufactured by Fisher, 
and were of analytical grade and Eudragit L 100 was bought from Fluka. All other 
materials were used of analytical grade and used as provided.  
  
 3.3.2  Methods   
                                  3.3.2.1 Preparation of electrospinning/ electrospraying solutions   
All solutions were % (w/v) unless otherwise stated. 10 % solutions of PVP were 
made in MeOH as it gave nice smooth fibers. However, this solution caused 
clogging on the electrospinning needle, presumably because MeOH is a low boiling 
solvent (64.7 0C) (Bertini et al., 1979). Subsequently DMF, which is a high boiling 
solvent, 153 0C,  (Admin, 2010) was used with MeOH in the ratio of MeOH:DMF 7:3 
to avoid this problem. Hemin solutions were made in DMF at 16.66 mg/mL. 15% 
PVP solutions were prepared in MeOH. Hemin in DMF, was added to the 15% PVP 
solution to achieve a final concentration of 10 % PVP with final ratio of MeOH and 
DMF 7:3. Hemin was added to the PVP solution to make a range of percentages 
from 0.1-5%. All solutions were stirred until completely dissolved. Solutions for 
electrospinning with Eudragit L 100 were made to 18.2% (w/v) in MeOH: DMAc 
(4:1) as this solvent combination gave smooth, particle-free fibers according to SEM 
and light microscopy. Hemin formulations with Eudragit L 100 were made with 26% 
Eudragit L 100 in MeOH: DMAc (4:1). Hemin was separately dissolved in DMAc 
(3.33mg/ml) and added to the 26% Eudragit L 100 solution to obtain 0.5 % hemin 
in 18.2 % of Eudragit l 100. The final ratio of MeOH to DMAc was 5:1. The use of 
other polymers is described in the results section 3.3.1.  
PVA nanofibers were successfully made by Nigadiman (2015), using deionized 
water as solvent. In this study PVA was mixed in deionized water to make 10% PVA 
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solution, then heated at 100 C̊ for two hours while mixing with a spatula, resulting 
in a thick paste.  
  
                                3.3.2.2 Single fluid electrospinning/electrospraying  
The electrospinning solution was loaded into a 5 mL syringe, avoiding the formation 
of air bubbles.  
The spinneret was attached directly to the syringe. Flow from the syringe was 
controlled by a ColeParmer pump (78-9100C). The negative, ground electrode of a 
high voltage DC supply (FuG Elektronik HCP 35 – 65000, supplied by Omiran Ltd, 
UK) was connected to the collector (dimension 20 X 20 cm) and the positive 
electrode to the spinneret. The collector was wrapped with aluminum foil. Polymer 
solution was ejected from the spinneret and voltage applied to the spinneret. The 
experiment was performed under ambient conditions at room temperature. An 
illustration of the electrospinning/electrospraying apparatus is given in chapter 
one, figure 1.2. The voltage range was 10-20 kV and the distance from tip to 
collector was kept between 12-15 cm.  
                                               
3.3.2.3 Dissolution studies   
In vitro dissolution tests were carried out for sets of PVP-360 fibers containing 
hemin in 10 mL or 100 mL of dissolution buffer. A standard dissolution apparatus 
was not used because it was not possible to prepare the large amounts of 
formulation, 6.52 g for 1 dm3, needed for each sample. Instead 65.2 mg of hemin 
PVP-360-1% fibers were added to 10 mL of isotonic phosphate-buffered saline 
(PBS), which when fully dissolved would create a 100 µM preparation of hemin. To 
measure the amount of dissolved fibers, duplicate 200 µl aliquots were collected 
up to 50 hrs as shown in the dissolution graphs in results and discussion section. 
The volume of the solution was maintained by addition of 400 µl of PBS. The 
aliquots were centrifuged at 14000 rpm to remove undissolved material then 180 
µl of supernatant was transferred to a 96 well plate. Hemin dissolution was 
assessed by absorbance at 400 nm in an Omega FLUOStar plate reader (BMG 
LabTech, Aylesbury, UK), based on peak absorption of the visible spectrum (Figure 
3.17). This experiment was repeated 3 times.   
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Dissolution of fibers was compared with controls of i) a physical mixture of PVP-360 
and hemin powders added to the dissolution medium, ii) dissolution of hemin in a 
solution of PVP-360 in PBS and iii) dissolution of hemin powder alone.  
Dissolution studies were done in the same pattern for preparations made with PVP-
40 and PVP-10 except particles were dissolved in situ on the collection foil rather 
than in a glass bottle, due to the low yields and stickiness of the material. The foil 
was folded from the side and the PBS was poured on to the sample. The solution 
was transferred to a centrifuge tube by pipette. The dissolution experiment was 
only done once for PVP-40 and PVP-10 as it was difficult to produce enough 
quantities of the material for analysis. To make the data reliable the experiment 
needs to be repeated at least twice.  
  
3.3.2.4 Characterization techniques of nanomaterial   
Precise characterization of nanomaterials made from electrospraying or 
electrospinning is crucial to associate nanomaterial physicochemical properties 
with cellular response. It is also essential for meaningful, accurate and reproducible 
results (Shang et al., 2014). In this part of the thesis different techniques used for 
characterization of hemin containing nanomaterials are discussed.  
  
 3.3.2.4.1 Infrared spectroscopy (IR)   
FTIR instrument and method for obtaining IR spectrum is given in section 2.2.2.1.  
  
 3.3.2.4.2 Ultraviolet-visible spectroscopy   
The UV-visible spectra of hemin preparations in PBS were obtained using a 
Shimadzu UV-1800 ultraviolet spectrophotometer over a wavelength range of 200-
600 nm. The spectra were used for measuring ʎmax for a range of concentrations 
of hemin, 10, 25, 50, 75, 100 and 500 µM, obtained by dissolution of PVP-hemin 
fibers with hemin content 0.1-5%. UV-visible spectra were also measured for 
preparations of PVP-40 and PVP-10 particles alone and with hemin. Spectra were 
also measured for the controls including fibers of PVP only, a physical mixture of 
PVP and hemin, hemin dissolved in a PVP solution and hemin alone in PBS. These 
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solutions were kept on a stirrer for five days before reading. Spectra were also 
taken of solutions of hemin in selected solvents.   
  
 3.3.2.4.3 X-ray diffraction   
The X-ray diffraction data was collected using a Philips PW1830 powder 
diffractometer operating at 40 kV and 25 mA, with Cu Kalpha radiation (ʎ=1.5418 
Å).  
 
 3.3.2.4.4 Energy dispersive X-ray spectroscopy (EDX/EDS)   
The instrument used for EDX was an Oxford Instruments Aztec Energy EDS control 
/ acquisition software, with Oxford Instruments Xmax50 (50 mm2) detector. EDX 
analysis was carried out at the Open University by Gordon Imalach.  
  
 3.3.2.4.5 Scanning electron microscopy (SEM)    
The instrument used for SEM was a Zeiss Supra 55VP FEGSEM. The imaging 
conditions were 3kV accelerating voltage, 20 micron aperture for good depth of 
focus, and high current mode for good resolution. Samples were mounted on 12 
mm diameter aluminium SEM stubs using carbon sticky tabs. Gold sputter-coating 
was achieved using a Polaron SC7640 sputter coater, with a coating time of 4060 
seconds to give 5-10 nanometres thickness coating. SEMs of all samples were 
carried out.  
  
 3.3.2.4.6  Microscopy   
An Olympus X81 light microscope used to take the images of fibers and particles at 
magnifications of 100x and 400x.  
  
 3.3.2.4.7  Dynamic light scattering   
A Malvern Zetasizer Nano-ZS system was used to measure the particle size of 
dissolved PVP preparations. 65.2 mg of PVP fibers only or PVP with hemin in 
different proportions, were dissolved in 10 mL of PBS or water. Each solution was 
  88  
stirred gently until the fibers were completely dissolved and 2 mL of solution was 
then transferred to a plastic cuvette. Three different data fitting algorithms were 
considered when fitting the normalized field autocorrelation functions obtained for 
each solution:    
(a) the general purpose (GP) NNLS (non-negative least squares) algorithm 
developed by Malvern as part of their proprietary software,   
(b) the CONTIN function, a well-known NNLS algorithm often used for DLS 
analysis, and  
(c)I    a triple exponential function.  
The triple exponential mentioned above is given by:  
                           𝑔(1)(𝜏) =  𝐴1 exp (−
𝑡
𝜏1
) + 𝐴2 exp (−
𝑡
𝜏2




Where the sum of the first two relative amplitudes 𝐴1 and 𝐴2 equals 1. The 
solutions were unable to be filtered and hence it is assumed that the third decay 
mode is likely to be due to dust and will not be considered further during the 
analysis.  
From application of the Stokes-Einstein equation for the diffusion coefficient (𝐷0):   
𝐷0 = 𝑘𝐵𝑇/6𝜋𝜂0𝑅𝐻  
 where 𝑘𝐵 is the Boltzmann constant (1.381 x 10-23 J K-1), 𝑇 is the temperature (here 
25 oC i.e. 298.15 K) and 𝜇 is the dynamic viscosity of the solvent (i.e. 8.90 x 10-4 Pa.s 






for which 𝑞2 reflects the distance the particle travels and can be calculated as:  
 








where 𝜆 = 633 × 10−9𝑚 and 𝜃 = 173°, the hydrodynamic radii (𝑅𝐻) can be 
obtained.   
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The triple exponential was found to fit well to the data here and therefore was used 
for detailed data analysis, although the Malvern GP NNLS algorithm is also used in 
this chapter for comparison purposes only.  
  
 3.3.2.4.8  Differential Scanning Calorimetry (DSC)    
A Mettler Toledo DSC822 Differential Scanning Calorimeter (maximum 700 ᵒC), 
with Mettler ‘Star’ software V.9 for control/acquisition/analysis, and Labplant 
RP100 Intracooler for sub-ambient cooling to -60 ᵒC was used in this research work. 
Maximum cell temperature is rated to 700 ᵒC but maximum operating temperature 
was limited by the sample pan material. Aluminium pans were used, limiting a safe 
maximum temperature to about 600 ᵒC. Heating rates were made variable up to 50 
ᵒC /min, though 10 ᵒC /min is a more common rate.  
   
 3.3.2.4.9 Measurement of iron content in fibers (Ferrozine Assay)  
This technique was adapted from a method used to measure total cellular iron by 
a colourimetric method using ferrozine (Fish, 1988) for cultured cells (Riemer et al. 
2004). It was used here to measure total hemin available in PBS, SIF (simulated 
intestinal fluid) and pH 2 solution after dissolving PVP-hemin nanofibers. 6.52 
mg/mL of fibers of PVP only or PVP with hemin in different proportions were 
dissolved in PBS and SIF. Each solution was stirred gently until the fibers were 
completely dissolved. Portions of the samples were spun at 12,000 rpm for 5 min, 
to remove small amounts of brown precipitate. The hemin was measured in both 
spun and unspun solutions and compared with standard FAS (ferrous ammonium 
sulphate) solution. 100 µL aliquots of each solution were treated with 100 µL of 
iron releasing solution made up of 4.5% (w/v) KMnO4 and 1.4 M HCl freshly mixed 
in a 1:1 ratio. The iron releasing solution digests proteins and heme to which iron 
is bound and releases the iron. Here this treatment was used to release iron from 
hemin wrapped in PVP. The samples were incubated at 60 0C for 2 hours in a 
heating cabinet. The samples were cooled to room temperature, and the volume 
of each sample was made up to 1.0 mL accurately with deionized water. 100 µL of 
iron detection solution (2.5 M ammonium acetate, 1 M ascorbic acid, 6.5 mM 
ferrozine) was added to each sample. The iron detection solution was made by 
adding 9.7 g ammonium acetate and 8.8 g ascorbic acid to about 10 mL of water, 
so that the volume was less than 25 mL. The mixture was heated for complete 
dissolution, 80 mg of ferrozine were dissolved, and the volume was adjusted to 25 
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mL (Riemer et al., 2004). The ascorbic acid in the iron detection solution reduces 
Fe3+ to Fe2+. It is the ferrous form of iron which binds to ferrozine and gives a purple 
colour (Jeitner, 2014; Riemer et al., 2004; Yamamoto et al., 2010).  The samples 
were centrifuged at 12,000 rpm for 5 mins. 200 µL centrifuged samples were taken 
for measurement of absorbance at 592 nm, with correction for light scattering at 
750 nm in a FluoStar Omega plate reader (BMG LabTech, Aylesbury, UK), in a 96-
well plate.  
Standards were prepared from a fresh solution of ferrous ammonium sulfate (FAS), 
made by dissolving 0.392 g of FAS in 10 mL of water to make a 0.1 M solution. Stock 
solutions of 1 mM and 100 µM were prepared by serial dilution in which 1 mL of 
each concentration was diluted 10 times by addition of 9 ml water. Standards were 
prepared and 100 µL of each standard was used for a standard curve.  
  
3.4 Results   
The aim of the work described in this report was to develop a formulation using the 
technique of electrospinning or electrospraying to create nano- / micro- sized 
formulations to improve the bioavailability of hemin, as a novel DDS (drug delivery 
system).   
  
 3.4.1  Development of a Hemin-Polymer formulation   
Hemin is poorly soluble in water and therefore a suitable organic solvent for 
electrospinning is needed.  
Also, in the initial phase of the work, a variety of polymers compatible with drug 
formulation were assessed, with the aim of identifying polymer and hemin mixes 
that could be prepared in compatible solvents.  
  
The solubility of hemin was checked in different solvents. Methanol, DMAc, DMF 
and THF were found to be good solvents for hemin. Hemin is partially soluble in 
EtOH as well. Solutions of hemin in THF, DMAc, MeOH, EtOH and CHCl3 are shown 
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THF                       DMAc                      MeOH                   EtOH                          CHCl3  
 5mg/mL            10mg/mL           10mg/mL            5mg/mL                     5mg/mL
 
  
Figure 3.4. Solubility of Hemin in different solvents. Hemin was completely soluble 
in THF, DMAc and MeOH at the concentrations indicated, and partially soluble in 
EtOH. Hemin was not soluble in CHCl3 and formed a layer at the top of the solvent.  
  
A selection of biocompatible polymers was assessed for suitability for the 
formulation. PVA (polyvinyl alcohol), PEO (polyethylene oxide), Eudragit L 100 and 
PVP-360 were investigated as materials for production of nanofibers by 
electrospinning.   
Attempts were made to prepare a solution of PVA in water (Nigadiman 2015) but 
the result was a paste of PVA contained bubbles which disappeared after a week. 
The paste did not remain stable for long as microbial growth was observed after 10 
days. The PVA paste was not suitable for electrospinning and behaved like an anti-
thixotropic material (behaves like a solid when force is applied). PVA was found to 
be insoluble in THF and DMF. For these reasons PVA was not investigated as a 
carrier for the hemin further. It is mentioned by Nigadiman (2015) as well that 
additional force was needed to extrude the solution from the syringe, due to the 
high viscosity.  
PEO did not dissolve in cool or hot water, but 20% PEO made a creamy solution 
when heated at 70 0C for 50 minutes in ethanol. The solution produced crystals 
after removing from heat within 10 minutes, and hence was impossible to use for 
electrospinning.   
Eudragit L 100 was selected because it is designed to limit release of API at pH 2 but 
would allow a sustained release at pH 6 (Cetin et al., 2010). This is the requirement 
for the hemin formulation, as it is required to be released in the intestine to avoid 
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gastric irritation and to promote duodenal uptake (Illangakoon et al., 2014).   
Eudragit L 100 was soluble in a combination of DMAc and methanol (1:5).  
PVP-360 was found to be soluble in EtOH, MeOH, DMAc and deionized water. 10% 
PVP 360 has been used to make fast dissolving fibers carrying either caffeine or 
paracetamol (Illangakoon et al., 2014).   
After comparing results from the above experiments, Eudragit L 100 and PVP 360 
were selected as being suitable candidates for electrospinning with hemin.   
  
The conditions for electrospinning in the first set of fibers prepared from PVP are 
given in table 3.1.   10% PVP-360 was prepared in MeOH and electrospun initially. 
Later in the project, DMF (30%) was mixed with MeOH as solvent to avoid clogging 
of the needle during electrospinning.  
  














a1  DMAc  10  0  0.5  14  11.67  Electrospraying  
a2  DMAc  10  0.1  0.5  14  11.67  Electrospraying  
b1  EtOH  10  0  0.75  12  13.28  Electrospinning  
b2  EtOH  10  0.1  0.75  14  13.55  Electrospinning  
c1  MeOH  10  0  1  14  8.18  Electrospinning  
c2  MeOH  10  0.1  1  14  11.32  Electrospinning  
  
Table 3.1. Electrospinning conditions of PVP-360 with or without hemin with three 
different solvents. The voltages of the samples were adjusted until the needle 
stopped dripping. The images of fibres from these conditions are shown in figure 
3.6.  
18.2% Eudragit L 100 was made in MeOH and DMAc, the solution was electrospun 
according to conditions mentioned in table 3.2. As shown in the image from light 
microscopy (figure 3.5), 18.2% of Eudragit L 100 and 10% of PVP 360 gave particle-
free fibers (figure 3.5). Both polymers gave a thick, consistent mat of fibers which 
was easy to produce and peal from the collector.  
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Figure 3.5. Light microscopy of electrospun fibers. a) Fibers from an 18.2% solution 
of Eudragit L 100 in DMAc and MeOH (1:5) and b) a 10% solution of PVP-360 in 
MeOH. The electrospinning conditions for these samples are given in table 3.2. The 
flow rate used for both samples was 0.5 mL/hr.  
  
Following these preliminary preparations, solutions of PVP 360 in DMAc, EtOH and 
MeOH were electrospun to select the best solvent for production of fibers. Images 
from light microscopy of electrospun preparations of PVP alone and with 1% hemin 
in these solvents are shown in figure 3.6.                                  
          
                                     
  
Figure 3.6. Effect of solvent on the quality of PVP-360 fibers produced alone and 
with 1% hemin by electrospinning. The electrospinning conditions for these 
samples are given in table 3.1.  Solvents used were: a1 and a2 (DMAc), b1 and b2 
(EtOH) and c1 and c2 (MeOH).  
  
As seen in the light microscopy images, PVP could successfully be electrospun into 
fibers from solutions prepared in MeOH and EtOH but not DMAc. Because hemin 
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was found to be more soluble in MeOH compared to EtOH, MeOH was chosen as a 
solvent for PVP. The electrospinning conditions for the samples shown in figure 3.6 
are given in table 3.1.  
  
Electrospinning was carried out at four different flow rates (0.5, 0.75, 1.0 and 1.5 
mL/hr) for both Eudragit L100 / hemin solutions and PVP / hemin solutions. The 
details of all experimental conditions are given in table 3.2.    
  
10% PVP 1% Hemin in methanol   
S.no  Flow rate (mLhr-1)  Distance (cm)  Voltage (kV)  Observation  
1  0.5  14  12.22  Electrospinnig  
2  0.75  14  14.12  Electrospinnig  
3  1.0  14  14.12  Electrospinnig  
4  1.5  14  14.12  Electrospinnig  
5 PVP 
ALONE  
1.0  14  8.18  Electrospinnig  
18.2% Eudragit 0.5% Hemin prepared in a mixture of 
methanol and DMAc (5:1)  
  
1  0.5  14  14.29  Electrospinnig  
2  0.75  14  13.99  Electrospinnig  
3  1.0  14  16.01  Electrospinnig  
4  1.5  14  16.01  Electrospinnig  
5 Eudragit 18.2% 
alone  
 0.5  14  14.29  Electrospinnig  
 
Table 3.2. Electrospinning conditions of PVP-Hemin 1% and Eudragit-Hemin 0.5% 
at different flow rates. The voltages of the samples were adjusted until the needle 
stopped dripping.  
Scanning electron microscopy (SEM) was used to assess fiber or particle quality, 
including the degree of uniform and homogeneous fiber/particle appearance, and 
fiber/particle diameter (Alyami et al., 2017; Oréfice et al., 2001; “Imaging fibers 
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with a SEM,” n.d.). The diameter of particles or fibers was measured from the SEM 
images using image J (Hotaling et al., 2015).    
SEM and light microscope pictures of PVP-360 1% hemin fibers obtained under 
different flow rates (except 0.5 mL/hr in table 3.2), and the frequency distribution 
graphs of fiber diameter, are shown in figure 3.7.  
           
Figure 3.7. Effect of flowrate [layer 1(0.75mL/hr), 2(1 mL/hr) and 3(1.5mL/hr)] on 
quality of PVP-360 1% Hemin fibers. Panels: A) Light microscope images (100 x) B) 
SEM (mag 10k x) and C) histogram showing frequency distribution of fiber 
diameters from 25 fibers (as total number of fibers in each SEM are less) in each 
SEM image.  
Electrospinning of 10 % PVP-360 / 1% hemin solutions in MeOH produced smooth, 
bead-free fibers at flow rates of 0.75, 1.0 and 1.5 mL/hr. According to the SEM 
images, the diameter of individual fibers varies with even one fiber at different 
points having different diameters, especially at the highest flow rate 1.5 mL/hr. The 
mean diameters (in nm) and standard deviation of fibers for all flow rates from 
lower to higher are 922.8 ± 203.4, 1111 ± 187.0 and 1409 ± 326.9. The means show 
that lower flow rates gave smaller diameters. The result showed that the standard 
deviation of diameter of 1.0 mL/hr flow rate fibers are varying least from the mean 
fiber diameter. It means that the fibers in 1.0 mL/hr sample is more homogenous 
than those produced at other flow rates. The D'Agostino & Pearson, normality tests 
were carried out with GraphPad prism for the frequency distributions shown in 
figure 3.7. All three samples passed the normality test. It means the mean, median 
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and mode of samples are almost the same, and the data is normally distributed, 
and samples are true representative of the whole population.  
Figure 3.8 shows the light microscope image, SEM image, and frequency 
distribution graph of fibers produced from 18.2% Eudragit in MeOH:DMAc (5:1). 
Details of experimental conditions for these samples are given in table 3.2.   
             
Figure 3.8. Analysis of Eudragit L 100 alone. Panels: A) Light microscope image (mag 
400 x) B) SEM (mag 10k x) and C) histogram of fiber diameter frequency distribution 
from 25 fibers in SEM image (25 fibers were selected as total number of fibers in 
SEM are less).                             
The mean diameters (nm) and SD of Eudragit L 100 fibers shown in figure 3.8 is 
1480.5 ± 477.5 nm. The sample passed the D'Agostino & Pearson normality tests, 
which means that the data has a normal distribution and the fibers are 
homogenous. The frequency distribution graph is not bell shaped, and this may be 
due to the smaller sample size used.  
Figure 3.9 shows the light microscope image, SEM images, and frequency 
distribution graphs of fibers produced from 18.2% Eudragit / 0.5% hemin in 
MeOH:DMAc (5:1) at four different flow rates. Details of experimental conditions 
for these samples are given in table 3.2.  
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Figure 3.9. Effect of flowrate [layer 1(0.5 mL/hr), 2(0.75mL/hr), 3(1 mL/hr) and 
4(1.5mL/hr)] on quality of Eudragit L 100 0.5% Hemin fibers. Panels: A) Light 
microscope image (mag 100 x) B) SEM (mag 10k x) and C) histogram of fiber 
diameter frequency distribution from 25 fibers (as the total number of fibers in SEM 
are less) in each SEM image, at different flow rates. The diameter of fibers 
increased with increasing flow rate except the sample collected at 0.75 mL/hr flow 
rate.   
As shown in panels B of figure 3.9, fibers obtained from Eudragit L 100 and hemin 
are smooth, homogeneous, uniform and particle free for each flow rate. The SEM 
images reveal the fibers to be flat with a depression in the middle, as though two 
fibers are joined, especially at flow rates 0.75, 1.0 and 1.5 mL/hr. The mean 
diameters and SD of all flow rates (0.5, 0.75, 1 and 1.5 mL/hr) from lower to higher 
are 1320 ± 152, 1561 ± 326.6, 1348 ± 157.6 and 1608 ± 314.8 nm, respectively.  
According to the mean, the fibers with smallest diameter are produced at the 
lowest flow rate, 0.5 mL/hr. On the other hand, the mean diameter of 1 mL/hr flow 
rate fibers is lower than those produced at 0.75 mL/hr, confirmed by physical 
appearance of the fibers in the SEM images. The standard deviation is highest for 
0.75 mL/hr flow rate, which means the diameter of fibers of 0.75 mL/hr flow rate 
vary more from mean than other flow rates. As with the PVP-360 Hemin samples 
the D'Agostino & Pearson normality test was carried out for the four Eudragit 
hemin samples as well. All four samples with four different flow rates passed the 
normality tests, which means that the data has a normal distribution and the fibers 
are homogenous. The diameter of Eudragit L 100 fibers are larger than Eudragit L 
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100 / 0.5% hemin fibers, except for 0.75 and 1.5 mL/hr flow rate samples, as shown 
in figure 3.9. This is a similar result to PVP fibers (figure 3.7) and PVP/hemin fibers 
(figure 3.10). It means hemin is affecting the diameter of polymer fiber. In 
comparison to PVP fibers, Eudragit L100 fibers are thicker, perhaps because of their 
dual nature.  
The focus of this project was to create a formulation that can deliver iron safely in 
the small intestine. Central to this is a requirement that the formulation can 
dissolve rapidly in the conditions found in the small intestine, especially the pH, but 
with the normally insoluble hemin maintained in a soluble form. Accordingly, 
before proceeding further with the development of the fibers, preliminary 
dissolution tests were carried out on PVP / hemin and Eudragit /hemin fibers. If the 
fibers did not dissolve easily, or released free hemin after dissolution, then they 
would not be useful. The solubility of both types of fibers was checked in PBS 
(isotonic phosphate-buffered saline). PVP / hemin fibers dissolved readily within 10 
minutes, but in contrast Eudragit / hemin fibers took 2-3 days to dissolve. These 
preliminary tests showed that PVP is a better choice for a hemin formulation 
because the digestion time of drugs in the gastrointestinal tract is 10 hours (Lee et 
al., 2014) and if the formulation does not dissolve in that time it will be excreted 
without absorption.  Accordingly, further development focused on PVP fibres.   
To find out the extent to which hemin can be incorporated into PVP-360 fibers, the 
hemin was added to create a 50-fold range of percentages, 0.1, 0.25, 0.5, 0.75, 1, 
5% (w/w) final concentration of hemin in the fibres, using 10% PVP-360 to prepare 
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 10% PVP with different % Hemin  
S. no  % Hemin   Flowrate (mL hr-1)  Distance (cm) tip to collector  
  
Voltage (kV)  
1  0.1  0.75, 0.5  14   12.81  
 14.96  
2  0.25  0.5  14   14.26  
3  0.5  0.5, 0.25  14   15.30  
 18.11  
4  0.75  0.5  14   13.75  
5  1.0  1.0  14   14.12  
6  5.0  0.75, 0.5  14   11.20   
18.38  
 
Table 3.3. Electrospinning conditions of PVP 360 with different % hemin.  
Fibers were successfully obtained at all concentrations and images from light 
microscopy and SEM, together with frequency distribution histograms, of PVP-360 
fibers with 0, 0.25, 0.5, 1.0 and 5.0% hemin are shown in figure 3.10.     
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Figure 3.10. Analysis of PVP-360 fibers with a range of hemin [layer 1 (0%), 
2(0.25%), 3(0.5%), 4(1%) and 5(5%) content. Panels: A) image from light 
microscopy, B) SEM, C) histogram of frequency distribution from 50 fibers diameter 
in each SEM image, except for 0.25% hemin containing PVP fibers i.e. for 25 fibers 
(because the total number of fibers in the SEM image are few). The diameters are 
much smaller in comparison with PVP with 1% hemin. The electrospinning 
conditions of the samples are given in table 3.3.  
PVP fibers with 0.1 and 0.75 % are not presented in figure 3.10. As shown in figure 
3.10, fibers of PVP360 / 0.25% hemin are mostly of diameter 200-400nm, these 
fibers have wide range of fiber diameter, some of them are thick but, for PVP-360 
/ 0.5% hemin are mostly from 200 to 600 nm. PVP-360 fibers are of larger diameter 
(881.9 ± 243 nm) than PVP-360 / hemin fibers. The mean diameter and SD of PVP-
360 / hemin (0.25, 0.5, 1 and 5%) fibers are 579.1 ± 407.8, 489.2 ± 267.7, 479.1 ± 
102.8, 525.6 ± 160.3 nm, respectively. The diameter of PVP-360 / 1% hemin fibers 
have the least standard deviation, indicating a greater homogeneity than the other 
preparations. PVP-360 / 0.5% hemin failed the normality test mentioned earlier. 
PVP-360 only and with 0.25, 1 and 5% hemin passed the normality test. A normal 
distribution can be interpreted as an indicator of homogeneity, with a unimodal 
distribution. There is a possibility of a bi- or even tri modal distribution for the 0.25 
and 0.5% fibers – this could be caused by fibers being dual or triple, visible through 
electron micrograph.            
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All the work described so far was carried out with PVP-360. To extend the work 
further it was decided to assess smaller forms of PVP, and work with PVP-40, 
average mw 40,000 Da, and PVP-10, average mw 10,000 Da. One of the reasons for 
working with all three forms of PVP is to compare their toxicity and uptake of the 
iron carried in hemin, in cultured cells, which will enable selection of a better carrier 
for hemin. Some work was already done on PVP-10 and PVP-40 in the initial stages 
of this project, so it was already known that these two-molecular weights can give 
fiber free particles, and so were included for comparison with PVP-fibers. 4% PVP-
10 and 5% PVP-40 solutions were selected because previous work (in chapter 2 in 
section 2.3.1) had shown that they gave round fiber-free particles.   
A 4% PVP-10 solution in methanol was selected for particle formation. The 
experimental conditions of electrospraying for PVP-10 alone and PVP-10 with 1% 
hemin are given in table 3.4.  
 
4% PVP-10 in methanol      




rate  Distance  to  Voltage (kV)  Humidity 
(%)  collector (cm)  
1  0  0.5   14   17.16  24  
2  1  0.5   14   17.16  23  
  
                    Table 3.4. Electrospraying conditions for PVP 10 alone and with 1% 
hemin.  
SEM and light microscope images of particles obtained under the conditions 
mentioned in table 3.4 are given in figure 3.11.  
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Figure 3.11. Analysis of PVP-10 particles alone (layer 1) and with 1% hemin (layer 
2). Panels: A) SEM (PVP-10 alone, mag 25k x, PVP-10 1%H mag 50k x), B) light 
microscope image (mag 100 x), C) histogram of frequency distribution from 100 
particles diameter in each SEM image. The electrospraying conditions are given in 
table 3.4.  
The SEM images in figure 3.11 clearly showed the successful production of fiber-
free particles under the conditions given in table 3.4. The light microscope pictures 
showed only a few particles in both samples, which means that the particles are 
too small to be visible under the resolution of a light microscope. The mean 
diameters (in nm) and standard deviation of PVP-10 and PVP-10/1% hemin 
nanoparticles were 118.2 ± 39.5 and 137.4 ± 67.0.  The D'Agostino & Pearson, 
normality test was carried out with GraphPad prism for the frequency distributions 
in figure 3.11. Both, PVP-10 nanoparticles, and PVP-10/1% hemin nanoparticles 
passed the normality test. In contrast to the outcome of hemin containing PVP-360 
fibers (figure 3.7), the hemin containing PVP-10 nanoparticles mean diameter is 
larger than PVP-10 nanoparticles. As seen in the SEM images, PVP-10 nanoparticles 
have narrower range of size (40-280 nm) compared with PVP-10/1% hemin 
nanoparticles.  
After working on PVP-10, it was found that the electrospraying was not productive 
(low yield) and it was difficult to remove particles from the foil. It was decided to 
make particles from PVP-40, which had been done previously successfully (chapter 
2 in section number 2.3.1). So, 5% of PVP-40 was selected for particle production 
as it gave round, fiber-free particles. The electrospraying conditions for PVP-40 only 
and PVP-40 / 1% hemin are given in table 3.5 and examples of particles are shown 
in figure 3.12.                    
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5% PVP 40 in methanol     




 Distance  to   Voltage (kV)  
collector (cm)  
1  0  0.5  14   12.25  
2  1  0.5  14   14.20  
  
                         Table 3.5. Electrospraying conditions of PVP 40 alone and with 1% 
Hemin.  
The SEMs of the samples mentioned in table 3.5 are shown in figure 3.12.  
           
Figure 3.12. Analysis of PVP-40 (layer 1) and PVP-40/ 1% hemin (layer 2) particles. 
Panels: A) SEM (PVP40 alone, PVP-40 1%H), mag 25k x, B) SEM (PVP-10 alone, PVP-
10 1%H), mag 10k x), C) histogram of frequency distribution from 100 particles 
diameter in each SEM image. The electrospraying conditions are given in table 3.5.  
The images in figure 3.12, show that it is possible to prepare particles from PVP-40. 
After successful production of PVP-40 particles, PVP-40/hemin particles were 
made. Firstly, 1% hemin was added to a 5% solution of PVP-40 in MeOH. The 
proportion of PVP-40 to hemin was 50:1.  
The mean diameters (in nm) and standard deviation of PVP-40 and PVP-40/1% 
hemin nanoparticles were 303.3 ± 125.0 and 264.3 ± 147.6. The hemin containing 
PVP-40 nanoparticles’ mean diameter is slightly smallerby about 10% than that of 
PVP-40 nanoparticles, but the standard deviation is larger. Some of the particles 
are elongated in shape for both PVP-40 and PVP-40/1% hemin particles (figure 
3.12).  
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Dissolution tests for PVP-10 hemin and PVP-40 hemin were carried out and are 
discussed later (figure 3.22 B and C).   
Different percentages of PVP-40 were tested to find out whether it was possible to 
produce fibers. 15 % PVP-40 also gave particles, as shown by SEM analysis in figure 
3.13.  
                 
                                      Figure 3.13. 15 % PVP-40 Nanoparticle SEM.  
Most of the particles in figure 3.13 are donut shaped. In comparison to 15 % the 25 
% PVP-40 solution gave mixture of particles and fibres. The light microscope picture 
of a sample is given in figure 3.14.  
                       
Figure 3.14. Material produced after Electrospraying/ Electrospinning of 25% PVP-
40. Light microscope image at 400 x. The image is enlarged to confirm the presence 
of fibres. The picture shows the microscope slide part on right side and coverslip 
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with material on left side to avoid misinterpretation due to dust on the slide and 
lens.  
After this 40% PVP-40 was electrospun, and this showed a significant presence of 
fibres. The light microscope picture of 40% of PVP-40 at 400 x is given in figure 3.15.  
                       
Figure 3.15. 40% PVP-40 Fibres. Light microscope image at 400 x. The 
electrospinning conditions of the sample are given in table 3.6.  
Figure 3.15 clearly shows the presence of fibres, but to confirm whether this 
preparation still contained particles, SEM analysis was necessary. The SEM images 
of electrohydrodynamically-formulated material prepared from 25, 40 and 55% 
(w/v) solutions of PVP 40 are shown in figure 3.16.  
             
Figure 3.16.  Electrospinning of different percentages of PVP-40. SEM of fibers 
obtained from A) 25 (mag 10k x), B) 40 (mag 10k x) and C) 55% (mag 2k x) PVP-40. 
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The electrospinning conditions of the samples are given in table 3.6. The scale in 
panels A, B and C are 2, 2 and 10 µM, respectively.  
According to the SEM image in figure 3.16, the 25% (w/v) solution of PVP-40 
produced particles containing fibers but the other two percentages produced fibers 
which were free from particles. The 40% solution produced fibers with three 
particles in the whole image (figure 3.16B), and no particles were observed in the 
fibers produced from the 55% solution (figure 13.6C). The diameter of fibers 
obtained from 25, 40 and 55% of PVP-40 were approximately 200, 300 and 3000 
nm respectively, according to the scales shown on the SEM images. As the 
percentage of the polymer increased, the viscosity (seen by observation) of the 
spinning solution also rises ultimately resulting in thicker fibers. The conditions of 
electrospinning or electrospraying for PVP-40 for 15, 25, 40 and 55% solution in 
methanol are given in table 3.6.                                  
  
PVP-40 in methanol      




 Distance to    Voltage (kV)  Humidity 
(%)  collector (cm)  
1  15  0.5  14   14.64  23  
2  25  0.5  14   16.25  24  
3  40  0.5  14   18.22  24  
4  55  0.5  14   17.20  23  
   
Table 3.6. Experimental conditions of electrospinning/electrospraying different 
percentages of PVP40 solution in methanol.  
If 1% hemin is to be incorporated into the 55% (w/v) solution of PVP-40, this would 
require a 5.5% (w/v) solution of hemin in MeOH which could be diluted 10x with 
60% (w/v) PVP-40 to produce an electrospinnable solution of 55% (w/v) PVP-40 
hemin with 0.55% (w/v) hemin, with a ratio of PVP-40: hemin of 100:1 in the fibers. 
The solubility of hemin in methanol is about 10 mg/mL or 1% (w/v) and when a 5% 
hemin formulation was made with 10% PVP-360 methanol the hemin did not 
dissolve completely and settled in the bottom. This made it impossible to make a 
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formulation of PVP-40 fibers with 1% hemin. In future work it might be worth trying 
PVP-40 at 45% and 50% as well.   
In the next section the absorption studies carried out on solutions of PVP-360, PVP-
40 and PVP-10 containing hemin will be discussed in detail.  
  
 3.4.2  Absorption spectroscopy   
Spectra of fiber of PVP/ hemin solutions were measured to see if the spectral 
properties of hemin were altered by PVP, to measure the extinction coefficient of 
hemin in PVP, and  to assess the molecular form of hemin – monomer or dimer in 
the PVP complex. Hemin solubilizes in aqueous solution by complexing with PVP, 
and it is found as a monomer in a neutral solution of PVP-hemin complexes 
(Inamura et al., 1989).  
The absorption spectra obtained for hemin formulations with PVP-360, PVP-40 and 
PVP-10 are given in figure 3.17 A, B and C, respectively. In all cases a concentration 
of 100 µM hemin was prepared for the three groups of formulations. For example, 
65.2 mg of PVPH100 was dissolved in 10 mL of PBS, to achieve 100 µM hemin, since 
hemin has a MW 652 Da.  
  
Figure 3.17. Absorption spectra of hemin formulations made with three different 
forms of PVP. A)  
PVP-360 B) PVP-40 C) PVP-10 all with 1% hemin and D) PVP 360 with different 
percentages of hemin. Each image A, B and C includes PVP-only fibers or particles, 
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a physical mixture of PVP and hemin, hemin dissolved in a PVP solution, hemin 
alone, and PVP-H samples.   
The ʎmax  for all formulations or mixtures containing hemin, and for hemin alone, 
was found to be 400 nm, which was also found by Han et al. (2013). This value of 
ʎmax was used in dissolution experiments to measure formation of soluble hemin-
PVP complexes at different time intervals (section 3.4.3). All formulations or 
mixtures containing hemin and hemin alone showed a shoulder in the absorption 
spectrum with a peak around 360 nm. This is indicative of a state of dimerization, 
known to occur to hemin in aqueous media (Kremer, 1989; Golnak et al., 2015). To 
confirm this interpretation, spectra of hemin were taken in solvents in which hemin 
is known to be monomeric, DMSO and MeOH (Figure 3.18B). Organic solutions of 
hemin have a sharp soret band, indicating that the hemin is monomeric (Brown and 
Lantzke, 1969). In the same series of measurements spectra were also taken of 
PVP-360 hemin fibers dissolved in PBS (phosphate-buffered saline) and HCl (figure 
3.18A).   
As expected, a single sharp Soret band at 400nm was found with solutions of hemin 
in DMSO or MeOH (Figure 3.18B) whereas a broad Soret band, with peaks at 360 
and 400nm were found for solutions of PVP-hemin fibers dissolved in PBS or 2M 
HCl (figure 3.18A).   
The absorbance at ʎmax of PH-1.0-F is low as compared to hemin in pre-dissolved 
PVP and hemin in PBS, as shown in figure 3.17A. Hemin in PBS did not dissolve 
completely. Similarly, the physical mixture of PVP and hemin and hemin added to 
PVP solution in PBS did not dissolve completely, but more than hemin alone in PBS.  
Absorbances at around 400 nm in the case of hemin formulations of PVP-40 and 
PVP-10 are lower than of hemin in pre-dissolved PVP and hemin in PBS. So, it was 
important to compare physical mix, hemin in pre-dissolved PVP and hemin in PBS 
by using DLS, to find out if it is worth using controls as hemin formulation instead 
of making fibers or particles.   
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Figure 3.18. UV-visible spectra of A) PVPH100 (F-HCL) in HCl and PBS (F-PBS) or B) 
hemin in MeOH or DMSO. The concentration of hemin in all the solutions is 100 
µM.  
Three different solutions, pH 2, SIF and PBS, were made to study simulated release 
of hemin from PVP-hemin nanofibers in the stomach, intestine and blood 
respectively. The UV-visible spectra obtained from the three different solutions are 
given in figure 3.19. The absorbances were measured with and without 
centrifugation of each solution, to observe absorption differences due to formation 
of macroscopic complexes.   
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Figure 3.19 Absorption spectra of PVP-360 with different percentages of hemin in 
PBS (phosphate buffer saline) layer 1, pH 2 (layer 2) and SIF (layer 3) of unspun and 
spun samples.       
The graphs (figure 3.20) were drawn between concentration of hemin and 
absorbance (at ʎmax) to measure extinction coefficients for each solution. The 
wavelengths used were those of highest absorbance, 394.5, 376 and 394 nm for 
PBS, pH 2 and SIF solution, respectively. The calculation was carried out for both 
spun and unspun solutions.  
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Figure 3.20. The relationship between concentration of hemin and absorbance 
obtained from UV-visible spectra at ʎmax in PBS layer 1, pH 2 (layer 2) and SIF (layer 
3) in both spun and unspun samples.             
The molar extinction coefficient obtained from each solution (unspun and spun) is 
given in table 3.7.  
 
Solution  Unspun (M-1cm-1)  Spun (M-1cm-1)  
PBS at wavelength 394.5 nm  3.49 x 104  3.2 x 104  
pH 2 at wavelength 376 nm  3.61 x 104  3.48 x 104  
SIF at wavelength 394 nm  3.02 x 104  2.89 x 104  
  
Table 3.7. Molar extinction coefficients obtained from hemin in PVP-hemin 
complexes in PBS, pH 2 and SIF solution. The extinction coefficient was found higher 
in pH 2 than other two solutions. The extinction coefficient of spun solution in each 
case is lower than normal solution.  
According to data in table 3.7 the extinction coefficient of PVP-hemin complex is 
highest in pH 2 solution which represent the stomach in the human body. The 
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extinction coefficient of spun solutions is less than unspun solutions and can be 
attributed to formation of fine macroparticulate material.  The precipitate is not 
immediately obvious and was first noticed when fresh solutions were left 
overnight. The differences in extinction coefficient could be explained by 
differences in solubility and or pH. Accurate measurement of the extinction 
coefficients will require independent measurement of iron concentrations in the 
solutions, instead of using estimates. 
 
 3.4.3  Dissolution studies   
Dissolution tests are used to simulate the availability of the active substance (API) 
from a formulation and model the duration of time for complete release of the 
active substance from the dosage form into solution. In preliminary studies, the 
solubility of PVP-360-H fibers and hemin alone were compared in PBS. In the first 
trial a quick comparison was made between PVP-360 hemin fibers and hemin 
alone, dissolving in 10 mL PBS to produce a 100 µM solution of hemin (figure 3.21). 
PVP-360 hemin fibers were found to dissolve rapidly and completely within 10 
minutes in PBS at room temperature (figure 3.21 B), whereas hemin hardly 
dissolved (figure 3.21A).   
                
 Figure 3.21. Dissolution of PH-1.0-F (A) and hemin alone (B) in PBS. The arrow 
indicates hemin alone in PBS is undissolved, floating at the top of the PBS.  
In the next set of experiments, dissolution of PVP-360 fibers containing 1% hemin 
was compared with three controls: dissolution of i) a physical mix of PVP 360 and 
hemin powders with the same mass as the PVP and hemin components of the 
fibers, ii) hemin powder in PBS with PVP pre-dissolved, and iii) hemin powder alone. 
To make 100 µM of hemin in 10 mL PBS, 65.2 mg PH-1.0-F was used. Control sets 
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were dissolved in 100 mL of PBS, whereas fibers were dissolved in 10 mL due to 
limited supplies as it takes a day to produce enough fibers for a single experiment 
in 100 mL PBS. Three sets of dissolution tests were carried out with separate 
preparations of fibers.   
The dissolution graphs for this experiment are shown in part A of figure 3.22.  The 
graphs confirm that hemin in fibers dissolved completely and rapidly within 10 
minutes (PH-1.0-F in Figure 3.22A) whereas the physical mix (PH-1.0-M) and hemin 
added to pre-dissolved PVP (H-PVP 360-PBS) control formulations, took several 
days to completely dissolve. Hemin alone (H in Figure 3.22A) eventually dissolved 
to about 30 µM, over a period of six days.  
The dissolution test was also carried out for a set of PVP-40 and PVP-10 
formulations, with a similar outcome, that the electrosprayed formulations 
containing hemin dissolved much more rapidly than the controls (Figure 3.22 B and 
C). The electrosprayed formulations of PVP-40 and PVP-10 could not be weighed 
accurately, and PBS was added directly to material stuck on to the collecting foil, 
and the particles dissolved immediately. The final concentrations of hemin that 
were achieved were much lower than the target of 100 µM due to the inaccurate 
measurement of particle mass. The extinction coefficient of hemin in different 
forms of PVP was assumed to be the same or considered not to vary much. An 
attempt was made to measure iron content of dissolved hemin fiber preparations 
using MCP-AES, but the technique consistently produced under-estimates, and 
further work is needed establish conditions for accurate measurement.  
It was of interest to find out the upper limit of hemin release when part of a 
composite in PVP-360 fibers. PVP-360 fibers were prepared with a range of hemin 
content 0.1, 0.25, 0.5, 0.75, 1 and 5% (w/w) and dissolved in PBS for 30 min. The 
data (Figure 3.22D) showed that there was limited enhancement of hemin release 
beyond a fiber content of 1%. This showed the saturation limit for hemin and 
suggests there may be no advantage in preparing fibers with more than 1% content 
of hemin. The relation between hemin release and percentage of hemin is not 
directly proportioned as shown in panel D of figure 3.22. This might be due to 
changes in the interaction between hemin and PVP at the higher concentrations of 
hemin, which lead to formation of greater proportions of macro-particulate 
material higher. 
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Figure 3.22. Dissolution of hemin formulations in PBS. Data are % release measured 
after spun at 400 nm in samples taken at indicated times. A) Set of PVP-360 
formulations, B) set of PVP-40 formulations,  
C) set of PVP-10 formulations, D) comparison of hemin dissolved after 30 min from 
PVP-360 fibers with different % hemin. Data are the mean ± SD of three 
independent assays carried out for all four sets.  
 
 3.4.4  Infrared (IR) spectroscopy         
This technique was used to determine the potential interactions between 
functional groups in the sample.         
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Figure 3.23. IR spectra of a PVP-360 set with 1% hemin. Comparison of IR spectra 
of 5 samples, PH- 
1.0-F, PVP-F, PH-1.0-M, PVP (polymer powder) and H (hemin).  
The IR spectra of all samples containing PVP are similar. Hemin has a carbonyl peak 
was at 1700 cm-1, and other peaks at 1272 due to C-N stretching, and 939 and 841 
cm-1 indicating C-H bonding vibration (Zhang et al., n.d.) The distinct IR spectrum of 
hemin is masked when mixed with PVP, due to the low content, 1%, of hemin in 
the formulations. The peaks present in the hemin at 3500 and 2919 cm-1 due to C-
H and hydroxyl stretching are not found. It seemed that this technique is not useful 
to confirm the presence of hemin, or to study its bonding interaction with PVP.  
The IR spectra of PVP fibers with 0.1-5% hemin, and spectra of PVP-40, PVP-10 
particles with hemin are given in figures 3.24, 3.25 and 3.26, respectively.  They all 
show a similar outcome, that any potential signals from hemin cannot be detected.
      
                                    Figure 3.24. IR spectra of PVP 360 fibers containing 0.1-5% 
hemin.   
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Figure 3.25. IR spectra of a PVP-10 set with 1% hemin. Comparison of IR spectra of 
5 samples, PH-1.0P, PVP-P, PH-1.0-M, PVP (polymer powder) and H (hemin).   
  
  
Figure 3.26. IR spectra of a PVP-40 set with 1% hemin. Comparison of IR spectra of 
5 samples, PH-1.0P, PVP-P, PH-1.0-M, PVP (polymer powder) and H (hemin).  
 
 3.4.5  X-ray diffraction   
X-ray diffraction was undertaken to find out the physical state of hemin embedded 
in PVP-360 nanofibers, whether it was distributed homogeneously or whether it 
was present in crystalline forms. The X ray diffraction spectrum of PVP powder and 
PVP-360 / hemin fiber are given in figure 3.27. In terms of the PVP, the two broad 
peaks at around 13o and 21o reflect the amorphous nature of PVP. The two sharp 
peaks seen in both XRD patterns are due to reflections from the aluminium 
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substrate (111) and (222) planes. Although there is a high signal to noise ratio in 
the PVP-hemin XRD pattern, the incorporation of hemin into PVP fibers does not 
show any significant sharp peaks other than those from the aluminium, suggesting 
that there are no crystalline regions i.e. the hemin is no longer crystalline so likely 
to be dispersed through the sample. However, the amorphous signals appear to 
have shifted slightly to lower 2. Unfortunately, because the machine needed 
maintenance only a single session of analysis was possible. Hemin alone and a 
physical mix of hemin and PVP powders need to be analysed and compared for 
completing this section. Samples need to be run for a longer time in order to reduce 
the signal to noise ratio.    
     
 
                 Figure 3.27. X-ray Diffraction of PVP-360 powder and PVP-360 hemin 
fibers  
  
 3.4.6  Energy dispersive X-ray spectroscopy (EDX)   
EDX is known as energy dispersive X-ray spectroscopy, which is sometimes denoted 
by EDS as well, and is used for elemental analysis and distribution in a sample. It 
was carried out to confirm the presence of iron in samples. It was only carried out 
on a few samples because of equipment failure. The EDX of PVP-360 fibers alone 
and with 1 and 5% hemin are given in figures 3.28, 3.29 and  
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Figure 3.29. Energy Dispersive spectroscopy analysis of PVP-360-1%H fibers. This 
showed the presence of C, N, O, Cu, Fe and Cl in sample. The electrospinning 
conditions of this sample are given in table 3.2.  
  
  
Figure 3.28.  Energy Dispersive Spectroscopy analysis of PVP-360 fibers with no hemin. 
    
  119  
  
Figure 3.30. Energy Dispersive spectroscopy analysis of PVP-360-5%H fibers. This 
showed the presence of C, O, Cu, Fe and Cl in sample. The electrospinning 
conditions of this sample are given in table 3.3.  
The EDX shown in figure 3.28 of PVP-360 fibers without hemin showed the 
presence of elements C, O and Cu, whereas EDX analysis of PVP-360 with 1% or 5% 
(w/w) hemin showed the additional presence of Fe and Cl which are part of hemin. 
We would not expect to see any Fe signal in the EDX spectrum shown in figure 3.28 
as PVP itself does not contain any iron so this analysis confirmed the absence of 
hemin in the sample. The percentage of Fe detected by EDX is low; in the sample 
with 1% hemin it is 0.2% by weight and in the sample with 5% hemin it is 0.6%. 11.7 
% N was found in the sample with 1% hemin which was found in both hemin and 
PVP structure as well. It’s difficult to explain the low value  of N – it should be 
present at about 13%, or more, in all samples, but it may be caused by a habitual 
EDX issue with low Z (atomic number) detection (“Using SEM/EDS for the 
Quantitative Analysis of Light Elements,” 2015). Gazulla in 2012, used a super ultra-
thin window to get over this issue of nitrogen.  
The EDX of PVP-10 particles only and with 1% hemin is given in figure 3.31 and 3.32, 
respectively.  
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Figure 3.31. Energy Dispersive spectroscopy analysis of PVP-10 particles alone. This 
showed the presence of Al, Fe and Si in sample. The electrospinning condition of 
this sample are given in table 3.4.  
  
  
Figure 3.32. Energy Dispersive spectroscopy analysis of PVP-10-1%H particles. This 
showed the presence of Al, O, Fe and Si in sample. The electrospinning condition 
of this sample are given in table 3.4.  
EDX of particles of PVP-10 alone (figure 3.31) showed the presence of Al, Fe and Si, 
with Fe at 0.8% (w/w) in this sample. The elements found in PVP-10 / 1% hemin 
particles (Figure 3.32) are Al, O, Fe and Si. Fe was measured at 1 % (w/w) in the 
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sample. Fresh samples of PVP-10 alone and with 1% hemin are needed to repeat 
the EDX to confirm the presence of hemin in the sample. The very high percentage 
of aluminium, 96.5% suggests that there was no sample in this analysis. Carbon is 
expected as the major element.   
Overall, the EDX analysis provided some confirmation that hemin was 
incorporated into fibers, but quantitation is not reliable. 
 
 3.4.7  Dynamic light scattering (DLS)   
DLS is used to determine the size of particles simply and readily in a biological 
media. This technique has low sensitivity for small particles and interference could 
be possible for light sensitive objects (Cho et al., 2013). There is another downside 
of using DLS which is mentioned by Mahl et al. (2011), that it can produce artefacts 
as large particles scatter light more strongly. This may produce false results if the 
sample is polydisperse. This technique was used here to determine the size of the 
particles obtained through the dissolution of PVP-360 fibres, and hemin containing 
PVP-360 fibres, in either HPLC-grade water or PBS. The size of particles determines 
how particles can be transported inside cells (Shang et al., 2014), where smaller 
particles may possibly move through passive diffusion inside the cells without use 
of energy (Yang and Hinner, 2014). However, high molecular weight species, 
including those larger than 100 nm e.g. carbon nanotubes, face difficulty in such 
passive translocation. Instead, their transport through the membrane is generally 
considered to be via pores, membrane fission and budding, surface aggregation, 
inclusion in the membrane or lipid membrane permeation (Pogodin et al., 2012).  
Previous research has found that PVP, a water-soluble polymer, exists in the 
monomeric state (confirmed through estimation of the radius of gyration) when in 
the dilute regime. In the semi dilute regime, aggregates of approximately 2-3 times 
the size of the monomer also seen (Sun and King, 1996). For PVP360, the 
concentration, which denotes the start of the semi-dilute regime is approximately 
10.5 mg/mL (Finch., 1984), although Sun and King (1996) reported aggregates for 
concentrations lower than this. This was evidenced by the presence of both fast 
and slow relaxation trends in the autocorrelation function, then fitted to a double 
exponential to estimate the sizes of the two populations. Sun and King (1996) also 
postulated that the aggregation was likely due to the hydrogen bonding network 
of water linking the molecules of PVP together through the carbonyl groups. This 
aggregation was significantly reduced when a denaturing agent (thiourea) was 
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added. This was believed to be due to the thiourea disrupting the non-covalent 
hydrogen-bonding network i.e. acting as a chaotropic agent.  
The graphs shown in figures 3.33a and 3.33b are the outputs obtained after analysis 
of the autocorrelation functions by Malvern proprietary software of PVP360 and 
PVP360-hemin solutions in water and in PBS, respectively. For figure 3.33a, the 
graph showed that there were two size populations of particles in the dissolution 
medium for the PVP 360 in water alone, agreeing with Sun and King (1996), even 
though here the concentration of PVP 360 was lower than the predicted overlap 
concentration. As the percentage of hemin in the PVP fibres is increased, the 
relative proportion of aggregated particles as opposed to monomers also 
increased, as does the size of the aggregate implying that as the quantity of hemin 
is increasing, particles are aggregating more.   
  
  
 Figure 3.33. Measurement of particles size of PVP-360 fibers containing 0-1% hemin using DLS in 
(a) water and (b) PBS.  
Triple exponential fits were carried out on the autocorrelation functions for the PVP 
360-hemin solutions and found to closely fit the data. Exemplar fits are shown in 
figures 3.34 and 3.35, with further examples given in the appendix.   
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                                 Delay time (ms)   
Figure 3.34. The triple exponential fit for PVP 360 fibers in water at 25 0C [SSR(sum 
of square of regression)= 0.010] 
  
        
 Delay time (ms)   
Figure 3.35. The triple exponential fit for PVP 360 containing 1% hemin fibers in 
water at 25 0C (SSR= 0.010)  
The ratio of the intensities of the two populations is plotted in figure 3.36 (a) in 
both water and PBS, showing an almost linear response for both until 1 % hemin, 
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which reflects the gradual shift away from the monomeric PVP form and towards 
aggregates. This is unexpected as the PVP concentration itself was not changed and 
suggests that hemin itself may create hydrogen bonds with PVP (C=O of PVP  with 
H-O of hemin) thus  forming aggregates, possibly in order to stabilize the 
monomeric form of hemin.   
Figures 3.36 (b) and (c) show the relaxation rates and estimated sizes of the two 
PVP populations, both in water and in PBS. In water, with increasing hemin, the 
relaxation rates of both PVP populations increased, leading to increased aggregate 
sizes. However, in PBS, although the smaller population appears to follow a similar 
trend for increased hemin concentration, the aggregates appear to reach a finite 
relaxation rate and hence size estimated at around 400 nm.   
A difference in behaviour of PVP-hemin when in PBS as opposed to water was also 
seen in the ratio of intensities of the two populations, where the population of the 
aggregates appears to increase more slowly when in PBS than in water. These two 
features are proposed to be due to the inherent chaotropic nature of PBS, which 
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(b)                                                                                    (c)  
 
  
Figure 3.36 (a) Relative intensities of the two different populations with respect to 
the percentage of hemin in each sample. For all three graphs, the solution is 
represented by triangles for water and circles for PBS. In figures (b) and (c), 
additionally, the filled markers represent the fast relaxation times (i.e. small 
particles) and the unfilled markers represent the slow relaxation times (i.e. PVP 
aggregates).   
 3.4.8  Differential Scanning Calorimetry (DSC)   
The differential scanning calorimetry (DSC) curves of pure PVP 360 and hemin 
confirmed that there was no melting peak in the case of hemin (as hemin is 
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a broad endothermic peak around 110 o C corresponding to dehydration (Baskakova 
et al., 2016; Illangakoon et al., 2014a). PVP is mostly an amorphous polymer that 
can undergo a transition phase when heated or cooled at a specific temperature, 
known as the glass transition temperature (𝑇𝑔), where the polymer is in a partial 
rubbery and partial glassy phase. Similar to data from Illangakoon et al (2014b), the 
transition temperature of PVP was 40-120 ᵒC. This study has shown that hemin 
inclusions in polymers had no significant effects on DSC result of polymers and 
polymeric nanocomposites. However, no coherent conclusion has been drawn 
about the effect of hemin inclusions on the 𝑇𝑔. Strong interactions and possible 
covalent bonding between hemin and polymer matrix most likely result in an 
increase in the 𝑇𝑔. This study also showed that there was no significant effect on 
the 𝑇𝑔 of PVP fibers with hemin incorporated at 1 wt% (figure 3.37). This may be 
attributed to the lack of strong non-covalent bonds between the hemin and the 
PVP or because hemin has no isotherm (Khan et al., 2013). The endothermic peaks 
of P360, PH-1.0-M, PH-1.0-F are almost same (i.e. around 110 ᵒC). This technique 
was not useful to confirm the presence of hemin in PH-1.0F fibers. The peak of 
P360-F was slightly different from P360, PH-1.0-F and PH-1.0-M. The endothermic 
peak for P360-F was around 150 ᵒC, the reason for the change in the shape of this 
peak is not known.   
 
 
Figure 3.37. DSC analysis of a PVP 360 set of hemin formulations. P360 (polymer 
powder), H (hemin powder), PH-1.0-M (physical mixture of PVP 360 and hemin), 
P360-F (PVP360 fibers) and PH-1.0-F (PVP 360 and hemin fibers).  
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 3.4.9  Measurement of iron content in fibers    
In this section, the experiments were conducted to find out the available iron 
content in PVP/hemin fibers. The measurement was conducted on both unspun 
and spun solutions of PVP/hemin in different biological media, by using the 
ferrozine assay. This was carried out to find out the effect of formation of 
macroparticulates on the available content of iron.  
The graphs obtained from the ferrozine assay of PVP-hemin fibers in PBS, SIF, and 
pH 2 solutions are shown in figures 3.38, 3.40 and 3.41, respectively. Standards 
were made using a soluble form (FAS) of iron and compared with iron bound in PVP 
fibers.                                   
 
Figure 3.38. Iron content of dissolved PVP-hemin fibers in PBS determined by a 
colourimetric assay. FAS was used to prepare standards. Fibers were dissolved to 
prepare a solution containing 500 µM hemin and diluted accordingly. Aliquots of 
fiber solutions were spun at 12,000 g for 5 min prior to assay to provide pairs of 
unspun and spun solutions of fibers. The measured value of iron content in fibers 
was about 36.36% less than expected. 14.28% of iron content in dissolved fibers 
was lost by centrifugation, due to formation of insoluble brown macroparticulate 
material.   
The results from the ferrozine assay shown in figure 3.38 indicate that PVP affected 
the assay. The quantity of iron differed by 36.36% in PBS and this needed to be 
confirmed by comparing three types of samples (standard, spun and unspun) using 
ICP-AES. The solution of dissolved fibers of PVP-hemin in SIF is shown in figure 3.39.    
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Figure 3.39. Image of solutions of PVP-hemin fibers (0-5%) in SIF after 
centrifugation. Sedimentation of macroparticulate material can be seen in the 
image, with increasing amounts as the percentage of hemin in the fibres increases.  
The results obtained from ferrozine assay carried out on PVP-hemin fibers in SIF is 
shown in figure 3.40. 
  
 
Figure 3.40. Iron content of dissolved PVP-hemin fibers in SIF as determined by a 
colourimetric assay. FAS was used to prepare standards. Fibers were dissolved to 
prepare a solution containing 500 µM hemin and diluted accordingly. Aliquots of 
fiber solutions were spun at 12,000 g for 5 min prior to assay to provide pairs of 
unspun and spun solutions of fibers. The measured value of iron content in fibers 
was about 20% less than expected. 50% of iron content in dissolved fibers was lost 
by centrifugation, due to formation of insoluble brown macroparticulate material.   
The results obtained from ferrozine assay carried out on PVP-hemin fibers in pH 2 
is given in figure 3.41.  
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Figure 3.41 Iron content of PVP-hemin fibers dissolved in pH 2 solution determined 
by a colourimetric assay. FAS was used to prepare standards. Fibers were dissolved 
to prepare a solution containing 500 µM hemin and diluted accordingly. Aliquots 
of fiber solutions were spun at 12,000g for 5 min prior to assay to provide pairs of 
unspun and spun solutions of fibers. The measured value of iron content in fibers 
was about 69% less than expected. 9.3% of iron content in dissolved fibers was lost 
by centrifugation, due to formation of insoluble brown macroparticulate material.   
The comparison of results from the ferrozine assay showed that iron content was 
less available in pH 2, only 31% compared with same concentration of standards.  
The ferrozine assay consistently gave lower measurements of iron content across 
several independent sets of assays.  The assay was designed to include strong 
denaturing chemical steps to liberate iron from heme embedded in heme-proteins 
(Riemer et al. 2014). When applied to solutions of PVP polymer fibers containing 
hemin the assay underestimated iron content by a significant margin, about 20, 40 
and 70% in the three sets of data presented. This could indicate a very tight 
association between hemin and PVP, possibly dependent on pH and ionic 
environment. Further investigation needs to be carried out to determine the iron 
content in PVP/hemin formulations, using another technique such as ICP-AES 
(inductive coupled plasma atomic emission spectroscopy).  
  
3.5 Discussion  
The aim of the later part of the work described in this report was to develop a 
formulation using the technique of electrospinning or electrospraying to create 
                                  
y = 0.000993x + 0.036971 
R² = 0.997091 
y = 0.000301x + 0.041435 
R² = 0.962206 
y = 0.000273x + 0.028154 








0 100 200 300 400 500 600 









  130  
nano- / micro- sized formulations to improve the bioavailability of hemin, as a 
supplement to treat anaemia. Hemin is poorly soluble in water and has not been 
widely used as an iron supplement, and only used intravenously, and seemed a 
good candidate for exploiting electrohydrodynamic approaches to enhance 
solubility and availability.  
In the early stages a suitable organic solvent for electrospinning was identified. 
Also, in the initial phase of the work, a variety of polymers compatible with drug 
formulation were assessed, with the aim of identifying polymer and hemin mixes 
that could be prepared in compatible solvents. Eudragit L100 (in DMAc and MeOH) 
and PVP 360 (in MeOH and DMF) were selected as being suitable candidates for 
electrospinning with hemin, as hemin is soluble in these solvents as well. Eudragit 
L 100/hemin and PVP 360/hemin gave thick consistent fibers. The effect of flow 
rate on Eudragit L 100/hemin and PVP 360/hemin was also studied. The correlation 
between diameter and flow rate of electrospinning of PVP 360/hemin and Eudragit 
L100/hemin fibers is shown in figures 3.42 and 3.43, respectively.  
                                         
Figure 3.42. The effect of flow rate of 10% PVP-360 / 1% hemin solution on 
diameter of fibers produced through electrospinning. The data are presented as 
mean (nm) + SD of diameters of 25 fibers, obtained from SEM and measured using 
Image J. There is a direct relation between flow rate and diameter. One-way Anova 
comparison of means indicated a significant difference between the diameter of 
the fibers with flow rate 0.75 mL/hr and diameter of the fibers with flow rate 1.0 
and 1.5 mL/hr [*, p <0.05]. The diameter of fibers prepared at 1 mL/hr flow rate 
were significantly different from diameters fibers prepared at 1.5 mL/hr flow rate 
[*, p < 0.05].       
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Figure 3.43. The effect of flow rate of 18.2% Eudragit / 0.5% hemin solution on 
diameter of fibers produced through electrospinning. The data are presented as 
mean (nm)+SD of diameters of 25 fibers, obtained from SEM and measured using 
Image J. There is no direct relation between flow rate and diameter of fiber. One-
way Anova comparison of means indicated some significant differences between 
pairs of means as indicated by * p<0.05, ** p<0.01, *** p<0.005.  
  
A trend for increasing diameter with increasing  flow rate  has been observed for 
8% PVA (0.5, 1, 1.2, 1.5, and 2 mL/hr), 25 % nylon (0.1, 0.5, 1, 1.5, and 2 mL/hr) and 
4% PVP  (0.5, 0.7, 1, 1.2, and 1.5 mL/hr) (Jabur et al., 2018). Experiments carried 
out in this research for PVP produced a similar trend, except for Eudragit. As it is 
clear from the work carried out in chapter 3, that the mean diameter of Eudragit L 
100 fibers (1480.5 nm) are larger than Eudragit / 0.5% hemin fibers (1320 nm), 
except for 0.75 and 1.5 mL/hr flow rate sample in figure 3.9. This is similar to the 
effect of hemin on PVP fibers, which can be seen from figure 3.7, PVP-fibers and 
PVP/hemin fibers (figure 3.10). The diameter of fibers of both polymers with and 
without hemin is given in table 3.8. Johnson mentioned the same behaviour i.e. the 
inclusion of drug reduces the fiber diameter due to a decrease in the fiber’s 
alignment (Johnson et al., 2016).  
               
                    PH-1.0-F flow rate 1 mL.hr-1   Eudragit-hemin fibers flow rate 0.5 mL.hr-1  
Diameter (Mean±SD 
nm)   
       479.1 ± 102.8                          1348 ± 157.6  
                  PVP fiber flow rate 1 mL.hr-1         Eudragit fiber flow rate 0.5 mL.hr-1  
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Diameter (Mean±SD 
nm)   
          881.9 ± 243                          1480.5 ± 477.5  
    
             Table 3.8. Diameter of fibers of PVP360 and Eudragit with and without 
hemin  
  
According to SEM, PVP 360/Eudragit and hemin fibers are smooth, homogeneous, 
uniform and particle free for each flow rate. In comparison to PVP fibers, Eudragit 
fibers are thicker, perhaps because of their dual nature, as if two fibers are joined 
together, indicated from SEMs of Eudragit fibers in section 3.8 and 3.9. Eudragit 
fibers are flat in appearance. The reason behind this is the traditional one-fluid 
electrospinning shares characteristics of both electrospraying and conventional 
solution dry spinning. During the process, methanol evaporated very quickly. This 
would make the electrospinning process very sensitive to small changes in the 
environment and thus result in nanofibers with a wide range of sizes and generate 
a solid “skin” on the surfaces of collected fibers with some solvent still trapped 
inside the fiber bodies. After spinning, the solvent contained in the fibers diffused 
out into the atmosphere, and the resulting barometric pressure distorted the 
cylindrical fibers to the flat morphology (Yu et al., 2014). Yu produced Eudragit 
fibers of 1280 nm diameter compared with 1300-1500 nm from the research 
carried out in this project, which was quite similar.  
  
The focus of this project was to create a formulation that can deliver iron safely in 
the small intestine. Central to this is the requirement that the formulation can 
dissolve rapidly in the conditions found in the small intestine, especially the pH, but 
with a normally insoluble hemin maintained in a soluble form. Before proceeding 
further with the development of the fibers, preliminary dissolution tests were 
carried out on PVP / hemin and Eudragit /hemin fibers. If the fibers did not dissolve 
easily or released free hemin after dissolution, this would limit their usefulness. The 
solubility of both types of fibers was assessed in PBS (isotonic phosphate-buffered 
saline). PVP / hemin fibers dissolved readily within 10 minutes, but in contrast 
Eudragit / hemin fibers took 2-3 days to dissolve. These preliminary tests showed 
that PVP is a better choice for a hemin formulation because the digestion time of 
drugs in the gastrointestinal tract is 10 hours (Lee et al., 2014) and if the 
formulation does not dissolve in that time it will be excreted without absorption.  
Accordingly, further development focused on PVP fibres.   
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To find out the extent to which hemin can be incorporated into PVP-360 fibers, 
hemin was added to create a 50-fold range of percentages, 0.1, 0.25, 0.5, 0.75, 1, 
5% (w/w), final concentration of hemin in the fibres, using 10% PVP-360 to prepare 
fibers. All the work described so far was carried out with PVP-360. To extend the 
work further it was decided to assess smaller forms of PVP, i.e. PVP-40, average 
mw 40,000 Da, and PVP-10, average mw 10,000 Da. One of the reasons for working 
with all three forms of PVP was to compare their toxicity and the bioavailability of 
the iron carried in hemin in cultured cells, which would enable selection of the best 
carrier for hemin. The SEM images of PVP-10 and PVP-40 clearly showed the 
successful production of fiber-free particles under the conditions given in table 3.6 
and 3.7. Electrospraying with PVP-10 and PVP-40 was not productive due to low 
yields and it was difficult to remove material from the collecting foil. Consequently, 
the cell work with lower molecular weight PVP was not carried out. The ʎmax for PVP 
is around 225 nm and that of hemin was found to be 400 nm, known as the Soret 
band, which was also found by Han et al. (2013). The ʎmax of PVP-hemin 
formulations, 397 nm, was used in dissolution tests. Aqueous solutions of hemin 
have a broad Soret band, indicative of dimerization (Kremer, 1989) and this was 
found to be the case for hemin-PVP mixtures (figures. 3.17, 3.18A). Organic 
solutions of hemin have a sharp Soret band, indicating that the hemin is monomeric 
(Brown and Lantzke, 1969), and this was confirmed for solutions of hemin in DMSO 
and MeOH (figure. 3.18B). It appears therefore that hemin is electrospun as a 
monomer but assumes a dimeric configuration at some stage. Alternatively, and 
perhaps more likely, during dissolution in PBS or DMEM for cell culture, hemin 
changes into the dimeric form, as these are aqueous solutions with broad Soret 
absorption bands. Inamura et al. (1989), explained that doublet and broad soret 
bands represent dimerization of hemin in the PVP-hemin complexes.  The 
comparison of this with the UV-visible spectrum of PVP-hemin complexes in PBS 
(figure 3.19 layer 1) and SIF (figure 3.19 layer3) confirmed that the complex is 
dimeric in these two solutions. The broad soret band of PVP-hemin complex in pH 
2 also gave the indication of presence of dimeric form.  
Dissolution tests were used to simulate the availability of the hemin from the 
formulation and to model the time duration for complete release of it from the 
dosage form into solution. In this research the release of free hemin was not 
observed, but instead, the PVP-hemin fibres dissolved quickly to form substantial 
amounts of insoluble material as well as a nanoparticulate form of hemin. PVP 
made hemin soluble in PBS. Hemin in fibers dissolved completely and rapidly within 
10 minutes (PH-1.0-F in Figure 3.22A) whereas the physical mix of PVP and hemin 
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(PH-1.0-M) and hemin added to pre-dissolved PVP (H-PVP 360-PBS), took several 
days to completely dissolve. Hemin alone (H in Figure 3.22A) eventually dissolved 
in PBS to about 30 µM, over a period of six days. The dissolution test was also 
carried out for a set of PVP-40 and PVP-10 formulations, with a similar outcome, 
that the electrosprayed formulations containing hemin dissolved much more 
rapidly than the controls. As mentioned earlier, due to low yield and difficultly in 
removing the formulation from the foil, the work on PVP-10 and PVP-40 was carried 
out at a preliminary level. PVP-360 fibers were prepared with a range of hemin 
content 0.1, 0.25, 0.5, 0.75, 1 and 5% (w/w) and dissolved in PBS for 30 min. The 
data (Figure 3.22D) showed that there was limited enhancement of hemin solubility 
beyond a fiber content of 1%. This showed the saturation limit for hemin and 
suggests that there may be no advantage in preparing fibers with more than 1% 
content of hemin. FTIR spectroscopy was used to determine the functional groups 
in the sample. The spectra of hemin alone and of hemin containing sample were 
measured to confirm the presence of hemin in the sample,and to assess molecular 
interactions. All four sets of IR spectra confirmed that this technique is not 
beneficial to assess the presence of hemin in PVP/hemin fibers or particles. The 
distinct IR spectrum of hemin was masked when mixed with PVP, due to the low 
content, 1% or 5%, of hemin in the formulations.  
EDX was used for elemental analysis of the sample. It was carried out to confirm 
the presence of iron in samples. The percentage of Fe and N was found lower than 
the actual percentages in the formulation. This is likely to be caused by a habitual 
SEM issue with low sensitivity for atoms with low atomic number (“Using SEM/EDS 
for the Quantitative Analysis of Light Elements,” 2015). Gazulla in 2012, used a 
super ultra-thin window to try to get over this issue for nitrogen.  
DLS was used to determine the size of particles simply and readily in biological 
media. This technique was used here to determine the size of the particles obtained 
through the dissolution of PVP-360 fibres, and hemin containing PVP-360 fibres, in 
either HPLC-grade water or PBS. The size of particles determines how particles can 
move into the cells (Shang et al., 2014), where smaller molecules may possibly 
move through passive diffusion inside the cells without use of energy (Yang and 
Hinner, 2014). However, high molecular weight species, including those larger than 
100 nm e.g. carbon nanotubes, face difficulty in such passive translocation. Instead, 
their transport through the membrane is generally considered to be affected via 
pores, membrane fission and budding, surface aggregation, inclusion in the 
membrane or lipid membrane permeation (Pogodin et al., 2012).  
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Previous research has found that PVP, a water-soluble polymer, exists in the 
monomeric state (confirmed through estimation of the radius of gyration) when in 
the dilute regime (lower than 10.5 mg/mL) but in the semi dilute regime, 
aggregates of approximately 2-3 times the size of the monomer are also seen (Sun 
and King, 1996). The overlap concentration, which denotes the start of the 
semidilute regime is approximately 10.5 mg/mL (Finch., 1984), although Sun and 
King (1996) reported aggregates for concentrations lower than this. This was 
evidenced by the presence of both fast and slow relaxation trends in the 
autocorrelation function, then fitted to a double exponential to estimate the sizes 
of the two populations. Triple exponential fits were carried out on the 
autocorrelation functions for the PVP 360-hemin solutions and found to closely fit 
the data. Sun and King (1996) also postulated that the aggregation was likely to be 
due to the hydrogen bonding network of water linking the molecules of PVP 
together through the carbonyl groups.   
According to DLS there are two size populations of particles in the dissolution 
medium for the PVP 360 in water alone, agreeing with Sun and King (1996), even 
though here the concentration of PVP 360 was lower (6.52 mg/mL) than the 
predicted overlap concentration. As the percentage of hemin in the PVP fibres is 
increased, the relative proportion of aggregated particles, as opposed to 
monomers, also increases, as does the size of the aggregate.   
A model was made to describe the behaviour of hemin/PVP fiber in biological 
media. It is based on the results obtained from dissolution experiments and DLS. 
PVP/hemin fibers in aqueous solution transfer in to two size populations (10-100 
nm and 100-1000 nm) PVP/hemin particles (hemin wrapped with PVP). However, 
some of the hemin which was on the surface of the fibers intertwined with PVP 
aggregated and formed insoluble hemin-PVP complexes. The schematic diagram of 
this phenomenon is given in figure 3.44.             
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Figure 3.44. The dissolution process of PVP/hemin fibers in aqueous medium. 
Firstly, the fibers swell in aqueous medium, A) hemin molecule on surface of fibers 
joined and made macromolecules, PVP molecule intertwined with it. Hemin 
molecule imbedded in fibers were convert in to two size PVP/hemin particles B) 
nanoparticles 10-100 nm C) nanoparticles 100-1000 nm.  
The described work in this chapter has revealed unusual behaviour of monolithic 
PVP-API composite nanofibers, in which the API interacts with polymer to form 
nanoparticles or insoluble aggregates, rather than dissociating as free API from the 
polymer.  The molecular basis for this behaviour is not clear and requires further 
investigation.  Future work in developing the potential of this system for delivery 
of hemin could include coaxial formulations with sheath polymers stable in gastric 
conditions, with a PVP core.  Despite the formation of insoluble aggregates, the 
rapid solubility of PVP-hemin fibers to form stable soluble preparations of hemin 
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Chapter 4  
Uptake of hemin-PVP nanoparticles by cultured cells – an in vitro 
study  
4.1 Introduction  
In this project, hemin loaded PVP fibers were prepared for the first time, as a 
potential new formulation for treatment of anemia. The fibers have been found to 
dissolve rapidly in physiological buffers, creating solubilised hemin packed in PVP 
nanoparticles. To assess the bioavailability of the iron in the hemin nanoparticles 
some preliminary studies were carried out in vitro, to assess iron uptake from the 
NPs by a variety of cultured cell models. It was also important to assess any 
potential toxicity of the hemin fibers.  
Three types of cells were used to assess cytotoxicity, uptake, and storage of iron. 
Firstly, HepG2 human hepatoma cells were selected as a model for liver cells 
(hepatocytes). Liver is the major organ of iron storage and helps to maintain the 
homeostasis of body iron levels. Liver can sense the level of iron in the body and 
respond by controlling uptake of iron from the diet, through the release of the 
regulatory hormone hepcidin (Anderson and Shah, 2013). HepG2 cells have been 
used to model iron homeostasis and regulation in the liver, latterly to investigate 
the molecular mechanisms by which production of hepcidin is regulated (Kulaksiz 
et al., 2004).     
The human monocyte cell line THP-1 was selected as a model for an important cell 
type that has a major role in systemic iron homeostasis, the monocyte-macrophage 
system (Andriopoulos and Pantopoulos, 2006; Ludwiczek, 2003). Macrophages 
capture and recycle senescent erythrocytes, extracting the iron from haemoglobin 
and exporting it for re-use (Silva and Faustino, 2015).  Macrophages are present 
throughout the body and those associated with the liver and spleen, recycle old red 
blood cells. Liver macrophages are also called Kupffer cells and it is possible to co-
culture THP1 and HepG2 cells to model the interactions between Kupffer cells and 
hepatocytes (Matak et al., 2009). THP-1 monocytes can be easily differentiated into 
macrophages and can provide a convenient model for characterising uptake of 
hemin nanoparticles by endocytic and phagocytic pathways.   
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Caco-2 cells, a cell line derived from human colon cancer (Lea, 2015), was selected 
as a third cell line because it has been widely used as a model for absorption of 
dietary components, including different formulations of iron (Tako et al., 2016).  
Caco-2 cells have been used in co-culture with HepG2 cells to model uptake and 
first-pass metabolism.  
In this chapter experiments are described in which the safety of hemin-NPs is 
assessed through assay of toxicity to cultured cells (Molinari et al., 2005). Iron 
uptake by cells was measured by a chemical assay based on chelation of Fe2+ by the 
chromophore ferrozine (Hirayama and Nagasawa, 2017).  Had time permitted later 
work would have assessed the bioavailability of iron from hemin-NPs, by increase 
of iron stored in cells, measured by the levels of the intracellular iron storage 
protein ferritin (Knutson, 2017).     
  
4.2 Materials and Methods  
4.2.1 Materials  
Hemin (relative molecular mass 651.9) was obtained from Calbiochem (Merck, UK). 
Polyvinylpyrrolidone (PVP) (average relative molecular mass 360,000), ferric 
ammonium citrate, ferrous ammonium sulphate, ferrozine, neocuproine, PSG 
(penicillin, streptomycin, glutamine), nonessential amino acids and FBS (fetal 
bovine serum) were all purchased from Sigma Aldrich. Methanol, ethanol, 
chloroform, dimethylformamide and trypsin were bought from Fisher. HepG2, THP-
1 and Caco-2 cells were purchased from the European Collection of Cell Cultures 
(ECCAC, Salisbury, UK). Dulbecco’s Modified Eagle Medium (DMEM), EMEM, RPMI-
1640 were obtained from BioWest (VWR, UK). Ferrozine (3-(2-pyridyl)-5,6-
bis(phenyl sulfonic acid)-1,2,4-triazine), and neocuproine (2,9dimethyl(1,10-
phenanthroline)) were from Sigma Aldrich.  
4.2.2 Methods  
4.2.2.1 Preparation of hemin solutions for treatment of cells  
Amounts of solid preparations of nanofibers were added to plain cell culture medium 
(DMEM) based on the mass of PVP-hemin fibers with 1% (w/w) content of hemin, 
needed to create a concentration of iron of 100 µM. For 10 mL of DMEM, 65.2 mg of 
PVP-hemin (1%) was added, containing 652 µg of hemin, or 1 µmole. Control 
treatments included DMEM containing 65.2 mg of PVP nanofibers or 65.2 mg of PVP 
powder. Fibers containing a range of hemin from 0.1 to 5% (w/w) were used, all 
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dissolved at 65.2 mg per 10 mL medium, giving a range of iron concentrations of 10 
to 500 µM.  
Each preparation of fiber was placed in a sterile plastic petri dish in a 
microbiological safety cabinet with the air flow switched off to avoid loss of the 
very light fibers. The fibers were exposed to UV light for 30 minutes for sterilization, 
and then 10 mL of DMEM was added to each petri dish. At this point the air flow of 
the safety cabinet was turned on, to provide the normal environment for handling 
cell cultures in a sterile way. The fibers were dissolved completely by pipetting the 
mixtures. Fresh solutions were prepared immediately before each set of 
treatments.  
  
4.2.2.2 Cell culture  
HepG2 cells were cultured in DMEM medium, supplemented with 10% (v/v) FBS, 
0.05% penicillin and 2% streptomycin. THP-1 cells were cultured in RPMI 1640 
medium, supplemented with 10% (v/v) FBS, 0.05% penicillin and 2% streptomycin. 
Caco-2 cells were cultured in EMEM medium with non-essential amino acids, 
supplemented with 10% (v/v) FBS, 2 mM glutamine, 0.05% penicillin and 2% 
streptomycin.  Cells were maintained at 37 °C in 5% (v/v) CO2 and sub-cultured 
twice a week. HepG2 and Caco-2 cells were grown in 25 or 75 cm2 flasks and 
detached by treatment with 0.02% (w/v) trypsin in PBS with 1 mM EDTA. THP-1 
cells were centrifuged at 150 g and the medium replaced. Generally, cells were 
subcultured at a dilution of 1:3 to 1:5.  
For treatments, cells were seeded at about 2 x 105 cells/mL in 6-, 24- or 96-well 
plates. HepG2 cells could grow to 80% confluency, usually in two days before the 
treatment. Growth medium was removed and replaced with plain medium 
containing a range of concentrations of hemin solutions (PVP-only, 0.1, 0.25, 0.5, 
0.75, 1 and 5% hemin containing PVP solutions). Cells were treated with 100 µM 
ferric ammonium citrate (FAC) as a positive control for iron uptake. Negative 
controls of cells without treatment and a blank well without cells were performed 
for each analysis. The cells were treated with the PVP-hemin solutions for 48 hours.  
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                        4.2.2.3 Light microscopy  
An Olympus X81 inverted light microscope was used to take the images of cells at 
magnifications of 100x and 200x.  
  
                        4.2.2.4 Cell viability assay  
The MTT assay (Mosmann, 1983) was carried out to quantify metabolic activity in 
cells, representing total cell number, as a means of measuring the potential toxicity 
of the PVP nanofiber treatments. The assay is based on the reduction of the yellow 
tetrazolium salt MTT (3-(4,5-dimethylthiazol-2-yl)-
2,5diphenyltetrazoliumbromide) to a purple MTT-formazan crystal (Mossman, 
1983). Viable cells reduce MTT into formazan mainly by the action of succinate 
dehydrogenase enzymes in the mitochondria, dead cells lose this ability (Gomez 
Perez et al., 2017). Hence, the percentage of viable cells relative to untreated 
controls was quantified by the MTT assay. 96-well tissue culture plates were seeded 
with the cells (5x 104 cells/mL growth medium) and left overnight.  Growth medium 
was replaced by plain medium containing nanofiber solutions comprised of iron 
over a range of 0 to 500 µM, 100 µM FAC and plain medium only as control. 
Treatments were performed in triplicate and incubated for another 24 h. The 
medium from each well was removed by aspiration at the end of the treatment and 
cells were washed with 200 µL PBS per well. 50 µL of 1.0 mg/mL MTT solution in 
plain DMEM was added to each well and the plate incubated for 4 h at 37 °C. The 
MTT solution was then removed and 50 µL of DMSO was added to dissolve the 
MTT-formazan crystals, by orbital rotation for 15 min. The optical density was 
determined at 590 and 650 nm for each well using a FluoStar plate reader (BMG 
Labtech, Aylesbury, UK).   
  
                      4.2.2.5 Perls staining of ferric iron  
HepG2 cells were cultured on coverslips to about 80% confluency and treated with 
PVP-hemin nanofibers as described above. The cells were washed with PBS twice 
and then fixed by treating with 4% paraformaldehyde/ PBS for 30 minutes at room 
temperature. Cells were washed with PBS once, then treated with 70% EtOH for 
storage at -20 0C, or the staining procedure was continued at this stage. Cells were 
hydrated with distilled water for 5 min, before staining. The water was drained off 
and the cells treated with a freshly prepared 1:1 mixture of 2% (v/v) HCl and 2% 
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(w/v) potassium ferrocyanide (freshly prepared) solution for 15 minutes. The cells 
were washed with water five times, and then counterstained with 1% (w/v) 
aqueous neutral red for 30 min. After washing with water twice, cells were 
dehydrated rapidly with alcohol. Coverslips were mounted onto microscope slides 
with 50% (v/v) PBS in glycerol (Bancroft, 1982).  
 
                       4.2.2.6 Ferrozine assay of cellular iron uptake  
Total cellular iron was measured to assess iron uptake by a colourimetric method 
using ferrozine (Fish, 1988) adapted for cultured cells (Riemer et al. 2004). HepG2 
cells were grown and treated with PVP-hemin nanofibers in 24-well plates. After 
treatment, medium was discarded, the cells were washed with PBS and then lysed 
by addition 250 µL of 50 mM NaOH, followed by incubation with rotation at room 
temperature for 2 h. 100 µL aliquots of cell lysate were treated with 100 µL of iron 
releasing solution made up of 4.5% (w/v) KMnO4 and 1.4 M HCl freshly mixed in a 
1:1 ratio.  The iron releasing solution digests proteins to which iron is bound and 
releases the iron. The samples were incubated at 600C for 2 hours in a fume hood 
as chlorine gas is released during heating. The samples were cooled to room 
temperature, and the volume of each sample was made up to 500 µL accurately 
with deionized water. 25 µL of iron detection solution (2.5 M ammonium acetate, 
1 M ascorbic acid, 6.5 mM neocuproine, 6.5 mM ferrozine) was added to each 
sample, mixed, incubated for 30 min.  The iron detection solution was made by 
adding 9.7 g ammonium acetate and 8.8 g ascorbic acid to about 10 mL of water, 
so that the volume was less than 25 mL. The mixture was heated for complete 
dissolution, 43 mg of neocuproine and 80 mg of ferrozine were dissolved, and the 
volume was adjusted to 25 mL. Cu2+ is also present in cells and can bind ferrozine. 
To avoid interference from copper ions the selective copper chelator neocuproine 
was included in the solution (Riemer et al. 2004). The ascorbic acid in the iron 
detection solution reduces Fe+3 to Fe+2. It is the ferrous form of iron which binds to 
ferrozine and gives a purple colour (Jeitner, 2014; Riemer et al., 2004; Yamamoto 
et al., 2010).  After incubation the samples were centrifuged at 12,000 rpm for 5 
min and 200 µL taken for measurement of absorbance at 550 nm, with correction 
for light scattering at 650 nm, in a FluoStar Omega plate reader (BMG LabTech, 
Aylesbury, UK), in a 96-well plate.  
Standards were prepared from a fresh solution of ferrous ammonium sulfate (FAS), 
made by dissolving 0.392 g of FAS in 10 mL of water to make a 0.1 M solution. Stock 
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solutions of 10mM, 1 mM and 100 µM were prepared by serial dilution in which 1 
mL of each concentration was diluted 10 times by addition of 9 mL water. Standards 
were prepared as indicated in table 4.1.  100 µL of each standard was used in the 
to obtain data for a standard curve.  
 
Fe (µM)  0  25  50  100  150  200  250  300  
FAS 
stock  




100 µM  1 mM  1 mM  1 mM  1 mM  
Vol FAS 
stock, µL  
-  25  50  100  15  20  25  30  
Vol H2O, 
µL   
100  75  50  -  85  80  75  70  
                        
Table 4.1. Preparation of standard concentrations of ferrous iron for the ferrozine 
assay.  
A standard curve obtained from the ferrozine iron assay is given in figure 4.1 The 
absorbances obtained from the colorimetric assay can be converted into 
concentrations using the equation obtained for the standard curve.  
 
 
Figure 4.1. Standard curve for the ferrozine assay. The data are means ± SD of 
triplicate measurements. R2 is the square of the correlation coefficient (r) and 
provides information about how far away the y values are from the predicted line. 
                  
y = 0.0025x + 0.094 
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A perfect line would have an R2 value of 1, and most R2 values for calibration curves 
are over 0.95. In biomedicine could be excepted below 0.9.  
                                                                                                  
                     4.2.2.7 Bradford protein assay  
This method was used for measuring protein concentration (Cheng et al., 2016), as 
it is important to know the amount of iron in cells relative to cell number, in this 
case measured as protein. Coomassie Brilliant Blue G-250 reacts with basic amino 
acid residues in proteins in the Bradford assay. This method is commonly adopted 
because of its ease, relative sensitivity, rapidity, and low interference by other 
materials (Ku et al., 2013).   
Bovine serum albumin (BSA) stock solution was made by adding 20 mg to 20mL of 
50 mM NaOH, as the cell lysate was in 50mM NaOH as well. A series of standards 
were made from the stock solution, as shown in the chart below.   
  
Conc BSA µg/m L  Vol of BSA stock solution 
(µL 
)  Vol of 50 mM NaOH 
( L 
)  
0  0  1000  
40  40  960  
60  60  940  
80  80  920  
100  100  900  
200  200  800  
300  300  720  
400  400  600  
500  500  500  
  
                         Table 4.2. Preparation of standard solutions for the Bradford protein 
assay.  
50 µL of each cell lysate and standards were placed in triplicate in a 96 well plate. 
50 µL of 50 mM HCl was added to each sample to neutralize the medium. 100 µL 
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of Bradford reagent was added to the standards and samples. The Bradford reagent 
was mixed in by shaking the plate for 10 seconds, which was then left it at room 
temperature for 15 minutes. The absorbance was recorded at 660 nm (Brady and 
MacNaughtan, 2015).  
The standard curve obtained from assay is given below in figure 4.2. This was used 
for determination of concentration of cells in each treatment.  
 
              
Figure 4.2. Standard curve for determination of concentration of protein in lysed 
cells. The data are means ± SD of triplicates. Some of the error bars are hidden due 
to symbols.  
   
4.3 Results  
The experiments were performed to assess the uptake of hemin from dissolved 
hemin-PVP fibers by cells, to investigate the application of the formulations as a 
new type of iron supplement to treat anaemia. The hemin uptake is studied in 
HepG2, THP-1 cells and in Caco-2 cells, respectively.  
  
                 4.3.1 Uptake of Iron from PVP-Hemin Fibers by HepG2 Cells  
Light microscopy was used for initial inspection of the cells’ morphology and 
histological staining, such as Perls’ stain for iron uptake (Ahrens et al., 2013; Panier 
et al., 2013). HepG2 cells for the control and treated plates were directly viewed 
under the microscope, shown in figure 4.3.  





















Conc of Protein, µg/ml 
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Figure 4.3. Light microscope images of HepG2 cells; (a) control, no treatment, then 
treatment with (b) 100 µM FAC, (c) PVP-360 only, PVP fibers containing hemin to 
give (d) 10 µM, (e) 25 µM, (f) 50 µM, (g) 75 µM, (h) 100 µM,  and (i) 500 µM  
concentration of hemin.  Cells were treated for 48 hr in serum-free medium and 
then viewed live. Healthy cells are elongated and flat; stressed cells appear 
rounded and either bright or granular and dark, which is the predominant 
appearance in panel (i).  
Control, healthy cultures of HepG2 cells are shown in figure 4.3 (a) in which cells 
had no treatment. When treated with FAC, or with PVP fibers delivering 10, 25, 75 
and 100 µM hemin, a small number of rounded stressed cells can be seen (Figure 
4.3 b-h). Fibers were generally well tolerated by the cells, but after treatment with 
PVP fibers containing the highest concentration of hemin there was obvious 
evidence of cell damage, shown by a large proportion of rounded cells (Figure 4.3i).  
To quantify the effect of PVP fiber treatment on cell viability, an MTT assay was 
carried out after treatments. The MTT assay was selected for this purpose as it is 
low cost, fast and simple (Pascua-Maestro et al., 2018). The amount of live biomass 
was measured by formation of formazan through metabolic activity of living cells. 
Data was measured as the absorbance of formazan at 590 nm, adjusted for light 
scattering due to debris or insoluble material left after cells are dissolved in DMSO, 
by the absorbance at 650 nm. To combine data from separate experiments, control 
values were normalised to 1, and all treatments are expressed as a proportion of 
control values.   
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Figure 4.4. Toxicity of PVP-hemin preparations to HepG2 cells. Data are the mean + 
SD from three sets of data and are normalised to control, untreated cells. 
Treatments are 100 µM FAC [FAC], PVP only fibers [PVP Only], PVP-hemin fibers 
producing: 10 µM hemin [PVP-H_0.1], 25 µM hemin [PVP-H_0.25], 50 µM hemin 
[PVP-H_0.5], 100 µM hemin [PVP-H_1.0] and 500 µM hemin [PVP-H_5.0]. One-way 
Anova comparison of means indicated a significant difference between the control 
and cells treated with PVP-H_0.5 [**, p < 0.01] and PVP-H_5.0 [*** p < 0.0001].   
It should be emphasised that in this experiment cells were treated with serum-free 
preparations, to ensure that the cells would remain locked in the quiescent or G0 
phase of the cell cycle. Under these conditions most treatments did not alter 
relative cell number significantly (figure 4.4). There is an uneven trend in the 
relative number of living cells, as the percentage of hemin is increasing. The cell 
number after treatment with 100 µM hemin is only 6.6% less than control cells and 
is higher than after treatments with all other fibers. Treatment with fibers 
producing 50 µM hemin produced a significant decrease in cell number of 42.3% 
and did not follow the trend. This may be due to sampling error or uneven 
experimental conditions in which cells were not always grown consistently, for 
example seeded at different densities. Despite the variation the treatment of cells 
with fibers producing 500 µM hemin induced a clear, significant (p < 0.0001) loss of 
76.7% of live cells. This is consistent with the stressed, rounded appearance of 
HepG2 cells treated with these fibers, shown in figure. 4.3i.    
Having established that HepG2 cells remain mostly viable after exposure to PVP 
fibers including hemin up to 1%, the next step was to assess the ability of the cells 
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is possible by measuring the increase in iron inside the cells that would be expected 
after uptake of the particles. A simple way of detecting excess iron in cells is by a 
histological stain called Perls staining, which is still used to detect excess iron 
loading in liver biopsies and has also been used on HepG2 cells (Cabrita et al., 2004). 
After treatment of HepG2 cells as described above, cells were fixed and stained. A 
blue stain is indicative of increased levels of iron in the cells, however none of the 
treatments gave rise to a visible stain. It is likely that the method is not sensitive 
enough to detect small changes in iron levels (Sun et al., 2015).  
A quantitative and sensitive assay of iron was needed and the chromophore 
ferrozine was used (Fish, 1988; Im et al., 2013; Jeitner, 2014). The basic principal of 
this method is that, ferrozine (3-(2-pyridyl)5,6-bis(4-phenylsulfonic acid)-1,2,4-
triazine ) forms a complex with ferrous iron which absorbs light of wavelength 550 
nm with a high extinction coefficient of 27,900 M-1 cm-1 (Fish, 1988; Jeitner, 2014). 
Cells are lysed and treated with acidic permanganate to release all the iron bound 
to heme or protein. Aliquots of cell lysates were assayed both for iron and for 
protein as a measure of cell biomass.  
Standard curves for both assays were used to convert absorbances to 
concentrations (figures 4.1 and  
4.2). The ratio of iron to protein was calculated as a measure of cellular iron 
content.                                   
                                       
Figure 4.5. Iron uptake by HepG2 cells. Data are the mean + SD from four sets of 
data. Treatments are 100 µM FAC [FAC], PVP only fibers [PVP Only], PVP-hemin 
fibers producing: 10 µM hemin [PVP-H_0.1], 50 µM hemin [PVP-H_0.5], 100 µM 
hemin [PVP-H_1.0] and 500 µM hemin [PVP-H_5.0]. One-way Anova comparison of 
means indicated a significant difference between the control and cells treated with 
PVP-H_5.0 [** p < 0.01].   
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The data (figure 4.5) shown a pattern of modest iron uptake with increasing 
concentration of hemin in the fibres. Treatments with FAC and PVP-H_1.0 had the 
same concentration of iron, 100 µM. Treatment with FAC induced a significant and 
marked, 89%, increase in cellular iron, but treatment with PVP-hemin fibers 
induced a more limited increase of 22%. Treatment with fibers containing the 
highest amount of hemin, 5%, resulted in a significant and marked increase in 
cellular iron of 119%, as compared to control. However, as demonstrated in figure 
4.4i, fibers containing 5% hemin were toxic to cells under these conditions.  The 
25% of cells that did survive the treatment evidently took up iron well.  
Over all the data shows limited uptake of iron from PVP-hemin fibers. As the 
medium used while treating the HepG2 cell with hemin preparation was serum 
free, this might be the reason for low uptake of iron. Another reason behind low 
hemin uptake may be that PVP/hemin nanoparticles did not interact well with 
HepG2 cells. The PVP/hemin nanoparticles might enter cells by pinocytosis and 
receptor mediated endocytosis with low efficiency.  
  
               4.3.2 Uptake of Iron from PVP-Hemin Fibers by THP-1 cells  
This cell line was selected as a second model for hemin uptake studies, as it is a 
monocyte line that could be used as a model for monocytes circulating in the blood 
and for macrophage iron recycling and homeostasis. Because THP-1 cells are non-
adherent, the experimental set-up is a little different from that used for HepG2 
cells. The hemin solutions were made in the same manner as described above, and 
a set of solutions is shown in figure 4.6.    
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Figure 4.6. Preparations of PVP or PVP-hemin fibers in DMEM. There are four 
preparations: PVP-360 only, P-H_0.5, P-H_1.0 and P-H_5.0 in DMEM to make 0, 50 
µM, 100 µM and 500 µM of hemin solutions with constant concentration of PVP, 
0.652% (w/v). As shown in the image, the colour of solution darkened as the 
percentage of hemin increases.    
PVP fibers containing three percentages of hemin (0.5, 1 and 5%) were selected for 
working on THP-1 cells. For treatments, 1 mL of THP-1 cells (5 x 105 cells) with 
greater than 95% viability, and in full medium, were mixed with 1mL of hemin 
preparation in a six-well plate, as shown in figure 4.7. It is important to note that 
THP-1 cells needed fetal calf serum to survive and so the treatment differs from 
that of HepG2 cells, which can survive in medium without fetal calf serum for a 
short period. THP-1 cells were therefore not arrested in the cell cycle and could 
continue growing in the treatment medium. Four sets of plates were prepared in 
the same manner. In each well 1 mL of full medium with FCS and 1 mL of 
preparation were added, and hence the actual concentration of hemin from the 
fibers was diluted two-fold.  
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Figure 4.7. Treatment of THP-1 cells with PVP fibers only and PVP fibers containing 
(0.5, 1.0 and 5.0%) hemin. C is control without any treatment (1 ml of plain DMEM 
only), FAC contains 100 µM of ferric ammonium citrate.  
After treatments, the wells were visually assessed by microscopy (figures 4.8 and 
4.9). The diameters of cells were measured using images from light microscopy 
analysed using Image J software and a frequency distribution graph obtained 
(figures 4.8 and 4.9).  
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Figure 4.8.  Light microscope images of THP-1 cells and frequency distribution 
graphs of cell diameter.  (a1,2) Control cells without any treatment, (b1,2) cells 
treated with 100µM FAC, (c1,2) cells treated with PVP fibers.   
Control cells with no treatment, and cells treated with FAC and PVP were found to 
be healthy, plump, and smooth as shown in figures 4.8 a1, b1 and c1. In contrast, 
cells treated with PVP-hemin looked stressed shrunken, and there is evidence of 
dead cells and debris, possibly apoptotic bodies (figure 4.9). Cells treated with 1.0 
and 5.0 % hemin containing fibers were especially affected. The diameters of 100 
cells were measured manually with the help of Image J, for each image from 
microscopy, and are plotted as a frequency distribution bar graph using GraphPad 
Prism software. The mean diameter and standard deviation of cells without 
treatment, FAC treated and PVP treated are given in table 4.3. The D'Agostino & 
Pearson, normality test was performed on each data. Control sample passed the 
normality tests whereas FAC and PVP treated sample failed the normality test. The 
FAC and PVP treatments seem to induce some cells, which are larger in diameter – 
this may be due to differentiation.  
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S.NO  Samples (THP1 cells)  Mean±SD of cell diameter, µm  
1  Control                     18.5±3.1  
2  FAC treated cells                     20.0±5.4  
3  PVP fibers treated cells                     20.2±4.2  
4  P-H_0.5 fibers treated cells                     16.7±3.4  
5  P-H_1.0 fibers treated cells                     13.3±2.6  
6  P-H_5.0 fibers treated cells                     16.2±3.4  
  
Table 4.3. Mean±SD of diameter 100 THP1 cells, measured with image J. Control 
(cells without treatment), FAC (positive control), PVP-fibers, P-H_0.5, P-H_1.0 and 
P-H_5.0 treated cells.                                          
          
Figure 4.9. Light microscope images of THP-1 cells and frequency distribution 
graphs of cell diameter.  (a1,2) Cells treated with P-H_0.5 fibers, (b1,2) cells treated 
with P-H_1.0 fibers, (c1,2) cells treated with P-H_5.0 fibers.    
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The mean diameter and standard deviation of cells treated with hemin containing 
fibers are mentioned in table 4.3. The mean diameters of untreated control cells 
(18.5 µm) or cells treated with  
PVP fibers (20.2 µm) were bigger than diameters of cells treated with hemin 
containing PVP fibers (13.3 -16.7 µm). The mean diameter of cells treated with 0.5 
% hemin containing PVP fibers (16.7 µm) was higher than cells treated with 1% 
hemin PVP fibers (13.3 µm). Cells treated with 5.0 % hemin PVP fibers, had a mean 
diameter (16.2 µm) larger than that of the cells treated with 1 % hemin (13.3 µm), 
but the cells were rough. 0.5, 1.0 and 5% hemin treated samples passed the 
D'Agostino & Pearson, normality test.   
After 48 hr treatment the numbers of live and dead cells were counted by Trypan 
blue staining using a hemocytometer.   
                                               
Figure 4.10. Toxicity of hemin preparations to THP-1 cells. Data are mean + SD from 
four sets of cells. X-axis labels indicate untreated cells (Control), cells treated with 
50 µM FAC (FAC) as a positive control, cells treated with dissolved PVP fibers at 
0.326% (w/v) (PVP only), cells treated with PVP-hemin fibers to give 25 µM (P-
H_0.5), 50µM (P-H_1.0) and 250 µM (P-H_5.0) hemin. One-way Anova comparison 
of means indicated a significant difference between the control/ FAC/ PVP only and 
cells treated with P-H_5.0 [*, p < 0.01].   
The viability of cells after treatment with FAC or PVP-only fibers is almost the same 
as control cells without treatment (figure 4.10). Viability of cells treated with PVP-
hemin fibers showed a tendency to decrease as the proportion of hemin in the 
fibers increased, and an average of 70% viability was found in cells treated with PVP 
fibers containing 5% hemin. There was also a change in appearance of the cells 
after treatment with PVP-hemin fibers (figure 4.9), with some evidence of cell 
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to the cells, which tolerated the treatments much better than HepG2 cells (figure 
4.4).  
After treatment with hemin fibers with the higher amounts of hemin, the cells 
acquired a light brown coloration, indicative of iron uptake. To assess levels of 
cellular iron the ferrozine assay was used, and the data were normalised to the 
total cell number, counted using a hemocytometer.  
The ratio of total iron taken up by the cells to total number of cells is shown in figure 
4.11.     
          
Figure 4.11.  Iron uptake by THP-1 cells. Data are mean+SD from five sets of cells. 
X-axis labels indicate untreated cells (Control), cells treated with 50µM FAC (FAC) 
as a positive control, cells treated with dissolved PVP fibers at 0.326% (w/v) (PVP 
only), cells treated with PVP-hemin fibers to give 25 µM (PH_0.5), 50 µM (P-H_1.0) 
and 250 µM (P-H_5.0) hemin. One-way Anova comparison of means indicated a 
significant difference between the control/ PVP only and cells treated with P-H_5.0 
fibers [**, p < 0.005] and there is significant difference between cell treated with 
P-H_0.5 and P-H_5.0 [*, p < 0.05].  
As shown in figure 4.11, the highest hemin concentration causes a large uptake of 
iron but, the cell viability was lower compared to other percentages of PVP-hemin 
fibers. The iron uptake by FAC is 7 times higher than control. The iron in 0.5, 1% 
hemin-PVP fibers treated cells were found 17.8 and 29.7 µmol/cell, whereas the 
iron uptake from 5 % hemin containing fibers by the cells was 100 times higher than 
control. There is a clear trend in increasing iron uptake with increasing hemin 
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content in fibers, but due to the big difference in iron uptake from 5% hemin 
compared with the other preparations the amount of iron uptake from each 
preparation is indicated for each sample in figure 4.11.   
  
               4.3.3 Uptake of Iron from PVP-Hemin Fibers by Caco-2 cells  
The Caco-2 cell line was selected as a third model for hemin uptake studies, as it is 
an intestinal cell line widely used as a model for absorption of dietary components, 
including different formulations of iron (Tako et al., 2016). Because Caco-2 cells are 
adherent, the experimental set-up was the same as used for HepG2 cells. The 
hemin solutions were made in the same manner as described in section  
4.2.2.1.   
PVP fibers containing three percentages of hemin (1, 2 and 5) were selected for 
working on Caco-2 cells. For treatments, 0.5 mL of Caco-2 cells (5 x 105 cells) with 
greater than 95% viability, were grown in full medium, the medium was replaced 
with 0.5 mL of hemin preparation in a 24-well plate, as shown in figure 4.13. It is 
important to note that Caco-2 cells needed fetal calf serum to survive and so the 
treatment differs from that of HepG2 cells, which can survive in medium without 
fetal calf serum for a short period. Caco-2 cells were therefore not arrested in the 
cell cycle and continued growing in the treatment medium. Two sets of plates were 
prepared in the same manner (one for MTT and one for ferrozine test).   
Light microscopy was used for initial inspection of the cells’ morphology. Caco-2 
cells in the control and treated plates were directly viewed under the microscope, 
shown in figure 4.14.  
    
Figure 4.12. Light microscope images of Caco-2 cells; (a) control, no treatment, then 
treatment with (b) 100 µM FAC, (c) PVP-360 only, PVP fibers containing hemin to 
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give (d) 100 µM, (e) 200 µM, (f) 500 µM concentration of hemin.  The scale bar is 
200 µm. Cells were treated for 48 hr in full medium and then viewed live. Healthy 
cells are elongated and flat; stressed cells appear rounded and either bright or 
granular and dark, which is the predominant appearance in panel (f).  
Control, healthy cultures of Caco-2 cells are shown in figure 4.12 (a) in which cells 
had no treatment. When treated with FAC, or with PVP fibers delivering 100, and 
200 µM hemin, rarely rounded stressed cells can be seen (figure 4.3 b-h). Fibers 
were generally well tolerated by the cells, but after treatment with PVP fibers 
containing the highest concentration (500 µM) of hemin there was obvious 
evidence of cell damage, shown by a large proportion of rounded cells and some 
round with rough surface (figure 4.12f).  
To quantify the effect of PVP fiber treatment on cell viability, an MTT assay was 
carried out after treatments. The MTT assay was selected for this purpose as is it is 
low cost, fast and simple (PascuaMaestro et al., 2018). The amount of live biomass 
is measured by formation of formazan through metabolic activity of live cells. Data 
is measured as the absorbance of formazan at 590 nm, adjusted for light scattering 
due to debris or insoluble material left after cells are dissolved in DMSO, by the 
absorbance at 700 nm. To combine data from separate experiments, control values 
were normalised to 1, and all treatments are expressed as times of control.   
   
               
Figure 4.13. Toxicity of PVP-hemin preparations to Caco-2 cells assessed by MTT 
assay. Data are the mean + SD from three sets of data and are normalised to 
control, untreated cells. Treatments are 100 µM FAC [FAC], PVP only fibers [PVP 
Only], PVP-hemin fibers producing: 100 µM hemin [PVP-H_1.0], 200 µM hemin 
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[PVP-H_2.0] and 500 µM hemin [PVP-H_5.0]. One-way Anova comparison of means 
indicated a significant difference between cells treated with PVP-H_5.0 [** p < 
0.05] and control, FAC, PVP only, PVP-H_1.0 and PVP-H_2.0.     
The viability of cells after treatment with FAC or PVP-only fibers is almost the same 
as control cells without treatment (figure 4.13). Viability of cells treated with PVP-
hemin fibers showed a tendency to decrease as the proportion of hemin in the 
fibers increased, and an average 7.12% viability was found in cells treated with PVP 
fibers containing 5% hemin. There was also a change in appearance of cells after 
treatment with PVP-hemin fibers containing 5% hemin (figure 4.12f), with some 
evidence of cell damage. The viability data showed that a hemin content in PVP 
fibers up to 2% is not strongly toxic to the cells.   
As shown in figure 4.14, the highest hemin concentration causes a large uptake but, 
the viability was found lower, as compared to other percentages of PVP-hemin 
fibers. There was no significant increase in iron after treatment of cells with FAC, 
PVP and PVP-H_1.0 fibers as compared with control cells. Increase in iron content 
after treatment with 2% hemin-PVP fibers was measured to 42%. The iron uptake 
from 5% hemin containing fibers increased by 79% compared to control, but most 
cells were stressed and there were clear signs of toxicity after the treatment (figure 
4.15f).    













































                            
Figure 4.14. Iron uptake by Caco-2 cells. Data are the mean+SD from three sets of 
data. Treatments are 100 µM FAC [FAC], PVP only fibers [PVP Only], PVP-hemin 
fibers producing: 100 µM hemin [PVPH_1.0], 200 µM hemin [PVP-H_2.0] and 500 
µM hemin [PVP-H_5.0]. One-way Anova comparison of means indicated a 
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significant difference between the control and cells treated with PVP-H_5.0 [* p < 
0.05].     
In cells treated with 5% hemin-PVP fibers Hep-G2 cells had similar iron content 0.29 
µmol/µg  to Caco-2 cells (0.27 µmol/µg).I Iron content in Caco2 cells was 0.22 
µmol/µg after treatment with 2% hemin PVP fibers. There was no significant 
increase in quantity of iron with respect to control from 1% hemin-PVP fibers by 
Caco-2 cells but, in Hep-G2 cells there was some uptake as seen in figure 4.5. There 
was clear uptake of iron from FAC in Hep-G2 cells compared to Caco-2 cells.  
In order to study the effect of microparticulate precipitate on cells, preparations of 
hemin fibers dissolved in biological medium were spun at 12,000 g for 5 minutes to 
remove the precipitate. Caco-2 cells were treated with supernatants and MTT and 
iron assays were carried out (figure 4.15 and 4.16).  
  
                        
                                        
Figure 4.15. Toxicity of centrifuged PVP-hemin preparations to Caco-2 cells 
assessed by MTT assay. Data are the mean from one set of data and are normalised 
to control, untreated cells. Treatments are 100 µM FAC [FAC], PVP only fibers [PVP 
Only], PVP-hemin fibers producing: 100 µM hemin [PVP-H_1.0], 200 µM hemin 
[PVP-H_2.0] and 500 µM hemin [PVP-H_5.0].  
The viability of cells after treatment with FAC, PVP-only fibers and 1% hemin-PVP 
fibers was higher than the control without treatment (figure 4.15). Viability of cells 
treated with PVP-hemin fibers showed a tendency to decrease as the proportion of 
hemin in the fibers increased, and an average 3.20% viability was found in cells 
treated with PVP fibers containing 5% hemin. The viability data showed that PVP-
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tolerated better by Caco-2 cells than the cells treated with unspun hemin 
preparations. (figure 4.13).  
Iron uptake from spun preparations of PVP-hemin fiber solutions by Caco-2 cells is 
shown in figure 4.16.  
 












































                                  
Figure 4.16. Iron uptake by Caco-2 cells treated with centrifuged PVP-hmein fiber 
solutions. Data are the mean from one set of data. Treatments are 100 µM FAC 
[FAC], PVP only fibers [PVP Only], PVP-hemin fibers producing: 100 µM hemin 
[PVPH_1.0], 200 µM hemin [PVP-H_2.0] and 500 µM hemin [PVP-H_5.0].  
The data shown in figure 4.16 indicate there is no clear trend in uptake of iron, with 
uptake less from from 2% hemin-PVP fiber solutions than from 1% hemin-PVP fiber 
solutions. The uptake of iron from spun preparations of hemin is lower than 
without spun preparations in Caco-2 cells. In case of 1% hemin-PVP fiber solutions, 
viability is higher in cells treated with spun preparations than in cells treated with 
unspun preparations. However, the differences are not large, and experiments 
need to be repeated to see if they are real or not.  
  
4.4 Discussion   
To assess the bioavailability of the iron in the hemin nanoparticles some 
preliminary studies were carried out in vitro, to assess iron uptake from the NPs by 
three cell culture models. It was also important to assess any potential toxicity of 
the hemin fibers.   
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Bioavailability of iron involves the absorption of iron from the intestine into the 
blood circulation and subsequent utilization of iron in the cells for ordinary 
metabolic processes. This has five stages: 1. Digestion, release of iron into the 
lumen of the intestine from the food matrix,  2. Crossing the mucus barrier which 
coats the intestinal apical cells, 3. The uptake of iron by intestinal enterocytes, 4. 
The transport of iron through the enterocytes into the blood, 5. The retention, 
utilization, and storage of iron in the body (Sandberg, 2010). HT 29 cells treated 
with methotrexate can be used as a model for intestinal mucosa, since these cells 
are transformed into mucus secreting differentiated cells when treated with 
methotrexate (Martínez-Maqueda et al., 2015). Caco-2 cells were selected as a 
combined in vitro digestion model which includes stages 1 and 3, and if the cells 
are cultured on inserts this model also can be used to assess the fourth stage, i.e. 
the transepithelial transport into the circulation (Sandberg, 2010). HepG2 and THP-
1 cells were selected as a model for in vitro retention, utilization, and storage of 
iron, which is stage 5 of iron bioavailability. HepG2 human hepatoma cells were 
selected as a model for liver cells (hepatocytes). Liver is the major organ of iron 
storage and helps to maintain the homeostasis of body iron levels (Scott and 
Guilliams, 2018). The human monocyte cell line THP-1 has been selected as a model 
for an important cell type that has a major role in systemic iron homeostasis, the 
monocyte-macrophage system (Andriopoulos and Pantopoulos, 2006; Ludwiczek 
et al., 2003).  Macrophages capture and recycle senescent erythrocytes, extracting 
the iron from haemoglobin and exporting it for re-use (Silva and Faustino, 2015). 
This might help in digestion of PVP/hemin nanoparticles which would directly enter 
in circulation.  
Studies on GIT mucosal absorption of particles delivered via the oral route showed 
that particle size is an important factor in absorption. NPs are able to use three 
routes for absorption: paracellular transport, transcellular transport and uptake by 
the M cells of gut (Hosny et al., 2015). A diagram illustrating the different routes 
for different particle size is shown in figure 4.17.  
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Figure 4.17. Uptake of NPs from the intestinal lumen by paracellular transport (50-
200 nm), transcellular transport (< 50 nm) and the M cells (200-5 µm). The uptake 
by a particular route depends on particle size (Barua and Mitragotri, 2014).  
Initially HepG2, the liver cells which help to maintain iron stores were used (Kulaksiz 
et al., 2004).  There is an uneven trend of decreasing cell number in case of HepG2 
cells, as the percentage of hemin was increased, but the cell number after 
treatment with 100 µM hemin is only 6.6% less than control cells and is higher than 
after treatments with all other fibers. This may be due to sampling error or uneven 
experimental conditions in which cells were not always grown consistently, for 
example seeded at different densities or allowed to grow for different periods 
before treatments. Despite the variation, the treatment of cells with fibers 
producing 500 µM hemin induced a clear, significant (p < 0.0001) loss of 76.7% of 
live cells. This is consistent with the stressed, rounded appearance of HepG2 cells 
treated with these fibers, shown in figure. 4.3i. A one-way ANOVA comparison of 
means in HepG2 cells indicated a significant difference between the control and 
cells treated with FAC [*, p < 0.05] and PVP-H_5.0 [** p < 0.01]. Overall, the data 
show limited uptake of iron from PVP-hemin fibers. This might be due to limited 
interaction between PVP/hemin NPs and potential endocytic or pinocytotic entry 
pathways (Lundquist and Artursson, 2016). This can be carried out by improvement 
or modification in hemin formulation, which is possible by using other polymers or 
using coaxial electrospinning with a shell polymer with better adhesive properties 
than PVP, which might improve interaction of formulation with the cells.  
The human monocyte cell line THP-1 has been selected as a 2nd model for iron 
uptake, since it has a major role in systemic iron homeostasis, the monocyte-
  162  
macrophage system (Andriopoulos and Pantopoulos, 2006; Ludwiczek, 2003).  The 
viability of THP-1 cells after treatment with FAC or PVP only fibers is almost the 
same as control cells without treatment (figure 4.10). Viability of cells treated with 
PVP-hemin fibers showed a tendency to decrease as the proportion of hemin in the 
fibers increased, and an average 70% viability was found in cells treated with PVP 
fibers containing 5% hemin. There was also a change in appearance of cells, they 
were rougher after treatment with 1% and 5% PVP-hemin fibers (figure 4.9), with 
some evidence of cell damage. The viability data showed that the hemin and PVP 
is not strongly toxic to the THP1 cells, which tolerated the treatments much better 
than HepG2 cells (figure 4.4). The highest hemin concentration caused a large 
uptake (119% increase in iron) and a relatively limited effect on cell viability, 
reduced to 77%.  Comapred with HepG2 and Caco-2 cells, which have an epithelial 
phenotype, THP1 cell tolerated the hemin fibers well and could take up iron. 
Further work is needed to find optimal conditions for iron loading with hemin fibers 
and to elucidate the mechanism of uptake.  For example, fibers with 3% and 4% 
(w/w) hemin could be assessed, along with a time-course of uptake.  Electron 
microscopy could be used to visualise uptake to help identify the pathway.     
Caco-2 cells, a cell line derived from human colon cancer (Lea, 2015), were selected 
as a third cell line because they have been widely used as a model for absorption 
of dietary components, including different formulations of iron (Tako et al., 2016). 
The viability of cells after treatment with FAC or PVP-only fibers is almost the same 
as control cells without treatment (figure 4.15). Viability of cells treated with PVP-
hemin fibers showed a tendency to decrease as the proportion of hemin in the 
fibers increased, and an average 7.12% viability was found in cells treated with PVP 
fibers containing 5% hemin, indicating a marked toxicity of the hemin fibers. There 
was also a change in appearance of cells after treatment with 5% PVP-hemin fibers 
(figure 4.14f), with some evidence of cell damage. The highest hemin concentration 
causes an apparent larger uptake of iron (79%) compared with other treatments, 
but the toxic effect of this concentration limits the usefulness of the formulation.  
Caco-2 cells did not respond to FAC, as compared to Hep-G2 cells. There was little 
uptake of iron from 1% formulation of hemin in Hep-G2 or Caco-2 cells (figures 4.5 
and 4.14) . 2% hemin formulation improved the level of iron in Caco-2 cells by about 
30 (figure 4.14) and it would be interesting to assess iron uptake from fibers 
containing hemin at 3% and 4%, to see if it is possible to identify a threshold 
toxicity.  
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The possible route for PVP/hemin nanoparticle uptake, being around 50 nm 
(according to DLS in chapter 3) can be pinocytosis (Schwarz, 2018). However, high 
molecular weight species, including those larger than 100 nm e.g. carbon 
nanotubes, face difficulty in such passive translocation. Instead, their transport 
through the membrane is generally considered to occur by membrane fission and 
budding, surface aggregation, inclusion in the membrane or lipid membrane 
permeation (Pogodin et al., 2012). PVP/hemin NPs with diameter more than 100 
nm can potentially move into the cell by any of these transport mechanisms. The 
NPs may also be transported into cells by the folate transporter due to the close 
structural resemblance between hemin and heme (West and Oates, 2008). The 
main uptake mechanism for nanoscale material in HepG2 cells was found to be via 
clathrin-mediated endocytosis and macropinocytosis (Brkić Ahmed et al., 2017). A 
diagram of the pathway of uptake of NPs from PVP/hemin fibers contained in a 
gastro-resistant capsule is shown in figure 4.18. Uptake of hemin by the cells is 
limited, it is a fundamentally important point – how can PVP NPs be efficiently 
targeted for enhanced bioavailability? To address this problem Jana et al. (2002) 
used Sendai viral envelopes to carry out delivery of hydrogel nanoparticles [cross 
linked PVP-NP (35-50 nm) containing fluoresceinated dextran (FITC-Dx)] through 
the process of fusion. Sendai viral envelopes facilitated the fusion of nanoparticles 
with cell membrane of HepG2 cells.   
Mucus immobilizes particles by hydrophobic and electrostatic interactions, which 
can result in less uptake of NP. To overcome this, it is necessary to develop 
mucolytic, mucoadhesive or mucus penetrating particles (Barua and Mitragotri, 
2014). Mucus penetrating particles (MPP) can rapidly diffuse through the mucus 
barrier in the intestine. This is made possible by the presence of a dense layer of 
low molecular PEG-chains on the surface of nanoparticles (Lundquist and 
Artursson, 2016). Modification of surface characteristics of NPs can offer higher 
penetration through the mucus membrane. Chitosan NPs with a PEO corona and 
with a lipid shell of pluronic F127 exhibited comparatively higher  efficiency  in  
penetration of the mucus membrane (Barua and Mitragotri, 2014).    
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Figure 4.18. Schematic diagram modelling the absorption and uptake of iron from 
gastro-resistant capsules containing PVP/hemin fibers. Endocytosis is considered 
as the entrance route of entrance of PVP/hemin NP in intestinal cells, via the heme 
endocytic pathway. The image of stomach is taken from (“PEPTIDE DELIVERY - The 
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Chapter 5 
Future work  
  
5.1 Potential of nanotechnology in drug delivery for cancer treatment  
5.1.1 Burden of cancer   
According to recent cancer research, in the UK, 1 in 2 people will be diagnosed with 
cancer at some stage of their life (Ahmad et al, 2015). This indicates that the burden 
of cancer disease may be on the rise. According to the Office for National Statistics 
(2016) 303,135 new cases of cancer were registered in England in 2014. This 
represents an increase of 3,135 cases from the previous year (excluding 
nonmelanoma skin cancers).   
There are various modalities of cancer treatment, one of which is chemotherapy. 
Anticancer drugs used in chemotherapy target the cancer cells, however there are 
potential side effects of these drugs. Some of these issues are linked with drug 
delivery resulting in poor bioavailability, high dose requirement, low therapeutic 
indices, and other side effects (Senapati et al., 2018). Hence, efforts are needed to 
improve cancer treatment options.   
 
5.1.2 5-Fluorouracil: An example of chemotherapeutic drug   
5-FU is used to treat solid tumours and is a standard chemotherapeutic agent which 
has been in use for several decades (Muthu et al., 2013). It is often used in 
combination for the treatment of colorectal, skin and / or breast cancers (Ito et al., 
2008). Colorectal cancer is one of the most common cancers in the UK (national 
statistics office UK 2016) and 5-FU is used alone as well as in combination with 
other chemotherapeutics (Wei et al., 2018). The mode of action of 5-FU involves 
inhibition of the enzyme thymidylate synthase which is involved in DNA replication 
after it is incorporated in RNA (Kitao et al., 2017).   
Here, 5-fluorouracil (5-FU) was selected as the model drug. The structure of 5-FU is 
shown in figure  
5.1.  
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                                                 Figure 5.1 Structure of 5-FU   
Unfortunately, 5-FU has severe side effects including hand-foot syndrome (Chiara 
et al., 1997), anorexia, diarrhoea (Boussios et al., 2012), enteritis (Zamani and 
Helman, 2004), and myelosuppression (Fata et al., 1999). To overcome these side 
effects, combination therapy and the timing of drug and sequence of drugs in which 
they are administered is critical (Muthu et al., 2013). Clinical and preclinical studies 
shown that the toxicity of 5-FU may be reduced, and antitumor activity may be 
improved by circadian modulation. An increase in 5-FU dose intensity and 
reduction in 5FU+LV toxicity is possible to obtain by a circadian (nonsinusoidally) 
modulated infusion. This study showed that toxicity reduction is mainly dependent 
on the quasi-intermittency (Falcone et al.,1999). 5-FU is absorbed non-uniformly 
from the intestine, it is also an analogue of pyrimidine uracil as it is metabolised 
through same metabolic pathway as uracil by uracil reductase or dihydropyrimidine 
dehydrogenase (Wilson et al., 2012).   
An efficient delivery system is required for target delivery of 5-FU, as it is rapidly 
eliminated. The half-life of parentally administered 5-FU is 8 to 20 minutes. The 
reason for quick elimination is rapid catabolism in the liver (Diasio and Harris, 
1989). Hence an efficient delivery system of 5-FU is required, which should possess 
characteristics such as small size, physical stability, biodegradability, controllable 
release, no storage or drug leakage problems and resistant against degradation 
(Jaferian et al., 2016).   
 
5.1.3 Formulation of 5 FU-PCL Nanoparticles for drug delivery  
Several biodegradable polymers have been used for the drug delivery of 5-FU which 
have increased the stability of the drug and provided controllable release. Alginate 
is a copolymer and its use has shown an increase in the drug load.   
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One recent approach involved molecular imprinting of 5-FU nanoparticles (NPs). 
Acrylamide or N,N′methylenebis (acrylamide) was used in this study as monomers 
while  AIBN  and EDMA were selected as an initiator and crosslinker  respectively. 
The nanoparticles obtained from this work have improved localization of drug with 
reduced liver side effects (Gardouh et al., 2018). Another appealing approach is to 
formulate 5-FU loaded nanoparticles by electrospraying.  
In the start of this PhD work, attempts were made to produce PCL and 5-FU NPs. 
Various forms of PCL containing NPs were generated, and they were characterised 
by using scanning electron microscopy (SEM), infrared spectroscopy (IR), and 
nuclear magnetic resonance spectroscopy (NMR). The next step involved 
attempting to form NPs loaded with the model drug and assessing viability of these 
NPs as potential DDS (drug delivery system) for 5-FU.   
Also, attempts to modify the surface characteristics of the NPs as carriers for 5-FU 
were also undertaken. This involved using co-axial electrospraying (discussed in 
chapter 1), generating NPs which had PCL in the core and PVP in the shell.  
Low molecular weight PVP successfully gave nanoparticles with less than 100 nm 
but the formulation of PCL (10-14) nanoparticles remained a challenge and there 
were problems in identifying the presence of PCL in the particles produced. Due to 
time constraints further work on this aspect of the project was abandoned and as 
there was no success in getting PCL nanoparticles to incorporate 5-FU.  
  
  
5.1.4 Potential for a formulation of 5FU-PVP Nanoparticles  
Successful formulation of PVP-Hemin could open doors for potential 5FU-PVP 
formulation. PVP nanoparticles could be used to incorporate 5-FU, which if 
successful could revolutionise the cancer treatment.   
  
5.2 PVP-Hemin formulation:  Improvement in Hemin Formulation  
To overcome difficulties of absorption and distribution there is a need to improve 
the hemin formulation. The PVP fibers could be viewed as a first attempt and 
subsequent work using electrospinning could include further investigate the use of 
small PVPs. Use of small molecular weight PVP might increase cellular uptake as 
discussed by Barua and Mitragotri (2014), according to which smaller polystyrene 
particles (300nm) showed higher intake in enterocytes and M cells in vivo than 
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larger particles. Using co-axial electrospinning by keeping PVP-hemin in the core 
and PVP in the shell is another approach to reduce toxicity.  
 
5.2.1 PVP-Hemin Formulation: Scope for further work  
Formulation of orally active hemin preparations for the treatment of anaemia may 
present new opportunities to treat anaemia. The preliminary work described in this 
thesis has identified a novel way in which hemin can be formulated in a soluble 
form, but with limited ability to be taken up by epithelial cells and marked toxicity 
when higher proportions of hemin are present in the formulations.   Some 
suggestions for improvement of the hemin-fiber formulations, or alternatives, are 
discussed here.  As a starting point, other polymers such as CA (cellulose acetate), 
Eudragit L 100, Eudragit S 100, and Eudragit E 100) could be assessed. These have 
better mucoadhesive properties than PVP and are resistant to gastric degradation. 
The formulations prepared with low molecular weight PVPs can be refined to make 
better yields, perhaps using coaxial electrospinning of core-shell fibers, with a PVP-
hemin core and another, mucoadhesive, polymer in the shell. The shell polymer 
could enhance mucosal diffusion and uptake. Mucoadhesive polymers such as 
PLGA, chitosan, PAA and PLGA, poly (sebacic acid) can be used to promote adhesion 
to the mucus layer to improve absorption of hemin in enterocytes. Removal of the 
mucus layer with a mucolytic agent can be an alternative method, but there will be 
chances of bacterial infection (Barua and Mitragotri, 2014). Pulmozyme®[ a 
recombinant human DNase (rhDNase)], Mucinex® (N-acetyl-L-cysteine; NAC) and 
Nacystelyn are examples of a few mucolytic agents described in the literature (Lai 
et al., 2009).    
The use of SLNs (solid lipid NPs), might be another approach to overcome the 
bioavailability issue. NPs with improved  physicochemical  properties,  including a 
positive surface charge, together with high affinity surface ligands [penetratin and 
Sec peptide] could  improve  apical  endocytosis (Lundquist and Artursson, 2016). 
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 Appendices  
                                                                      Appendix A  
  
                            
Figure A1. SEM of particles obtained from 5% (w/v) sample SPCH (with a 1ml/hr 
flow rate, 15 kV voltage 15 cm distance from tip to collector).  
  
                           
Figure A2. SEM of particles obtained from 2% (w/v) sample SPCH (with a 0.5ml/hr 
flow rate, 15.01 kV voltage 18.7 cm distance from tip to collector).  
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                                                                            Appendix B  
  
 Sample code  Voltage/ kV  Tip to collector 





SPCH 1  15.00  18.00  1.00  Electrospraying  
SPCH 2  15.00  20.00  1.00  Electrospraying  
SPCH 3  15.00  16.00  1.00  Electrospraying  
SPCH 4  15.00  16.00  1.50  Electrospraying  
SPCH 5  15.00  18.00  1.50  Electrospraying  
SPCH 6  17.63  18.00  1.00  Electrospraying  
SPCH 7  14.00  20.00  1.00  Spitting  +  
spraying  
SPCH 8  14.00  16.00  1.50  Spitting  
+spraying  
SPCH 9  14.00  18.00  1.50  Dripping  
SPCH 10  13.00  16.00  1.50  Spitting  +  
spraying  
SPCH 11  13.00  18.00  1.50  Dripping   
SPCH 12  15.00  20.00  1.50  Electrospraying  
SPCH 13  12.00  16.00  1.00  Spitting  +  
electrospraying  
                   
             
         Table B1. Processing parameters used for SPCH of 0.5 % (w/v) solution in 1,2- 
dichloroethane.  
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                              Figure B1. SEM micrograph of sample SPCH 4 from table B1.  
  
                                 
                             Figure B2. SEM micrograph of sample SPCH 1 from table B1.  
  
                              
                       Figure B3. SEM micrograph obtained for sample SPCH 5 from table B1.  
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                         Figure B4. SEM micrograph obtained for sample SPCH 2 from table B1.  
  
  
                               
                    Figure B5. SEM micrograph obtained for sample SPCH 12 from table B1.  
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                                                                             Appendix C  
  
  
Sample code  
  
PCL flow rate  
(mLhr-1))  






         
   
Voltage(kV)  
         
Observation  
CPVCH 1  0.5  1.5  10  15  Electrospraying  
CPVCH 2  0.25  1.5  10  15  Solution 
dripping/no 
electrospraying  
CPVCH 3  0.25  1.5  15  15  Electrospraying  
CPVCH 4  0.5  1.5  10  20  Electrospraying  
CPVCH 5  0.5  1.5  15  20  Electrospraying  
CPVCH 6  0.5  1.5  20  20  Electrospraying  
CPVCH 7  0.25  1.5  10  20  Electrospraying  
CPVCH 8  0.25  1.5  15  20  Solution 
dripping/no 
electrospraying  
CPVCH 9  0.25  1.5  20  20  Solution 
dripping/no 
electrospraying  
                                   
Table C1. Processing parameters used for CPVCH. 4% solution of PCL in 1,2- 
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                         Figure C1. SEM micrograph of sample CPVCH 5 from table C1.  
  
                                 
                         Figure C2.   SEM micrograph of sample CPVCH 6 from table C1.  
 
 
                         Figure C3. SEM micrograph of sample  CPVCH 4 from table C1.  
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                    Figure C4. Figure C3. SEM micrograph of sample  CPVCH 3 from table C1.  
 
 
                      Figure C5. Figure C3. SEM micrograph of sample  CPVCH 7 from table C1.  
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                                                                               Appendix D  
  
                                   
Figure D1. SEM micrograph image of  CPV2H 5% (w/v) PVP outside (1.5ml/hr) and 
10% (w/v) PVP inside (0.5ml/hr) at 15 kV and 10cm tip to collector distance.  
  
                                               
Figure  D2. SEM micrograph image of CPV2H  5% (w/v) PVP outside (1.5ml/hr) and 
5% (w/v) PVP inside (0.25 ml/hr) at 15 kV and 10 cm tip to collector distance (outer 
ring).  
  
                                        
Figure D3. SEM micrograph of CPV2H  5% (w/v) PVP outside (1.5ml/hr) and 4% (w/v) 
PVP inside (0.25 ml/hr) at 15 kV and 10 cm tip to collector distance  
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Figure D4. SEM micrograph of CPV2H 5% (w/v) PVP outside (1.5ml/hr) and 2% (w/v) 
PVP inside (0.25 ml/hr) at 20 kV and 10 cm tip to collector distance (outer ring).  
  
                                         
Figure D5. SEM micrograph of CPV2H  5% (w/v) PVP outside (1.5ml/hr) and 1% (w/v) 
inside (0.25ml/hr) at 15 kV and 10 cm tip to collector distance.  
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                                                                       Appendix E   
                                       
  
                                            
  
                                     Figure  E1. SEM of sample CPV2M 21 from table 2.1.                          
  
  
                           
  
                                       Figure E2.  SEM of sample CPV2M 23 from table 2.1.                     
  
           
                           
  
                                       Figure E3.  SEM of sample CPV2M 22 from table 2.1.                          
  
  
  213  
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                                                                    Appendix F  
  
   
                        
  
Figure F1. (a) SEM of particles (b) frequency distribution graph particles  obtained 
for sample CPV2L 12 from table 2.2  
              
  
  
                          
   
Figure F2. (a) SEM of particles (b) frequency distribution graph particles  obtained 
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Figure F3. (a) SEM of particles (b) frequency distribution graph particles  obtained 




                                 
  
Figure F4. (a) SEM of particles (b) frequency distribution graph particles  obtained 
for sample CPV2L 8 from table 2.4.  
  
      
  
                        
Figure F5. (a) SEM of particles (b) frequency distribution graph particles  obtained 
for sample CPV2L 3 from table 2.2.  
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                                                           Appendix G  
  
  
   
               Delay time (ms)   
Figure G1. Triple exponential fit for PVP 360 containing 0.1% hemin fibers in water 
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                  Delay time (ms)   
Figure G2. Triple exponential fit for PVP 360 containing 0.25% hemin fibers in water 
at 25 0C (SSR= 0.002)            
  
 
            Delay time (ms)   
Figure G3. Triple exponential fit for PVP 360 containing 0.5% hemin fibers in water 
at 25 0C (SSR= 0.007)  
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         Delay time (ms)   
Figure G4. Triple exponential fit for PVP 360 containing 0.75% hemin fibers in water 
at 25 0C (SSR= 0.004)  
  
    
                   Delay time (ms)   
Figure G5. Triple exponential fit for PVP 360 containing 5% hemin fibers in water at 
25 0C (SSR= 0.003)  
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                 Delay time (ms)   
Figure G6. Triple exponential fit for PVP 360 containing 0.1% hemin fibers in PBS at 
25 0C (SSR= 0.003)  
 
      
                     Delay time (ms)   
Figure G7. Triple exponential fit for PVP 360 containing 0.25% hemin fibers in PBS 
at 25 0C (SSR= 0.005)  
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 Delay time (ms)   
Figure G8. Triple exponential fit for PVP 360 containing 0.5% hemin fibers in PBS at 
25 0C (SSR= 0.012)  
  
 
       Delay time (ms)   
Figure G9. Triple exponential fit for PVP 360 containing 0.75% hemin fibers in PBS 
at 25 0C (SSR= 0.006)  
